No retraction, correction or concern found when last checked on Oct 18, 2026.
Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings
Gabriel S Dichter, Cara A Damiano, John A Allen
Journal of Neurodevelopmental Disorders · 2012 · Review
Abstract
This review summarizes evidence of dysregulated reward circuitry function in a range of neurodevelopmental and psychiatric disorders and genetic syndromes. First, the contribution of identifying a core mechanistic process across disparate disorders to disease classification is discussed, followed by a review of the neurobiology of reward circuitry. We next consider preclinical animal models and clinical evidence of reward-pathway dysfunction in a range of disorders, including psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive compulsive disorders), neurodevelopmental disorders (i.e., schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorders, Tourette's syndrome, conduct disorder/oppositional defiant disorder), and genetic syndromes (i.e., Fragile X syndrome, Prader-Willi syndrome, Williams syndrome, Angelman syndrome, and Rett syndrome). We also provide brief overviews of effective psychopharmacologic agents that have an effect on the dopamine system in these disorders. This review concludes with methodological considerations for future research designed to more clearly probe reward-circuitry dysfunction, with the ultimate goal of improved intervention strategies.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.
Introduction
Despite the categorical nosology of the Diagnostic and Statistical Manual of Mental Disorders (DSM), different neurodevelopmental and psychiatric disorders share phenotypic features, etiologies, and aberrant neurobiological processes. Indeed, there are multiple examples of distinct disorders that are characterized by common pathophysiological mechanisms. For example, anxiety disorders and mood disorders share hyperactive amygdala responses to negatively valenced stimuli and schizophrenia and post-traumatic stress disorder are both characterized by prefrontal dysfunction during tasks that require sustained attention. Such overlap suggests the utility of examining common patterns of dysregulated brain function and associated phenotypes with the ultimate goal of more accurately linking pathophysiological processes to rationally derived and targeted interventions.
The identification of common neurobiological deficits across disparate neurodevelopmental and psychiatric disorders has helped to motivate goal 1.4 of the NIMH Strategic Plan, the Research Domain Criteria project (RDoC; http://www.nimh.nih.gov/research-funding/rdoc.shtml), which aims to foster research that uses neuroscience tools to investigate constructs that cut across traditional nosological classification boundaries. Although optimal methodological approaches to address these questions are still emerging, the ultimate goal of this framework is to refine classification and develop empirically derived approaches to treatment. At the heart of this approach is the search for dysfunctional mechanistic processes shared by disorders with seemingly disparate phenotypic profiles, a strategy that represents a particular instantiation of the endophenotypic approach to identifying pathophysiological disease mechanisms.
The functioning of reward-processing systems through development has recently garnered increased research attention in both nonclinical and clinical contexts, and the functioning of so-called ‘positive valence systems’ has been proposed as one of the five domains relevant to the NIMH RDoC project. Given the focus of this thematic issue on reward processing in autism specifically, the purpose of this review is to place dysfunctional reward processing in autism within the larger context of emerging evidence that reward-circuitry dysfunction may be present in multiple distinct disorders, and may thus represent a common target for treatments of these disorders.
In this review, we summarize preclinical models and clinical research addressing reward-circuitry dysfunction in a range of neurodevelopmental and psychiatric disorders and genetic syndromes. Specifically, we focus on the functional output of ascending mesolimbic dopamine (DA) projections systems, referred to broadly in this review as ‘reward-processing’ systems. In its fundamental unit, the mesolimbic DA pathway consists of a population of DA-containing neurons in the ventral tegmental area (VTA) that project to neurons in the nucleus accumbens (NAc); however, these VTA neurons also extend projections into the amygdala, the bed nucleus of the stria terminalis, the lateral septal area, and the lateral hypothalamus (collectively, these connections comprise the entire mesolimbic DA system). The processes subserved by these systems have been referred to by multiple names in the research literature, including ‘motivation’, ‘goal-directed behaviors’, ‘incentive salience’, and simply ‘drive’. Furthermore, it is clear that these DA systems affect not only reward processing, but a number of related functions, including punishment, decision-making, cognition, reward prediction, and reward valuation.
Organization and criterion for disorders included in this review
This review is organized as follows. First, we briefly outline the neurobiology of the reward system and discuss potential molecular and cellular mechanisms underlying dysregulated reward-pathway functions. Next, animal models of neurodevelopmental and psychiatric disorders that involve dysregulated reward systems are reviewed, followed by a review of clinical studies of reward-circuitry function within multiple disorders, with a particular emphasis on functional neuroimaging studies and molecular-imaging studies that address striatal DA transmission. We first present psychiatric disorders (i.e., substance-use disorders, affective disorders, eating disorders, and obsessive–compulsive disorder (OCD)), then neurodevelopmental disorders (i.e., schizophrenia, attention deficit/hyperactivity disorder (ADHD), autism spectrum disorders (ASDs), Tourette’s syndrome (TS), and conduct disorder/oppositional defiant disorder (CD/ODD)), and finally genetic syndromes (Fragile X syndrome (FXS), Prader–Willi syndrome (PWS), Williams syndrome (WS), Angelman syndrome (AS), and Rett syndrome (RS)). For all disorders, we emphasize how phenotypic expression of disparate symptoms may be interpreted within the context of reward-processing deficits. We also include brief summaries of effective pharmacologic treatments for each disorder affecting DA function. We conclude with suggestions for directions for future research aimed at treatment of reward-system dysfunction. To constrain the scope of this review, we have considered only disorders primarily considered as psychiatric and neurodevelopmental disorders and genetic syndromes. We therefore have not included disorders such as Huntington’s disease and Parkinson’s disease that are both considered to be neurodegenerative diseases coded as Axis III conditions in the DSM (‘general medical conditions’) and that are typically listed as an associated feature of an Axis I condition.
Although this review focuses primarily on DA transmission in the mesolimbic pathway, multiple other brain neurotransmitter systems are crucially involved in reward processing. For example, pharmacological studies in rodents indicate that distinct serotonin-receptor subtypes expressed both within and outside the mesolimbic system can modulate responses to either natural rewards or drugs of abuse. Whereas norepinephrine has been traditionally associated with stress responses, both DA and norepinephrine are released in an opposing manner in the bed nucleus of the stria terminalis, in response to either aversive or rewarding taste stimuli, indicating interplay in these chemical systems. Endogenous opioids, including endorphins, enkephalins, and dynorphins, can modulate DA transmission in the mesolimbic pathway. Substance-abuse studies have shown that alcohol, which promotes gamma-aminobutyric acid (GABA)A receptor function, may inhibit GABAergic terminals in the VTA and hence disinhibit these DA neurons, thereby facilitating mesolimbic reward-pathway transmission. Abusive opiates such as heroin function similarly, but in an indirect manner: they inhibit GABAergic interneurons in the VTA, which disinhibits VTA DA neurons and thus enables activation of the reward pathway. These observations highlight the importance of GABA transmission in the VTA for reward processing. Finally, synaptic transmission in the NAc relies on glutamatergic inputs from multiple areas, and glutamate can induce modifications in dendritic morphology, ionotropic glutamate receptors, and the induction of synaptic plasticity in the NAc, implicating glutamatergic transmission in coordinating reward processing. These examples indicate that processing of rewarding information involves a complex crosstalk between the DA mesolimbic system and other neurotransmitters, and that interdependency probably occurs across multiple systems and circuits. To simplify this considerable complexity, we aim in this review to summarize the importance of animal models and clinical findings in addressing dysfunction in systems mediating reward processing (broadly defined) by focusing on striatal DA responses to rewarding stimuli.
Brain reward circuitry
Responses to rewards are mediated primarily by the ascending mesolimbic DA system that is highly similar between humans and other animals (Figure 1 shows structures that will be discussed as part of the mesolimbic DA system). Although the terms ‘reinforcement,’ and ‘reward’ are often used interchangeably, these terms have discrete behavioral definitions, and describe largely distinct neurobiological processes. Indeed, there are multiple constructs mediated by the mesolimbic system, and at least four such systems have been described in depth in numerous seminal reviews: 1) reward motivation, also termed anticipation (typically subsuming what is colloquially described as ‘wanting,’) refers to processes that facilitate anticipation of reward and approach behaviors towards biologically relevant goals, including reward valuation, willingness to expend effort to obtain rewards, reward prediction, and reward-based decision-making; 2) reward outcome (or the hedonic responses widely referred to as ‘liking’ or ‘pleasure’) includes both consummatory behaviors during reward obtainment and the processes associated with regulation of such behaviors; 3) reward learning includes reward processes that shape the experience-dependent learning that guides future behaviors; and 4) reward-related habitual behavior reflects those processes that are initiated based on reward feedback, but that persist even in the absence of such feedback.
The neurobiological bases of reward-processing behaviors are well understood in animal contexts, and cognitive affective neuroscience techniques have facilitated the investigation of reward circuits in human clinical contexts. The mapping of brain-reward regions began with the seminal discovery that animals are willing to work to obtain electrical stimulation to mesolimbic brain regions. Subsequent research showed that activity of DA neurons within mesolimbic pathways that project from the VTA to the NAc serve to reinforce responses to both primary rewards (for example, food) and secondary rewards (for example, money). Reward information is processed via a limbic cortico-striatal-thalamic circuit that interdigitates with the mesolimbic DA pathway, and the NAc serves as a DA-gated mediator for information passing from the limbic system to the cortex. This tract is composed of projections from A10 cells in the VTA to cells in limbic areas, including the NAc, the amygdala, the olfactory tubercle, and the septum. This tract has been linked to primary rewards, secondary rewards, and emotional processes, and is part of the limbic-striatal-pallidal circuit that is involved in motivated behavior.
Primary DA centers in the mammalian brain are located in two mesencephalon structures: the substantia nigra and VTA. These distinct brain nuclei contain DA-synthesizing neurons that project to the NAc (mesolimbic pathway), the cortex (mesocortical pathway), and the caudate putamen (nigrostriatal pathway). The central node within the mesolimbic DA reward system is the NAc within the ventral striatum. The NAc, along with the extended amygdala, mediates reward-based drive and motivation, and receives afferents from a number of limbic regions, including the medial and orbital frontal cortices, the hippocampus, and the amygdala. Of particular relevance to reward-based processes is the ventromedial shell of the NAc (the core region regulates cognition and motor control), that serves as an interface between limbic and motor circuits, translating emotions into actions. For this reason, as will be reviewed below, most animal models and clinical neuroimaging studies on reward-related processes focus on functioning of the NAc, and of related afferent and efferent projection regions within the striatum and frontal lobes.
Mechanisms of neurotransmission in the mesolimbic reward pathway
The molecular and cellular mechanisms that facilitate neurotransmission in the mesolimbic DA reward pathway involve the cellular elements modulating synaptic DA neurotransmission, including neurotransmitters, transporters, receptors, G proteins, second-messenger-generating enzymes, ion channels, and immediate early response genes that regulate neuronal functions (Figure 2). Afferents from the VTA of the mesolimbic DA system project outward, and primarily terminate onto the MSNs, which are the principal cell type in the NAc, and produce and secrete GABA, the main inhibitory neurotransmitter used in the CNS. These MSNs are also the main projection or output neurons of the NAc.
Neurotransmission within the mesolimbic pathway begins with an action potential that is generated in VTA neurons, resulting in the presynaptic release of DA. Neurotransmission of the DA signal to MSNs in the NAc is mediated by binding to specific DA receptors. These DA receptors are part of the Gprotein-coupled receptor superfamily, and upon binding DA, activate heterotrimeric G proteins (Golf/Gs or Gi/o) that in turn regulate the activity of effector proteins such as ion channels, or the enzyme adenylyl cyclase that produces the second messenger cAMP. Five distinct DA receptors (D1 to D5) can mediate neurotransmission, and are coupled positively to activation of adenylyl cyclase (D1 and D5 receptors) or negatively to inhibition of adenylyl cyclase (D2, D3, D4). Consequently, MSNs that express D1-like receptors become activated by DA, resulting in an increase in cAMP synthesis, whereas MSNs that express D2-like receptors respond to DA by decreasing cAMP synthesis. cAMP in turn activates protein kinase A, that phosphorylates target proteins resulting in modulation of neuronal activity, gene expression, and target-protein functions. The response to DA in this neuronal pathway is terminated by reuptake of DA into the presynaptic neuron terminals, which is controlled by the DA transporter (DAT). In addition, the enzymes monoamine oxidase (MAO) and catechol-o-methyltransferase (COMT) can regulate DA levels by breaking down DA to the metabolites homovanillic acid or 3-methoxytyramine (3-MT), respectively.
Given its anatomical organization, the NAc is considered a limbic–motor interface translating information about rewards into appropriate behavioral responses to obtain these rewards. The major effect of DA transmission is to modulate the sensitivity of NAc MSNs to other types of input. For example, DA modulates the sensitivity of MSNs to excitatory glutamatergic projections from pre-frontal and limbic regions, and thereby modulates firing activity of NAc neurons. The result of DA transmission on NAc neuronal firing is largely determined by the types of DA receptors expressed in post-synaptic MSNs. Although the precise causal link between DA release and NAc cell firing is unclear, D1 and D2 receptors are generally considered to exert opposite effects at the cellular level, with D1-like receptor-expressing cells responding to DA with excitatory increases in firing activity, and D2-like receptor-expressing cells responding with decreased firing activity. However, in the context of DA release in the brain, a cooperative interplay between NAc neurons that encode reward information probably occurs. For example, DA increases spike firing in MSNs, requiring coactivation of both D1 and D2 receptors. Furthermore, transmission of DA to the NAc occurs with the same temporal resolution as NAc neuron-patterned cell firing, and this DA release and firing are coincident during goal-directed actions in rodents. In addition, the frequency of firing activity of VTA neurons may be a key component in modulating the mesolimbic reward pathway and encoding reward information. Studies using channel rhodopsin to precisely control VTA neuron firing activity suggest that phasic, but not tonic, activation of VTA neurons is sufficient to drive behavioral conditioning to rewards and elicit DA transients, and thus indicates the likely importance of the frequency of VTA neuron firing activity.
Potential molecular and cellular mechanisms underlying dysregulated reward systems
Disruption of molecular, cellular, or circuitry mechanisms that are essential for the reward system may, in theory, result in aberrant reward-system function. Although a primary (or even common) molecular mechanism for dysregulating the reward system has yet to be identified, we briefly consider in the following section some of the potential molecules and mechanisms that may underlie abnormal reward processing.
Because the major neurotransmitter mediating mesolimbic transmission is DA, alterations in the synthesis, release, or reuptake of DA may result in an abnormally functioning reward system. Amphetamines and cocaine mediate their effects in the mesolimbic pathway by increasing the release of DA. Cocaine and amphetamines, both of which directly interact with the DAT, exert their effects, at least in part, by blocking (in the case of cocaine) or reversing the direction of (in the case of amphetamine) this transporter, resulting in increased synaptic DA. Indeed, chronic administration of cocaine upregulates striatal DAT expression in rhesus monkeys, an effect that persists for more than 30 days after cocaine withdrawal. Increased DA-transporter expression has also been shown in post-mortem analyses of brain tissue from human subjects addicted to cocaine. Such studies indicate that alterations in DAT expression or function can result in an altered reward system in response to drugs of abuse.
Similarly, alteration in the expression or regulation of DA receptors would also be expected to dysregulate reward-system functions. Altered DA receptor function could involve increased or decreased receptor expression or signaling responsiveness to DA thereby altering the reward system. For example, the DA hypothesis of schizophrenia suggests that excess mesolimbic DA levels may be pro-psychotic, and involve alterations in the activity of striatal D2 receptors, which are the major site of action for typical antipsychotic medications. There is clear evidence of dysregulated striatal DA function in schizophrenia, and a meta-analysis of multiple studies indicated a significant increase in striatal D2 receptors in patients with schizophrenia who were not on medication. Studies have also suggested an increased affinity of D2 receptors for DA in schizophrenia, which may produce D2 receptor supersensitivity in the NAc, contributing to psychosis. In an interesting animal model correlate to these studies, transient overexpression of D2 receptors in the striatum of mice resulted in deficits in prefrontal working memory, resembling some of the features of human schizophrenia. Studies such as these indicate that alterations in DA receptor expression (or function) can result in a dysfunctional reward system.
Molecules that are activated downstream of DA receptor signaling in the NAc also play important roles in mediating reward responses and changes in their function may also dysregulate the reward system. These molecules include the heterotrimeric G proteins activated by DA receptors and also the adenylyl cyclases. Interestingly, genetic knockout of adenylyl cyclase type 5 in mice prevents the reward response to opioids such as morphine. Further down in the DA signaling pathway of MSNs is the DA- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) (Figure 2). DARPP-32 is activated by D1 receptor cAMP signaling in the NAc by protein kinase A phosphorylation, that regulates the activity of protein phosphatase (PP)-1. Phosphorylated DARPP-32, by inhibiting PP-1, acts in a combined manner with other protein kinases to increase the level of phosphorylation of various downstream effector proteins, and modulation of protein phosphorylation by DA is thought to play an important role in drug reward. DARPP-32 may thereby influence the long-term neuronal adaptations associated with natural rewards or with rewards from drugs of abuse. Support for this concept is provided in genetic models in mice lacking the DARPP-32 gene, which results in decreased responses to cocaine in conditioned place preference behaviors. Therefore, alterations in DARPP-32, PP-1, and the phosphoproteins that these regulate in MSNs, may dysregulate the reward pathway.
Two transcription factors, ΔFosB and cAMP response element binding protein (CREB), are activated by DA receptor signaling in the NAc, and both are important mediators of reward responses because they control the expression of numerous genes. One of the most dramatic examples of protein expression induction is in the transcription factor ΔFosB, a Fos family protein, which accumulates in the NAc after chronic exposure to drugs of abuse, including alcohol, amphetamine, cannabinoids, cocaine, nicotine, opiates, and phencyclidine. Overexpression of ΔFosB in the NAc increases behavioral responses to cocaine, opiates, sucrose and wheel-running, including increased incentive drive for these rewards. Conversely, blockade of ΔFosB function in the NAc by overexpression of a dominant negative antagonist causes the opposite effects.
CREB is another transcription factor that is directly activated by protein kinase A in response to DA signaling in the NAc. Activation of CREB seems to produce similar behavioral responses to rewarding stimuli: in numerous experimental systems, increased CREB activity in the NAc is negatively related to behavioral responses to cocaine, opiates, and alcohol. CREB is also induced in the NAc by natural rewards (such as sucrose), and similarly reduces an animal's sensitivity to the rewarding effects of sucrose. Therefore, any changes in the activation and induction of CREB, ΔFosB, (and probably many other transcription factors) would be expected to regulate or dysregulate the reward system.
Finally, although the molecules highlighted here are clearly involved in DA mesolimbic transmission and reward responses, this represents only a brief overview and readers are encouraged to see other recent reviews of this topic.
Considerations for animal models that focus on reward-system function
Animal models, particularly those using rodents, have provided key mechanistic insights that have elucidated the neurobiology of the brain reward system. Although animal models cannot recapitulate the entire spectrum of phenotypes apparent in clinical presentations of illness, they provide powerful approaches for experimental studies using various environmental, genetic, pharmacological, and biological manipulations. With regard to studying behavior, a high degree of experimental control can be achieved by precisely controlling the animal's life experiences, environment, diet, and history of drug exposure, enabling inferences to be made concerning the causality of effects seen in experimental studies. However, for complex psychiatric disorders with largely unknown genetic etiologies, environmental insults, specific pathologies, or biomarkers, the building of animal models with high construct validity has not yet been possible. With this limitation in mind, an alternative strategy has been to develop mouse genetic models (for example, knockout or transgenic mice) of psychiatric disorders with relevant behavioral phenotypes (face validity) that are responsive to pharmacotherapies that are clinically effective (predictive validity).
Considerations for clinical studies that focus on reward-system function
Primary rewards are vital to gene propagation, and thus responses to such stimuli have been shaped by evolution to elicit approach-oriented behaviors. These stimuli include food and sexual behavior (given that sustenance and procreation are crucial for the survival of a species), and social interactions with conspecifics. Nonclinical human neuroimaging studies indicate that the mesolimbic DA response to primary rewards may operate similarly in humans in response to more abstract, or secondary, rewards such as monetary incentives. Recent evidence suggests a common ‘neural currency’ for coding monetary and primary (for example, food) rewards. Thus, most clinical studies investigating responses to rewards have used monetary incentives as a proxy for primary rewards, because money is adaptable to the research environment, may be parametrically scaled, may be won or lost, and may be delivered at precise intervals.
It should be noted that few of the preclinical and clinical studies reviewed here involve longitudinal data collection, and it is difficult to make any inferences about the developmental nature of reward-processing systems in the disorders reviewed. In this regard, although our goal is to propose a possible common framework for conceptualizing a range of seemingly disparate phenotypes and possibly to ultimately identify novel biological markers and influence nosological classification, inferences about etiology must be appropriately cautious in the context of largely cross-sectional data.
Substance-use disorders
Perhaps the greatest convergence of empirical evidence supporting reward-network dysfunction in psychiatry emanates from research on substance-use disorders. The 12-month prevalence estimates for substance-use and abuse disorder are about 3.8%. Contemporary theories addressing the pathophysiology of substance-use disorders highlight altered motivational states, cognitive control, inhibitory function, and decision-making, mediated in large part by dysfunctional output of mesolimbic and mesocortical brain systems. Although the scope of this review is constrained to a consideration of reward processes, rather than to related constructs such as inhibition and impulsivity, it should be noted that the ‘impulsivity hypothesis’ of addiction vulnerability stresses shared neurobiology and patterns of heritance between risk for addiction disorders and conduct disorder, including evidence of intergenerational transmission of both alcoholism risk and impulsivity in large-scale twin studies, and common patterns of enhanced behavioral sensitivities to reward stimuli and risky decisions.
The rewarding effects of drugs of abuse derive in large part from the sizeable increases in extracellular DA in limbic regions, and in the NAc in particular, during drug use. In addition, drug-induced increases in striatal DA have been linked with subjective feelings of euphoria. The firing of DA cells that accompanies drug use encodes a number of reward properties, including reward expectancy, reward learning, and the consolidation of contextual memories. All of these processes are believed to contribute to the intense motivation to attain drugs of abuse.
It has been proposed that the crucial mechanism for the development of addiction is drug-induced activation of DA transmission in the mesolimbic pathway, also referred to as the ‘dopamine hypothesis of addiction’. To better understand the neurobiology of drug abuse and addiction in humans, several animal models have been developed to investigate different aspects of drug addiction. Among these, the models that incorporate self-administration of drugs are thought to best capture the human condition because animals voluntarily seek drugs and because drugs that are self-administered by animals correspond well with those that have abuse potential in humans.
Preclinical models
From mechanistic neurobiological and behavioral studies in rodents, it has become clear that the mesolimbic pathway is a key component for the rewarding effect of drugs of abuse, and is essential for behaviors related to drug reward, salience, and motivation. For example, using rodent models, researchers have determined that nearly all psychoactive drugs of abuse (for example, cocaine, amphetamines, alcohol, opiates, cannabinoids, nicotine) induce alterations in the transmission of DA within the mesolimbic pathway, with most of these drugs increasing extracellular concentrations of DA. Studies using an in vivo microdialysis technique, which measures minute changes in brain neurotransmitter levels in the behaving animal, have shown that drugs of abuse can increase tonic DA concentrations in the NAc. In addition, studies using fast-scanning cyclic voltammetry, which can detect the level of DA release in the intact brain on a timescale of seconds, have shown an increased frequency of spontaneous phasic DA signals in the NAc in response to cannabinoids and nicotine in awake, behaving animals, and also temporally distinct DA signals in response to cocaine.
Dopamine neurotransmission is strongly implicated in the reinforcement of self-administering drugs or electrical stimulation in animals. The seminal animal research by Olds and Milner provided the initial foundation for our modern understanding of brain-reward mechanisms. In those pioneering studies, rats were given the ability to self-administer electrical stimulation to various brain regions including the mesolimbic pathway. The rats persistently and repeatedly chose to stimulate the VTA mesolimbic DA pathway (but not other brain areas), often to the exclusion of other behaviors. Behavioral studies in rodents also indicate that DA is essential for the self-administration of drugs of abuse for which the mesolimbic pathway has been identified as a crucial substrate. Drug self-administration is the ‘gold standard’ of animal models of drug abuse. In the typical drug self-administration procedure, animals obtain a drug by performing a simple behavior (such as pressing a lever), and animals will readily self-administer the same drugs that are abused by humans.
The importance of mesolimbic DA transmission to drug self-administration is supported by pharmacological and lesion studies. Direct DA receptor agonists can mimic the effects of substances of abuse, and these agonists are self-administered both systemically and locally into the NAc in rats and monkeys. By contrast, DA receptor antagonists administered systemically increase the rate of operant responding for cocaine in animals. In addition, lesion or inactivation of the mesolimbic DA system in the VTA or in the NAc decreases cocaine, amphetamine, heroin, and nicotine self-administration in rats. These findings indicate the crucial importance of the mesolimbic DA system in drug-taking.
Clinical studies
There is a confluence of clinical evidence that substance-use disorders are characterized by relative hyperactivation of mesolimbic regions in response to drug cues (that is, increased reward motivation). This pattern is evident across various subtypes of substance-abuse disorders, suggesting the central involvement of striatal regions encoding reward prediction and/or anticipation in substance-abuse disorders. Wexler and colleagues presented cocaine-addicted subjects with videotapes containing cocaine-associated cues, and reported relatively increased anterior cingulate cortex (ACC) activation during the presentation of the cocaine cues, despite decreased overall frontal lobe activation. Further, these effects were evident even in the absence of self-reported cravings, suggesting that brain-imaging effects did not simply recapitulate experiential responses to the cocaine cues “Buhler and colleagues” assessed anticipatory responses to cues predicting cigarette and monetary rewards in nicotine-dependent smokers and non-dependent occasional smokers. The non-dependent group showed relatively increased mesocorticolimbic reactivity to stimuli predicting monetary reward compared with stimuli predicting cigarette rewards, and subsequently spent relatively more effort to obtain money relative to cigarettes. By contrast, the nicotine-dependent group showed equivalent responses to both categories of reward cues, and anticipatory mesocorticolimbic activation predicted subsequent motivation to obtain both rewards, suggesting an imbalance in reward motivation in response to drug-predicting cues relative to monetary cues in those with nicotine dependence. Myrick and colleagues reported that activation in the NAc, anterior cingulate, and left orbitofrontal cortex in response to alcohol images predicted cravings in alcoholics. Oberlin and colleagues reported that the magnitude of striatal activation to alcohol cues (the odors of the preferred alcohol drink) in heavy drinkers was modulated by antisocial trait density. Finally, Filbey and colleagues showed that regular marijuana users who abstained from use for 72 hours were characterized by relatively increased reward-circuitry activity, including the VTA, thalamus, ACC, insula, and amygdala, in response to tactile marijuana cues. These studies reflect the overall pattern of data in a range of substance-abuse disorders, which shows relatively increased mesolimbic activation in response to drug cues, accompanied by increased states of reward motivation in response to these cues.
In contrast to the hyperactive responses of reward circuitry to drug-related cues, there is evidence that substance-use disorders are alternatively characterized by a reduced motivation for non-drug rewards. As a number of researchers have described, substance-use disorders are typically accompanied by decreased reward motivation for typical and non-pathological rewards, a phenomenon that has been variously termed ‘motivational toxicity’ and ‘reward-deficiency syndrome’. For example, Asensio and collegues reported hypoactivation of the dorsal and ventral striatum and the dorsomedial pre-frontal cortex when cocaine addicts viewed pleasant images not linked to substance cues. Gilman and Hommer reported subjective hypoarousal to normative positive images in alcohol-dependent participants. Bühler and collegues reported mesocorticolimbic hypoactivation during monetary-reward motivation in nicotine-dependent participants, which predicted motivation to obtain rewards. Andrews and colleagues reported decreased NAc activation to monetary-reward outcome that predicted family history of alcoholism. In a study using multi-modal psychophysiological measurements, Lubman and colleagues reported decreased arousal ratings and physiological measures of reward motivation to pleasant pictures relative to drug-cue images in opiate-dependent participants. Luo and colleagues found relatively decreased right ventral striatal activation during the anticipation of delayed relative to immediate monetary rewards in cigarette smokers (that is, decreased reward motivation for delayed monetary rewards). However, Jia et al. reported that treatment-seeking adults with cocaine dependence were characterized by striatal hyperactivation during monetary-reward outcome and that striatal activation during reward motivation predicted treatment outcome.
Attenuated motivation for non-drug rewards has also been reported in younger populations at risk for substance abuse. Schneider and colleagues found that adolescents with risky substance- use patterns had reduced striatal activity relative to low-risk adolescents during monetary-reward motivation[ Similarly, Peters and colleagues reported reduced ventral striatal responses during the anticipation of food reward in adolescent smokers. Notably, Andrews and colleagues found this effect in family members of those with substance abuse, suggesting that this pattern may be evident even in the absence of the direct effects of repeated drug use on the brain. Overall, these studies highlight that the effects of altered mesolimbic function in substance-use disorders may be characterized not only by increased reward motivation for substance-related stimuli, but also by decreased reward motivation for natural rewards (but there are exceptions), which may lead to increased drug-seeking behaviors. In this regard, Koob and Le Moal described an allostatic mechanism through which the reward system may become desensitized with repeated exposure to addictive drugs, due to gradual modulation of an organism’s ‘set point’ of responsivity to external rewards.
Molecular-imaging studies of substance-use disorders have focused on imaging the D2 post-synaptic receptor. There are multiple lines of evidence that cocaine dependence is associated with a decrease in D2 receptor binding, a pattern that seems to persist after disease remission. Decreases in D2 receptor binding have also been found in heroin addiction, alcohol dependence, methamphetamine abuse, prompting a number of researchers to posit that low D2 receptor availability may serve as a biomarker for substance abuse, potentially reflecting an altered sensitivity to various rewards. Although these molecular-imaging studies suggest decreased reward motivation in addiction that is consistent with the ‘reward-deficiency syndrome’ hypothesis of addiction, functional brain-activation studies paint a less consistent picture, probably due to variability in samples, task demands, patient characteristics, and unknown effects of a history of addictive behavior on functional responses to reward stimuli. Future research that combines molecular and functional imaging approaches will be necessary to elucidate the causes and consequences of altered reward processing in substance-use disorders in at-risk individuals.
Dopaminergic treatments
A number of agents that modulate functional output of DA systems are effective first-line treatments for substance-use disorders. Modafinil is a non-amphetamine stimulant with DA and glutamatergic effects, and with moderate effectiveness for the treatment of cocaine dependence and possibly methamphetamine dependence. Bupropion is a DA and norepinephrine reuptake inhibitor that is an effective treatment to promote smoking cessation. Dextroamphetamine causes release of DA (as well as norepinephrine and serotonin) and is an effective treatment for amphetamine abuse. Finally, risperidone, a D2-receptor antagonist, has shown promise for the treatment of methamphetamine abuse, and aripiprizole, a partial D2 agonist is a promising treatment for amphetamine abuse.
Affective disorders
Unipolar major depressive disorder (MDD) is associated with significant psychosocial and medical morbidity and mortality, and has an estimated lifetime prevalence of 14.6%. Anhedonia, the decreased response to pleasurable stimuli, is a defining symptom of the disorder to the extent that MDD may be diagnosed even in the absence of depressed mood if anhedonia and other secondary symptoms are present. Anhedonia is also a central feature of a number of neurobiological theories of depression that posit that deficits in emotional and motivational responses to appetitive stimuli are core features of the disorder, and the anhedonic endophenotype of MDD is perhaps the most well supported.
Preclinical models
Because anhedonia is a defining symptom of affective disorders, animal models of hedonic deficits have been addressed in preclinical models of affective disorders. Chronic mild stress has been reported to induce an anhedonic-like state in rodents,that resembles the affective disorder phenotypes in humans. In particular, Willner and colleagues originally reported that chronic and sequential exposure of rats or mice to a mild stress regimen caused decreases in responsiveness to rewards, commonly reported as a decrease in the consumption of and preference for sucrose solutions, and a decrease in the rewarding properties of pharmacological and natural rewards in the place preference behavioral paradigm. The chronic stress paradigm is considered to have a greater etiological relevance and face validity in mimicking MDD than other animal models, and therefore has become one of the most widely used preclinical paradigms of affective disorders. Chronic mild stress causes significant reductions in absolute and relative sucrose intake in rats, that is associated with a decrease in striatal DA activity, and is reversed after chronic antidepressant administration with imipramine. Decreased DA release to the NAc has been shown to occur after exposure to chronic repeated or an unavoidable stress regimen in rats, suggesting that stress significantly reduces mesolimbic DA transmission in rodent models. Altered DA function may also be related to changes in D1 receptors, which have been shown to alter functional output in the rat limbic system after chronic unpredictable stress. Therefore, stress-induced neurochemical changes, including decreased DA activity in the mesolimbic pathway, contributes to decreased natural reward (sucrose)-seeking in this animal model of affective disorders.
Clinical studies: unipolar major depressive disorder
Reward-system dysfunction in MDD is well established. Behavioral studies have reliably found that individuals with MDD show a blunted response to a range of rewarding stimuli. Reward learning has also been found to be impaired in MDD, and this impairment is correlated with the severity of anhedonic symptoms. Additionally, the severity of MDD has been found to correlate strongly with the magnitude of the rewarding effects of administration of oral D-amphetamine, which increases DA availability, and anhedonic symptoms in the general population predict rewarded effort-based decision-making.
Functional neuroimaging studies in MDD have consistently indicated hypoactivation in reward-processing regions, including the dorsal and ventral striatum and a host of other reward structures, including the medial prefrontal cortex, the pregenual and subgenual anterior cingulate, and the medial frontal gyrus.
Reduced mesolimbic activity in MDD has been found during reward anticipation and outcomes in both adults and children and during reward learning. For example, Smoski et al. reported that during a gambling task, outpatients with unipolar MDD had reduced striatal activation during reward selection, reward anticipation, and reward feedback (but see Knutson et al. for a report of intact striatal function but increased ACC activation in depression during reward anticipation). In a follow-up study, Dichter and colleagues reported that when these same patients were treated with behavior-oriented psychotherapy designed to increase interactions with potentially rewarding situations, striatal regions showed increased functioning during reward anticipation, similar to results of Forbes et al.. Finally, there is also evidence that reward-network function shows greater impairment in MDD while patients are processing pleasant images relative to monetary rewards.
Altered reward-network responsivity may also be characteristic of individuals with a history of MDD but without significant current symptoms, suggesting that anhedonia may represent a trait marker of MDD vulnerability, independent of current MDD state. McCabe et al. found decreased ventral striatal activation during reward outcome in response to the sight and flavor of chocolate in euthymic individuals with a history of depression, and Dichter and colleagues reported reward-network hyperactivation during reward anticipation and hypoactivation during reward outcomes in individuals with remitted unipolar MDD. Although studying patients with remitted depression is not sufficient to establish reward-processing deficit as a trait marker of depression, given that the effect of past illness and treatments on brain function may not be conclusively excluded, it is nevertheless a necessary initial step to identify this disease trait. It also has the advantage of mitigating the potential confounding effects of current mood state, illness severity, non-specific effects of chronic illness and stress, and effects of psychotropic medication usage. Thus, examining linkages between brain function and a history of MDD holds the promise of ultimately aiding in the identification of trait-like endophenotypic vulnerability markers predictive of MDD onset before clinically impairing symptoms appear.
Further converging evidence of the crucial role that reward-network functioning plays in MDD is found in literature documenting the remarkable consistency with which antidepressant response is predicted by pretreatment functioning of the ACC. The ACC plays a central role in processing positively valenced emotions and other rewards, and in coding value representations of anticipated rewards, as shown in studies of sleep deprivation, psychopharmacological intervention, cognitive behavioral therapy and a combined approach of therapy and psychopharmacological intervention.
Given the linkages between anhedonia, unipolar MDD, and mesolimbic dysfunction, and the prevalence of anhedonia in a number of other Axis I disorders, including bipolar disorder, schizophrenia, and post-traumatic stress disorder, an area of neglected study is the direct comparison between MDD and these other conditions. A notable exception is a study by Lawrence et al., in which euthymic and depressed patients with bipolar disorder and patients with unipolar depression viewed faces with varying emotional intensities. Whereas the bipolar group was characterized by differential ventral striatal responses to nearly all emotion categories, the unipolar group was characterized by blunted response to happy but not sad stimuli, suggesting that diminished reward outcome to pleasant stimuli may uniquely characterize unipolar MDD relative to bipolar MDD. Future three-group studies comparing MDD with other disorders characterized by anhedonia are needed to distinguish similarities and differences between these conditions with respect to processing reward stimuli.
Molecular-imaging studies of unipolar depression have reported decreased monoamine signaling, which is consistent with functional brain-imaging data suggestive of altered reward processing. In addition to a substantial body of literature on positron emission tomography (PET) addressing serotonin (5-HT)2 receptor density in depression, DAT-binding potential has received considerable attention. Dunlop and Nemeroff summarized the literature to date addressing molecular-imaging studies of DA signaling in MDD. These studies have indicated increased D2 receptor binding in the basal ganglia, striatum, and putamen, whereas other studies have reported lower or no difference in striatal D2 transporter binding potential.
Clinical studies: bipolar disorder
Bipolar disorder is a mood disorder characterized by one or more episodes of mania, defined as abnormally increased energy levels, cognition, and mood, and has an estimated lifetime prevalence estimate of around 1%. Mania has been conceptualized as a tendency to show heightened response to positive emotions and rewards, along with excessive goal pursuit and unrealistically high expectancy of success. It has been suggested that these symptoms may reflect upregulation of the mesolimbic DA system in bipolar disorder. Behavioral studies of response to rewards in bipolar disorder indicate deficits in behavioral adaptation to changing reward contingencies and prolonged elevation of mood in response to monetary reward in euthymic patients with bipolar disorder. Reward motivation is also atypical in individuals with bipolar disorder, as shown by a self-report measure of reward responsivity and in eye-tracking studies of monetary gains and losses.
Although functional MRI studies have identified prefrontal dysfunction in bipolar disorder and manic psychosis, evidence for abnormalities in reward-related neural network function in mania is scarce. Although several studies have suggested alterations in the shape, size and function of the basal ganglia in bipolar disorder, there are only three published functional neuroimaging research studies addressing responses to rewards in bipolar disorder. Abler et al. reported decreased NAc activation during monetary-reward outcome, a pattern that was not evident in a group of patients with schizophrenia scanned using the same paradigm. Lawrence and colleagues reported increased ventral striatal and ventral prefrontal cortical responses to mildly happy facial expressions in bipolar disorder. Finally, Jogia and colleagues reported relative ACC hyperactivation during reward processing in bipolar disorder. The paucity of functional brain-imaging research on reward processing in bipolar disorder is striking, given the increasing recognition of reward-system dysfunction in the related conditions of unipolar MDD and schizophrenia, and the conceptual linkages between the symptoms of mania and functions of striatal DA that have been suggested for nearly 20 years.
Molecular-imaging studies of striatal DAT availability in bipolar disorder generally suggest increased functional DA throughput (but Suhara et al. reported an exception). Amsterdam and Newberg reported higher striatal DAT binding in the right posterior putamen and left caudate in a small number of patients with bipolar disorder; Chang and colleagues reported that unmedicated euthymic subjects with bipolar disorder had significantly relatively higher whole striatal DAT binding; and Anand and colleagues reported relatively lower DAT availability in the dorsal caudate nucleus (DCN) bilaterally. There is also evidence that the presence of psychosis may moderate patterns of DA receptor binding. Specifically, striatal D2 receptor signaling seems to be greater in psychotic patients with bipolar disorder, whereas no differences in D2 availability were found between non-psychotic patients with bipolar disorder and controls.
Dopaminergic treatments
Bupropion, a DA and norepinephrine reuptake inhibitor, is an effective antidepressant that seems to specifically increase feelings of positive affect. Other examples of DA agents effective in the treatment of MDD include the selective D2/D3 receptor agonists pramipexole and piribedil the catechol-O-methyltransferase inhibitor tolcapone,, and the preferential presynaptic DA antagonist amisulpride,. Particularly relevant in the present context are previous reports that although both DA and non-DA agents can be used to effectively treat mood disorders, DA agents generally have superior effects on symptoms of anhedonia, specifically when compared with non-DA agents. Tremblay and colleagues reported that depressed patients had relatively greater increases in striatal and orbitofrontal cortex activation in response to emotional pictures after administration of dextroamphetamine (a stimulant associated with increased DA release). This highlights the crucial role that the selection of reward-relevant outcome measures will have for studies addressing the efficacy of DA agents in the treatment of mood disorders.
Eating disorders Preclinical models
Feeding is a complex process that involves a sensory response to the sight and smell of food, previous feeding experiences, satiety signals elicited by ingestion, and hormonal signals related to energy balance. DA release in specific brain regions is associated with pleasurable and rewarding events, and the mesolimbic system is thought to reward positive aspects of feeding. Some of the most elegant and informative studies clarifying the involvement of DA in feeding and other neurobiological functions come from the studies of Palmiter and colleagues. Zhou and Palmiter developed a DA-deficient mouse by genetically deleting tyrosine hydroxylase, the key enzyme required for the synthesis of L-3,4-dihydroxyphenylalanine (L-DOPA), the chemical precursor of catecholamines. These DA-deficient mice cannot make DA, and are born normal but fail to thrive, have decreased food intake, gradually become hypoactive and hypophagic, and die at 3 weeks of age. However, intervention and treatment of the mice with L-DOPA to restore striatal DA levels to 10% of the levels in normal mice is sufficient to elicit normal feeding behavior and animal survival. Moreover, restoration of tyrosine hydroxylase gene expression using gene therapy was able rescue the deficient feeding behavior in these DA-deficient mice. Using gene therapy to enable DA production within only the caudate putamen restored mouse feeding on regular chow diet, and also normal nest-building behavior, whereas restoration of DA production into the NAc only restored the exploratory behavior.
A salient result from these animal studies is that DA transduction in the central or lateral regions of the caudate putamen was sufficient to permanently rescue mice from the starvation that would occur inevitably without daily L-DOPA injections. However, restoration of DA into the NAc in these studies was not sufficient to rescue normal feeding behavior, but this may have been due to an inability to anatomically restore gene expression throughout the entire NAc. Interestingly, when the DA-deficient mice are crossed with obese leptin (Ob/Ob)-deficient mice, the lack of DA blocked the increased feeding behavior normally present in the leptin (Ob/Ob)-deficient mice. Taken together, the DA-deficient mouse studies indicate the essential requirement of DA for normal feeding behavior and survival.
In addition, there is extensive experimental evidence in animal contexts supporting a role for the mesolimbic reward pathway on appetitive and motivational behaviors. Mesolimboic DA release is associated with most pleasurable or rewarding events, and food is one type of reward that is often used during the training of animals. There is an increase in DA release (measured in awake, behaving animals by microdialysis or by fastscanning cyclic voltammetry) in the NAc in response to unexpected food rewards or stimuli that predict food rewards. Moreover, drugs that enhance operant responding for such food rewards, such as amphetamine, are most effective when administered into the NAc, whereas DA receptor antagonists administered into the NAc block the stimulant effects. Pharmacological control of the output from the NAc shell can also have profound effects on food consumption, as does surgical or chemical lesion of the nigrostriatal or mesolimbic DA pathways. These results suggest that DA release in the striatum is required to integrate relevant signals for sustained feeding. These studies emphasize the importance of DA transmission and the mesolimbic reward pathway for food consumption, feeding behavior, and food rewards in animal models.
Bulimia nervosa
Bulimia nervosa (BN) is an eating disorder characterized by recurrent binge eating followed by compensatory behaviors. It typically has its onset during adolescence, has an estimated prevalence of 1-2%, is more common in females, and is characterized by, among other features, impulse-control dysregulation. There is high comorbidity between BN and substance abuse, and there is a considerable body of data suggesting that disturbed appetitive behaviors for food in BN may reflect a dysregulation of reward mechanisms that is common to both BN and substance-abuse disorders. Indeed, early hallmark preclinical studies by Hoebel and colleagues highlighted commonalities between BN and addiction disorders in terms of neurobiology, psychopharmacology, neurochemistry, and behavior. Binge eating has also been suggested to serve an emotion regulatory function, and thus has many qualities of reward-mediated behaviors.
Clinical studies
There has been a small handful of functional neuroimaging studies of response to rewards in BN, with a wide range of rewarding stimuli presented. It is important to note that functional brain imaging studies in eating disorders have the methodological challenge of confounds associated with nutritional imbalances in affected individuals. One way to overcome this is to focus on individuals who are recovered from these disorders at the time of scanning, but it is important to note that such an approach may minimize the extent of brain responsivity differences that would characterize individuals meeting current criteria for this disorder.
Several studies have reported reduced reward motivation for food rewards in eating disorders. Joos and colleagues found reduced activation of the ACC in individuals with concurrent BN during the presentation of visual food cues, and Bohon and Stice reported trends towards decreased right insular cortex activation to the anticipated receipt of chocolate milkshake solution and in the right posterior and dorsal insula in response to milkshake consumption in women with BN. Other studies have found atypical responses during reward outcome for monetary and food rewards. Wagner and colleagues reported that women who had recovered from BN had equivalent DCN responses to monetary-reward outcomes, whereas CN responses in the control group were specifically linked to monetary gains relative to losses. Frank and colleagues reported decreased ACC reward outcome responses to the blinded administration of glucose in participants who had recovered from bulimia. By contrast, Uher and colleagues reported increased activation of the ACC, orbitofrontal cortex, occipital cortex, and cerebellum in response to food rewards in patients with bulimia; however, they did find hypoactivity in the lateral prefrontal cortex in patients with BN when compared with controls.
Several studies have included different patient groups relevant to eating disorders, allowing for identification of brain imaging patterns specific to different types of eating disorders. Schienle and colleagues examined reward outcome by presenting food images to overweight and normal-weight controls, overweight individuals with binge-eating disorder, and normal-weight individuals with BN. These authors reported increased medial orbital frontal cortex activation in the binge-eating disordered group, and greater cingulate cortex and insula activation in the bulimic group, relative to all other groups. Brooks et al. compared neural responses to food-reward outcomes in individuals with BN and with anorexia nervosa (AN), and found that individuals with BN had relatively greater activation in the dorsolateral prefrontal cortex, the insular cortex, and the pre-central gyrus. These studies compliment candidate genetic behavior investigations in BN that have reported altered allelic frequencies for the DAT gene and DA receptor genes in individuals with bulimia.
Molecular-imaging data addressing striatal DA function in BN are lacking. In the only preliminary study to be published, Tauscher and colleagues reported a 15% reduction in striatal DAT availability in BN, although the study included only sub-threshold cases and an unmatched control group.
Dopaminergic treatments
Only fluoxetine, which primarily affects serotonin, is approved by the US FDA for the treatment for BN. Of the numerous trials of the effects of psychopharmacologic agents for the treatment of BN, none has been primarily a DA agent.
Anorexia nervosa
AN is characterized by extremely low body weight, distorted body image, and fear of gaining weight, with an estimated prevalence of 0.7%. Watson and colleagues outlined a framework delineating linkages between AN and reward-processing deficits. Their model stressed the highly social nature of eating, the overlapping reward circuitry of gustatory and social stimuli, and the tendency of individuals with AN to deprive themselves of pleasure. Additionally, Zucker and colleagues described commonalities between AN and ASD in social and interpersonal impairments, suggesting that impaired social function and social motivation may be a novel framework to conceptualize core deficits of AN.
Clinical studies
Individuals with AN report a heightened response to both punishment and reward outcome, even in the absence of clinically significant symptoms of anxiety or depression. Fladung and colleagues assessed responses to images depicting a female body with underweight, normal-weight, and overweight canonical whole-body features. They reported higher ventral striatal activation during processing of underweight images compared with normal-weight images in women with acute AN, but the reverse pattern in the control group. Joos and colleagues also reported hyper-reactive reward-outcome responses in anorexia during the processing of food-reward images.
A small handful of studies have directly compared reward responses in AN and bulimia. Wagner and colleagues reported increased CN activation to monetary-reward outcomes in women recovered from anorexia, and relatively equivalent CN responses to monetary gains and losses (a strongly similar pattern of results to that found by Wagner et al. in bulimia in), suggesting possible similarities in reward-circuitry response in AN and bulimia. Uher and colleagues also found similar brain-activation patterns in individuals with AN and bulimia, with both groups showing hyperactivation relative to controls in areas relevant to reward processing, including the ACC and the orbitofrontal cortex.
However, other studies have emphasized brain-activation differences during reward outcome between anorexia and bulimia. Brooks and colleagues found that in response to food-reward outcomes, individuals with anorexia had greater activation of the dorsolateral prefrontal cortex, the cerebellum, and the right pre-cuneus relative to controls. They also had greater activation of the caudate, superior temporal gyrus, right insula, and supplementary motor area, and greater deactivation in the parietal lobe and dorsal posterior cingulate cortex relative to those with bulimia. It should be noted that this study did not include a non-food-reward condition, a design feature that would be necessary to assess the functional integrity of brain-reward systems to different classes of rewards.
Interestingly, individuals at risk for an eating disorder (that is, those with higher dietary restraint) have enhanced anticipatory responses to food rewards in the orbitofrontal cortex and the dorsolateral prefrontal cortex, suggesting that hyperactive functioning of anticipatory reward processing may be a risk factor for eating disorders. Complimenting these functional magnetic resonance imaging (fMRI) studies is a report of higher 11 C-raclopride binding potential in the ventral striatum in women who were recovered from AN, suggesting that DA activity is enhanced in this population, and significant relations between multiple DRD2 polymorphisms and AN.
Dopaminergic treatments
Psychopharmacologic treatments for AN have yielded only moderate success, and the majority of treatments are antidepressants that act primarily on non-DA systems. A small number of double-blind trials have evaluated the effects of antipsychotics, with essentially non-significant effects.
Schizophrenia
Schizophrenia is a complex and debilitating disorder that typically emerges in late adolescence and early adulthood, and is characterized by hallucinations and delusions (positive symptoms), social withdrawal, alogia, and flat affect (negative symptoms), and cognitive disabilities, and has an estimated lifetime prevalence of 1%. Anhedonia has been hypothesized to be a core feature of schizophrenia, and it has been suggested that individuals with high levels of social anhedonia are more likely to develop schizophrenia-spectrum disorders, although the link between anhedonia and the so-called schizophrenia prodrome has not been firmly established. The centrality of incentive motivation deficits to schizophrenia is suggested by the long-standing hypotheses regarding the role of DA disturbances in the pathophysiology of the disorder.
Preclinical models
The DA hypothesis of schizophrenia suggests that excess DA transmission may be pro-psychotic, and originally gained support from pharmacological evidence that drugs that decrease DA activity (for example,, the phenothiazine neuroleptics) are antipsychotic, whereas drugs that promote DA activity (for example,, amphetamines) are psychotomimetic. Indeed, the medications that have proven successful for treating schizophrenia/psychosis are drugs that primarily antagonize D2 receptors; however, most clinically effective antipsychotics also exhibit a myriad of other actions that contribute to both therapeutic and side-effect profiles.
Current models of schizophrenia suggest that the disorder is due to both common and rare gene mutations, copy-number variations, and possibly epigenetic factors, all of which can affect multiple brain neurotransmitter systems and multiple risk genes. Using pharmacological and genetic approaches, animal models have been developed for schizophrenia, which manipulate or alter mesolimbic DA transmission as a means to understand the disease and/or test therapeutic strategies.
In rodent models, hyperlocomotive behaviors and disruptions in the pre-pulse inhibition (PPI) response (a measure of sensorimotor gating) are generally viewed as being psychotomimetic, as both hyperlocomotion and disrupted PPI can be normalized and attenuated by antipsychotic medications. However, no current behavioral paradigms truly capture the positive symptoms of schizophrenia (such as hallucinations and delusions). PPI is a cross-species measure that refers to the ability of a non-startling ‘pre-stimulus’ to inhibit the response to a startling stimulus. There have been numerous reports of PPI deficits in patients with schizophrenia; however, exactly which endophenotype in schizophrenia is manifested as disrupted PPI remains debated. Swerdlow and colleagues persuasively suggested that PPI deficits are a useful psychophysiological outcome for basic studies in humans and animals to probe neural circuitry and as a pharmacological screen. Indeed, PPI testing is commonly used in screening for potential antipsychotic drugs that act via antagonism of mesolimbic DA transmission. Studies in mice have indicated that administration of direct-acting DA agonists (such as apomorphine) and indirect DA agonists (such as cocaine) to mice disrupt PPI primarily via D1 receptors, whereas D2 receptors seem to modulate amphetamine-induced PPI deficits. By contrast, both apomorphine-induced and amphetamine-induced PPI disruptions in rats are blocked by DA D2 antagonists. In addition, normalizing PPI deficits in rodent models has enabled drug discovery for potential antipsychotic medications, some of which have proven successful in treating schizophrenia.
Mice lacking the DAT gene display markedly increased levels of DA in the mesolimbic system and striatum, that results in hyperlocomoter behaviors and also deficits in PPI. The DAT knockout mice phenotypes resemble amphetamine-like effects, and both hyperlocomotion and PPI deficits can be reversed with either D1 or D2 receptor antagonists, the atypical antipsychotics clozapine and quetiapine, various antidepressant drugs, and monoamine transporter inhibitors. Thus, the DAT knockout mouse may be a useful animal model for predicting the efficacy of novel drugs for disorders such as schizophrenia that are characterized by a dysregulated limbic DA system.
In alignment with the DA hypothesis of schizophrenia, an increased level of striatal D2 receptors has been seen in patients with schizophrenia who are not on medication, which may result in D2 receptor supersensitivity in the ventral striatum contributing to psychosis. Kellendonk et al. attempted to model this D2 receptor elevation in genetically engineered mice, in which they transiently and selectively overexpressed D2 receptors in the striatum including in the caudate putamen, the NAc, and olfactory tubercle. It was found that 30% of striatal MSNs overexpressed these engineered receptors, thereby elevating the D2 receptor level to about 15% higher than that of normal mice. To study the behavioral consequences of D2 receptor upregulation in the striatum, the mice were analyzed using a battery of behavioral tasks, and were shown to have several abnormal cognitive phenotypes, including working-memory deficits, reversal-learning impairment and decreased social interactions. In a follow-up study, Li and colleagues reported that this D2 receptor overexpression in the striatum causes an increase in the firing activity of layer V cortical pyramidal neurons, and also a decrease in both the frequency and amplitude of spontaneous inhibitory post-synaptic currents, indicating reduced inhibitory transmission in the prefrontal cortex. Taken together, the mouse model suggests that overexpression of D2 receptors (similar to that seen in some individuals with schizophrenia) will alter striatal MSN activity, resulting in dysregulated GABA transmission and inhibitory activity in the cortex. Because a core symptom of schizophrenia is cognitive impairment (for example, deficits in working memory, attention, executive function), this mouse model may provide a link explaining how altered mesostriatal and mesolimbic DA receptors and DA transmission can alter cognitive processes in the frontal cortex, possibly by dysregulating circuit pathways that link connectivity between the striatum and pre-frontal cortex. The reader is referred to other seminal reviews of schizophrenia animal models that highlight altered DA and reward-pathway transmission.
Clinical studies
Patterns of responses to rewards by patients with schizophrenia are complex. Patients report normal intrapsychic emotional experience, but communicate symptoms of anhedonia during structured interview. Individuals with schizophrenia show diminished positive and negative emotions in response to emotional movie clips, food, and social exchange, even when taking medication. However, individuals with schizophrenia also report similar or heightened subjective emotional experience, including in response to movie clips, pictures, food, and even odors.
In contrast to the mixed self-report and interview profiles of hedonic capacity in schizophrenia, psychophysiological studies of patients with schizophrenia indicate comparable or more exaggerated facial responsivity to positive and negative stimuli, assessed via facial electromyography, skin conductance, and affective modulation of the startle eyeblink response. These lines of evidence suggest that schizophrenia is characterized by deficits in the expression of pleasant emotions but not in the experiential or physiological components of emotions.
Studies that have differentiated between reward motivation and reward outcome in schizophrenia have found mixed results. Although some studies have found that individuals with schizophrenia are impaired during reward motivation and outcome, others have not found a selective impairment in reward motivation. This discrepancy may be attributable to different levels of symptom severity in the patients sampled, as there is some evidence that the severity of clinical symptoms is correlated with reward motivation and outcome processing in schizophrenia.
Behavioral studies of reward learning have reported that sensitivity to reward is intact in schizophrenia, but deficits are evident in rapid reward learning on the basis of trial-to-trial feedback, such as reversal learning, and in reward-related decision-making. However, reward learning may be typical in schizophrenia over longer learning trials, and in individuals with less severe symptoms. Overall, however, studies of reward learning in individuals with schizophrenia are consistent with the framework that patients with schizophrenia have intact hedonic responses but impaired motivation and reward representation, leading to a failure to motivate their behavior for rewards.
Neuroimaging studies of responses to rewards in schizophrenia generally suggest decreased NAc activation during monetary-reward anticipation (but seefor an exception) in both patients taking medication and patients not taking medication. However, there is also evidence that these effects may be mediated by the predictability or certainty of rewards, as individuals with schizophrenia have reduced activation of the ventral striatum to unexpected reward outcomes, but have enhanced responses to expected rewards. There is also evidence of inverse relations between negative symptoms and NAc activation during reward anticipation and between lateral PFC activation during reward outcomes. Waltz et al. used computer simulations to show that the reward-processing deficits in schizophrenia are consistent with impaired functioning of DA. A handful of studies also suggest that striatal responses during monetary anticipation in schizophrenia are partially normalized by the antipsychotic, olanzapine but not by other antipsychotics, suggesting that this neural signature may be a state, rather than trait, marker of schizophrenia. Finally, Grimm and colleagues reported reduced striatal activation in schizophrenia to food cues when medication dose and weight were used as covariates, highlighting a possible mechanism underlying weight gain in schizophrenia.
Molecular-imaging evidence indicates dysregulated striatal DA function in schizophrenia. A meta-analysis of 17 studies found significant elevation of striatal D2 receptors in patients with schizophrenia who were not being treated with medication, although no consistent clinical correlates of this pattern were evident. Studies have also suggested an increased affinity of D2 receptors for DA in schizophrenia, that may produce a D2 receptor supersensitivity in the NAc contributing to psychosis. Additionally, a PET study found higher synaptic DA concentrations in the ventral striatum in schizophrenia.
Dopaminergic treatments
First-line treatments for schizophrenia include DA D2 receptor antagonist agents that primarily treat so-called positive symptoms. First-generation compounds, such as chlorpromazine and haloperidol, work primarily as D2 receptor antagonists. Second-generation, or ‘atypical,’ antipsychotics, such as clozapine (which has affinity for D2 and D4 receptors), risperidone, olanzapine, and quetiapine, primarily affect DA and 5-HT systems, but with markedly reduced extrapyramidal side effects. Finally, third-generation antipsychotics, such as aripiprizole, are partial D2 receptor agonists with high affinity and low intrinsic activity, and these drugs may act as ‘DA stabilizers’ because of their ability to stabilize, rather than simply upregulate or downregulate functional output of DA systems.
Attention-deficit hyperactivity disorder
ADHD is characterized by symptoms of inattention, hyperactivity, or impulsivity that produce impairment in cognitive, behavioral, and interpersonal domains Although for many years ADHD was believed to be a disorder of childhood and adolescence, it is now recognized to occur also in adulthood.ADHD affects approximately 8 to 9% of school-aged children and 4 to 5% of adults. ADHD is characterized by symptoms of age-inappropriate inattention, impulsiveness, and hyperactivity. It disrupts academic and social development, and is associated with considerable psychiatric comorbidity, including impaired academic, occupational, and social functioning, increased rates of substance abuse and traffic accidents, and persistent neuropsychological impairments.
Dysregulated reward processing has been proposed as a central mechanism in prevailing theoretical models of ADHD. The ‘DA transfer deficit’ theory of ADHD highlights altered phasic DA responses to cues that predict rewards, resulting in decreased conditioning to reward cues, blunted reward anticipation, weaker influence of rewards on behavior, and ultimately poorer behavioral control. This model explains not only empirical brain-imaging data of reward processing in ADHD (reviewed below) but also the consequences of these processes on motivated behaviors.
Clinical genetics studies have indicated that multiple genes are important in the development of ADHD. Recent meta-analyses of candidate gene association studies have found consistent evidence of significant associations between ADHD and polymorphisms in several candidate genes that are almost exclusively involved in the regulation of dopaminergic and serotonergic transmission (including the dopamine transporter (DAT1) gene, the dopamine D4 receptor (DRD4) gene, the dopamine D5 receptor (DRD5) gene, the serotonin transporter (5-HTT) gene, the 5-hydroxytryptamine receptor 1B (HTR1B) gene, and synaptosomal-associated protein 25 (SNAP25). Among these, perhaps the most commonly replicated risk gene associations were reported for DAT1 and DRD4; however, even for these genes, substantial population heterogeneity is seen in ADHD.
Preclinical models
Animal models of ADHD are expected to show phenomenological similarities to the clinical condition and mimic aspects of the three core symptoms of the disorder; that is, hyperactivity, impulsivity, and impaired sustained attention. In addition, proof of predictive validity of ADHD animal models often includes evidence of improved behavioral outcome after treatment with effective ADHD therapeutics, including stimulants such as methylphenidate and amphetamine (reviewed below) which increase DA transmission and levels by reuptake inhibition of monoamine transporters.
Two commonly used ADHD rodent models are the DAT transgenic knockout mouse model and the spontaneous hypertensive rat (SHR) model, both of which exhibit altered mesostriatal DA transmission and model some aspects of ADHD behavior. Mice lacking DAT have increased dopaminergic tone and represent a genetic animal model in which certain endophenotypes of ADHD can be recapitulated. In DAT knockout mice, DA is cleared very slowly from the synaptic cleft, causing a five fold elevation of extracellular DA in the striatum (that is, a hyperdopaminergic state). DAT knockout mice have been suggested to model ADHD because they are hyperactive (), have reduced extinction of responses in food reinforcement operant tasks, and also have impaired learning and memory. However, DAT knockout mice provide an extreme model because only a mild reduction in midbrain DAT binding has been seen in human adolescents with ADHD, and the model also does not agree with several studies have that found increased DAT in the striatum of children and adults in ADHD. Nonetheless, the DAT knockout mouse provides very useful information concerning the neurobiological consequences of impaired DAT function which present as ADHD-like behaviors.
The most widely studied rodent model of ADHD is the inbred SHR. The SHR is a convincing model to study because these rats have been shown to display many behavioral characteristics apparent in ADHD, including poor performance in sustained attention tasks, hyperactivity, impulsivity, sensitivity to delay, and increased variation in performance of operant tasks. Impulsivity is seen in SHR as an inability to inhibit a response during the extinction phase of an operant task, and an inability to delay a response in order to obtain a larger reward. It seems that the SHR exhibits these ADHD-like behaviors due to a genetic alteration in the DAT gene. The SHR possesses a 160-bp insertion in the noncoding region upstream of exon 3 of the DAT gene, which is of significance because a variable number of tandem repeats in the 3′-untranslated region of the DAT gene has been associated with ADHD in several family studies. DAT gene expression is transiently reduced in the SHR midbrain during the first month after birth, and increased in adult SHR compared with controls, which results in abnormal mesostriatal DA transmission in the rats during postnatal development, and possibly in adulthood. In addition, several other animal models have informed ADHD research; many of these models have implicated mesolimbic DA transmission as a feature underlying ADHD-like behaviors. The reader is encouraged to see other comprehensive reviews.
Clinical studies
Etiological models addressing cognitive dysfunction in ADHD have focused on altered reward sensitivity, including diminished influence of reward on skills, now-versus-later decision-making, and altered sensitivities during reward learning. Altered reward processes are mediated via alterations in DA and other catecholamine function in ADHD. Individuals with ADHD display a range of reward deficits, including impaired behavioral modification to rewards. A classic finding in childhood ADHD is hypersensitivity to reward delays (that is, "delay aversion"), which is independent of inhibitory deficits yet correlates with hyperactivity symptom severity. The ‘dynamic developmental theory’ of ADHD put forth by Sagvolden and colleagues hypothesizes that downregulated frontolimbic DA results in lower tonic DA, a steeper and shorter delay-of reward gradient, and ultimately increased impulsivity and slower extinction of impulsivity. Longer delays between a behavior and its consequence then result in relatively reduced effects of the consequence for exerting control over the behavior in ADHD.
Although individuals with ADHD may report enhanced reward outcome responsivity, behaviorally, individuals with ADHD display a range of motivational deficits, including impaired behavioral modification in response to rewards, enhanced motivation for larger but riskier rewards, and decreased motivation for social rewards.
Although the majority of fMRI studies in ADHD have focused on attentional processes, such as cognitive control and response inhibition, a smaller subset of studies have focused on reward processing. Such studies have direct conceptual linkages to the constructs of impulsivity and delay aversion that are core features of the disorder. These studies have shown decreased ventral striatum activation during monetary-reward anticipation, atypical orbitofrontal activation during monetary-reward outcome, and decreased DCN and amygdala activation during delayed reward outcome. Children with ADHD have reduced NAc activity when anticipating monetary rewards, which is seen particularly in drug-naive children, in carriers of the DAT nine-repeat allele, and in response to seeking gains rather than avoiding losses. This pattern is present during cues of both immediate and delayed rewards. Plichta and colleagues also found relations between striatal responsivity to immediate and delayed rewards and ADHD symptom severity. Furthermore, a negative correlation between NAc activation during reward motivation for a range of rewards (monetary, verbal feedback, and loss avoidance) and the number of reported ADHD symptoms was found in the general population. Finally, a study by Wilbertz and colleagues found decreased differentiation between high-incentive and low-incentive rewards in the medial orbitofrontal cortex and in physiological arousal in patients with ADHD that correlated with risky decision-making and delay-discounting.
Molecular-imaging studies in ADHD suggest that impaired frontostriatal activation to rewards in ADHD may be linked to altered DA transmission. Ernst and colleagues found relatively higher right midbrain accumulation of 18 F-DOPA in children with ADHD, that was correlated with symptom severity, and a study of children with ADHD by Volkow et al. found lower specific DA binding to DATs and to D2 and D3 receptors in the NAc, midbrain, and left caudate, with D2 and D3 receptor binding in the NAc, midbrain, caudate, and hypothalamus significantly related to inattention symptoms. A follow-up study showed that decreased DA binding to these receptors was also correlated with lower scores of self-reported motivation. Levels of tonic and phasic DA have also been found to be lower in individuals with ADHD whereas the density of DATs, which downregulate DA activity, is higher in ADHD.
Dopaminergic treatments
Methylphenidate is the most commonly prescribed medication for childhood ADHD, and has binding affinity for both the DA and norepinephrine transporters. D-amphetamine is the major pharmacological ingredient in dextroamphetamine and lisdexamfetamine dimesylate, and both are believed to exert their therapeutic actions by enhancing the function of noradrenaline and DA. Finally, bupropion has been used off-label for treating ADHD, yet it has been shown to have only very moderate efficacy for treating core ADHD symptoms.
Obsessive–compulsive disorder
OCD has an estimated prevalence of 1 to 3%, and is characterized by recurrent anxiety-provoking thoughts or impulses (obsessions), typically followed by repetitive ritualistic behaviors to relieve anxiety (compulsions). Although OCD is formally classified as an anxiety disorder, it has many phenotypic features resembling addictive behaviors, including tolerance and withdrawal-like behaviors, suggesting linkages between core symptoms and reward-circuitry processes. Indeed, it has been theorized that compulsive behaviors may persist at least in part due to the rewarding effects of anxiety-reduction that accompanies them, and that OCD should be labeled as a disorder of behavioral addiction rather than as an anxiety disorder in the DSM-V. Although OCD is grouped here as a psychiatric disorder (rather than a neurodevelopmental disorder), it is important to note that it is commonly seen in both children and adults.
Preclinical models
Animal models of OCD have focused on studying obsessive-like behaviors related to grooming and repetitive movements. In mice, the neural substrate for the stereotyped grooming sequence (whisker grooming or coat grooming) lies in several brain regions including the brain stem and the striatum, where the striatum is thought to regulate the initiation and modulation of these grooming behaviors.
Profiles of DAT knockout mice indicate involvement of altered mesolimbic DA transmission in OCD. DAT knockout mice show an overall increased level of DA transmission, resulting in increased DA tone, hypermotoric activity, and overall increased movement. The DAT knockout mice also have stronger and more rigid self-grooming patterns, with mutants displaying sequential super-stereotypy, evidenced by having more stereotyped and predictable self-grooming sequences. Synapse-associated protein 90/PSD-95-associated protein (SAPAP)3 is a post-synaptic scaffolding protein at excitatory synapses, that is expressed at high levels in the striatum. An engineered genetic knockout of SAPAP3 in mice increases anxiety and compulsive grooming behaviors, leading to facial hair loss and skin lesions, providing a genetic animal model for OCD-like behaviors. SAPAP3-deficient mice have dramatically increased grooming bouts, and spend significantly more time self-grooming than their genetically normal littermates. Physiological studies indicate that the mutant mice have multiple deficits in the excitatory synapses of the striatal MSNs, including increased striatal excitatory and NMDA-dependent neurotransmission.
Also related to genetic mouse models of OCD are the Slitrk5 knockout mice. Genetic deletion of Slitrk5 in mice also results in excessive grooming associated with facial hair loss and skin lesions and with impaired corticostriatal neurotransmission. Although evidence for a direct disruption in mesolimbic transmission in SAPAP3 and Slitrk5 knockout mice has not been reported, the altered excitatory transmission apparent in the striatum may also dysregulate the reward pathways.
Clinical studies
Behaviorally, patients with OCD show evidence of impaired reward learning and impaired performance on gambling tasks that predict pharmacologic treatment response. Despite the overlap of OCD and substance-use disorders in terms of phenotype, neurobiology, comorbidities, and neurochemistry, few empirical studies have directly assessed reward-system integrity in OCD. Using a monetary incentive-delay task, Jung et al. found increased frontostriatal activation during monetary-reward outcome, and decreased lateral prefrontal and inferior parietal cortex activation during loss anticipation, but no group differences during monetary-reward anticipation. However, Figee and colleagues did find relatively decreased NAc activity during reward anticipation in OCD, particularly in those patients with contamination fear. Finally, Pena-Garijo and colleagues found that individuals with OCD had reduced activity in the ACC and the CN during a reward-learning task. Clearly, more research is needed in this area, in particular studies of mesolimbic responses to disease-relevant stimuli and studies of the relationships between brain function in response to reward stimuli and treatment outcomes.
A review of PET studies by Whiteside et al. indicated differences in radiotracer uptake in the orbital gyrus and the head of the CN in patients with OCD, and a quantitative, voxel-level meta-analysis of functional MRI findings by Menzies and colleagues reported abnormalities in the orbitofronto-striatal regions in OCD. A recent review and meta-analysis of in vivo imaging studies assessing striatal DA systems in OCD found evidence of reduced D2 receptor binding in the neostriatum and ventral striatum, and reduced D1 striatal receptor binding.
Dopaminergic treatments
Although the most widely prescribed agents to treat OCD are tricyclic antidepressants and selective serotonin reuptake inhibitors, these agents show a 40 to 60% inadequate response rate. Recently, second-generation antipsychotic agents have shown benefit, either alone or as adjunctive therapy. Specifically, high-dose olanzapine, quetiapine, and risperidone have all shown at least minimal clinical benefit relative to placebo treatment. Finally, reports that the ventral striatum is an effective target for deep brain-stimulation treatment in OCD, particularly in patients identified as otherwise treatment-resistant, further implicates the mesolimbic DA system in OCD.
Autism spectrum disorders
ASDs affect up to 1% of the general population, and are characterized by a triad of symptoms that includes impaired communication, social impairments, and restricted and repetitive behaviors and interests.
Preclinical models
Studies aimed at modeling, in animals, the core phenotypes associated with ASDs have focused on studying social and repetitive behaviors in mice and pair-bonding behaviors in the prairie vole (Microtus ochrogaster). Although there is no clinical evidence supporting disordered attachment profiles in autism, these rodent models may provide a bridge to define and translate the neurobiology of mammalian social behavior into a better understanding of ASD. As discussed in greater detail below, there is compelling evidence that the mesolimbic DA pathway is altered in a mouse model of FXS, and that DA signaling in the NAc is important for social pair bonding in the prairie vole, suggesting that altered reward processing can influence social behaviors.
The study of social bonding in the prarie vole is one animal model that has informed preclinical studies relevant to ASDs. Prairie voles display characteristics associated with a monogamous lifestyle, including a lack of sexual dimorphism, biparental care of offspring, and the formation of pair bonds between males and females. In the laboratory, male and female prairie voles show a robust preference to pair-bond and associate with a familiar partner, and the neurobiology and behavior of this social-bonding attachment has been studied extensively. Vole pair bonds can be assessed by testing for partner preference, a choice test in which pair-bonded voles regularly prefer their partner to a conspecific stranger. Several studies have indicated that mesolimbic DA pathways regulate vole pair-bonding and social behaviors. After extended cohabitation with a female, male voles show behaviors indicative of pair-bond maintenance, including selective aggression towards unfamiliar females. These voles also show a significant upregulation in NAc D1-like receptors, and blockade of these receptors abolishes the selective aggression of the males toward unfamiliar females. Mating between voles can facilitate partner preference formation, and is associated with increased extracellular DA in the NAc. This partner preference can be blocked by microinjection of the D2 antagonist eticlopride into the NAc (but not the prelimbic cortex), whereas the D2 agonist quinpirole can facilitate formation of vole partner preferences; decreasing NAc cAMP signaling probably underlies these effects of D2 receptors. Interestingly, in a comparative study of monogamous versus promiscuous voles, the monogamous voles exhibited increased mesolimbic DA release into the NAc in response to amphetamine, suggesting increased DA release or clearance in the monogamous species. However, when amphetamine or a selective D1 receptor agonist was administered systemically to male voles, this interfered with mating-induced pair bonding, and this disruption seems dependent on D1 receptor activation. Taken together, these prairie-vole social-bonding studies indicate that the mesolimbic DA is essential for the social pair-bond with D2-like receptors in the NAc.
Other neurotransmitter systems seem to converge within the NAc to modulate and control vole social-bonding behavior. For example, activation of cortisol-releasing factor (CRF) receptors by microinjections of CRF directly into the NAc accelerates partner preference formation in male prairie voles. Oxytocin transmission and oxytocin receptors in the NAc seem to facilitate maternal behavior in female voles. Furthermore, prairie voles have higher densities of NAc oxytocin receptors than is found in nonmonogamous vole species, and blocking NAc oxytocin receptors prevents partner-preference formation. These studies suggest that oxytocin facilitates affiliation and social attachment.
Although the challenge remains to translate these observations and mechanisms from rodents to human autism studies, these animal model findings have had a significant influence on our understanding of mammalian social behaviors, and have generated testable hypotheses about the reward system and underlying molecular neurobiology. The reward-system involvement in social engagement and social-bond formation may also have implications for understanding the core social deficits characterizing ASDs.
Clinical studies
A number of theorists have suggested that the social-communication deficits that characterize ASDs reflect decreased motivation to engage in reciprocal social behaviors in infancy and early childhood, which may ultimately result in fewer experiences with social sources of information. Because children with ASD may lack the motivation to participate in activities in which social skills are typically forged, the resulting relatively impoverished social environment may further compound the social impairment caused by low social motivation, and further negatively influence the development of social cognition and language skills. Consistent with this model, very young children with ASD display decreased orienting to social stimuli, and atypical social orienting has been shown to predict decreased social competence in adolescents and young adults with ASDs. There is also evidence that social motivation remains impaired in individuals with ASD despite growth in other areas of cognitive development. For instance, older children with ASDs report experiencing less pleasure from social rewards, and social stimuli are relatively less salient for individuals with ASD. More generally, individuals with ASD have been found to report lower levels of reward responsivity, and behavioral studies have also found evidence for impaired reward learning in individuals with ASD.
However, despite the accumulating evidence for reward-processing deficits in ASD, relatively few published studies have assessed the neural bases of reward processing in this population, and results of these studies are decidedly mixed. Schmitz and colleagues investigated the neural substrates of reward learning in the context of a sustained attention task with monetary rewards, and reported decreased activation in the left anterior cingulate gyrus and left midfrontal gyrus on rewarded trials in patients with ASD. They also found that activity in the anterior cingulate gyrus during this task was negatively correlated with social ability, supporting the hypothesized link between that reward-processing dysfunction and the core social impairments in ASD. Scott-Van Zeeland and colleagues investigated the neural correlates of implicit reward learning in children with ASDs using both social and monetary rewards. They found diminished ventral striatal response during social-reward outcomes and also, but to a lesser extent, with monetary-reward outcomes. Activity within the ventral striatum was found to predict social reciprocity within the control group but not the ASD group. This finding is consistent with previous research examining the effect of reward type on task performance, which indicates that children with ASD may be less motivated by social than non-social rewards. Dichter and colleagues recently reported results of an fMRI study of reward anticipation and outcome using monetary and social (faces) rewards within the context of an incentive-delay task. The ASD group displayed bilateral amygdala hyperactivation during face-reward anticipation and bilateral insular cortex hyperactivation during face-reward outcomes. Further, activation in the left and right amygdala during face anticipation predicted the severity of social impairments in the ASD sample.
EEG and event-related potential (ERP) studies have largely supported these fMRI findings. Kohls and colleagues examined responses in children with ASDs during a rewarded go/no-go paradigm involving social (smiling faces) and monetary rewards, using an ERP marker of reward-system activity. In the ASD group, they found unimpaired behavioral task performance but a decreased response to reward conditions that required an active response for both social and monetary rewards A recent EEG study found evidence of relatively decreased left-sided frontal EEG activity in response to faces, a pattern suggestive of decreased motivational approach) By contrast,, Larson and colleagues reported that an ERP marker of reward processing was unimpaired in ASD, highlighting the need for future research to examine differential brain activation to reward gains and losses in ASD.
Restricted and repetitive behaviors and interests are also a core symptom of ASDs, and a number of etiologic models of repetitive behaviors highlight that reward-processing deficits may bias attention and exploration towards non-social aspects of the environment. This general behavioral tendency may ultimately lead to the development of stereotyped movements and circumscribed interests that characterize ASDs. To investigate the hypothesis that reward-processing dysfunction in ASD may contribute to the development of circumscribed interests, Dichter and colleagues conducted a fMRI study in which stimuli reflecting circumscribed interests were presented to individuals with ASDs within the context of an incentive-delay task. The ASD group showed decreased NAc activation during monetary-reward anticipation, but ventromedial prefrontal cortex hyperactivation when viewing the circumscribed interest reward outcome, suggesting that ASDs are characterized by reward-circuitry hypoactivation in response to monetary incentives but by hyperactivation during circumscribed interest reward outcomes.
Manipulating the consistency, immediacy, or saliency of rewards has been a central feature of long-standing effective behavioral interventions for ASD. Such programs are designed to scaffold reward understanding for children with ASD to ultimately alter behavior and enhance learning. Even with this scaffolding, however, reward-based interventions are not successful for all children with ASD, and there is some evidence that individual differences in reward motivation may predict differences in response to treatment. Such variability suggests an urgent need to identify neurobiological markers to aid in the prediction of responses to reward-based behavioral interventions in ASD, and to understand how these markers may be functionally related to behaviors relevant to treatment success.
Aberrant serotonin function has consistently been linked to genetics, neuropharmacology, and brain metabolism of individuals with ASD. There are few studies of striatal DA binding in ASD, and to date there has been no consistent evidence of striatal DAT-binding differences in ASD, although a recent study with a relatively large sample found evidence of higher DAT binding in the orbitofrontal cortex in ASD. Ernst and colleagues found reduced ventromedial prefrontal cortex DA metabolism in children with ASDs, whereas Nieminen-von Wendt and colleagues found no such evidence. A small pilot study of 13 children with ASDs who received a 6-month course of fluoxetine treatment showed that good clinical responders had a significant decrease in striatal DAT binding, suggesting that studies of modulation of striatal DAT binding may be relevant to understand potential mechanisms of action of treatments for ASD, even when such treatments do not primarily affect DA systems.
Dopaminergic treatments
Although SSRIs have been a promising class of agents to target repetitive behaviors in ASD (but inefficacy has also been reported), the only two drugs currently approved by the US FDA for the treatment of ASDs are the second-generation antipsychotic risperidone (a DA antagonist) and the third-generation antipsychotic aripiprazole (a D2 partial agonist). Although both are approved for the treatment of irritability, an associated ASD symptom, both have shown efficacy in reducing core symptoms as well. Specifically, randomized controlled trials of risperidone in individuals with ASD found significant reductions in challenging behaviors, such as irritability and hyperactivity, and significant improvement in core autism symptoms. Randomized controlled trials of aripiprazole have also found a decrease in irritability and hyperactivity and decreased instances of repetitive behaviors in children with ASD over the course of treatment.
Other commonly used treatments for ASD include other antipsychotic agents, psychostimulants (for example, methylphenidate), which generally upregulate norepinephrine and/or DA function and reduce hyperactivity but have a relatively poor side-effect profile, and naltrexone, a DA modulator.
Tourette’s syndrome
TS affects 0.3 to 0.8% of the population, and is characterized by motor and vocal tics (rapid, recurrent, stereotyped motor movements or vocalizations) performed in response to somatosensory or environmental cues. This defining feature of TS suggests involvement of nigrostriatal DA motor control systems, and thus it is not unexpected that striatal systems linked to reward processing have been implicated in the disorder, through not using tasks assessing response to rewards.
Preclinical models
Animal models relevant to TS have focused on rodent genetic models and behavioral phenotypes such as stereotypy. The DAT knockout mouse is one model involving hyperdopaminergia that results in increased levels of DA in striatal brain regions, which may model some of the motor abnormalities apparent in TS. Excessive sequential stereotypy of behavioral patterns (sequential super-stereotypy) in TS is thought to involve dysfunction in the nigrostriatal DA systems, and DAT knockout mice exhibit complex restricted patterns of stereotyped movements similar to the sequential super-stereotypy seen in TA. The genetic factors underlying TS are largely unknown; however, a rare mutation in the gene SLITRK1 is associated with human TS. The SLITRK1 protein is a single-pass transmembrane protein that displays similarities to the SLIT family of secreted ligands, which have roles in axonal repulsion and dendritic patterning in neurons, but its function and developmental expression remain largely unknown. A SLITRK1 knockout mouse model of TS has recently been developed. SLITRK1 knockout mice exhibit increased anxiety-like behavior in the elevated plus-maze test and neurochemical analyses identified increased levels of norepinephrine and its metabolite 3-methoxy-4-hydroxyphenylglycol in the prefrontal cortex and NAc, but DA levels were not altered. Administration of clonidine, an α2-adrenergic receptor agonist often used to treat patients with TS, attenuated the anxiety-like behavior of SLITRK 1-deficient mice, providing predictive validity in this TS mouse model. Interestingly, SLITRK 1 expression in mouse, monkey, and human brain is developmentally regulated in the neuroanatomical circuits most commonly implicated in TS. In the striatum, SLITRK 1 expression is high in striosomes/patches during early brain development but significantly diminishes later, suggesting a possible role in establishing corticostriatal circuitry. In addition, SLITRK 1 expression is also restricted to striatal projection neurons of the direct pathway where it could influence striatal circuitry; however, to date, direct evidence of SLITRK 1 knockout affecting either mesolimbic or nigrostriatal DA pathways has not been reported.
Clinical studies
The DA hypothesis of TS was originally proposed nearly 30 years ago, and has been corroborated by post-mortem data; however the identification of an underlying DA deficit leading to dysfunction in TS has proven to be elusive. Available evidence suggests that a phasic DA imbalance, similar to that seen in schizophrenia, may help to explain the pathophysiology of TS. Supporting this framework, reward learning is enhanced in people with TS who are not on medication, and impaired in people with TS taking DA receptor antagonists.
Although there are no published functional neuroimaging studies of response to rewards in TS, a recent fMRI study of tic inhibition implicated the striatum and associated dorsal frontal regions during tic suppression, corroborating other evidence that the magnitude of basal ganglia and thalamus activation during voluntary tic suppression correlated inversely with the severity of tic symptoms. Thus, a model has been proposed in which frequent prefrontal activation during tic suppression may produce compensatory prefrontal cortex hypertrophy that aids in tic suppression, although it is not presently clear how such basal ganglia and prefrontal characteristics effects reward processing in TS. Variants in the DA receptor gene DRD2 have also been associated with genetic risk for TS, but this finding is not consistent.
An early study of monozygotic twins discordant for TS severity found evidence in affected twins of increased D2 receptor binding in the head of the CN, but not putamen, which predicted disease severity. Single-photon emission computed tomography investigations in TS have found higher DAT binding in the right caudate, the striatum, the putamen after amphetamine challenge, and the basal ganglia. However, a handful of studies have found no differences in striatal DAT binding in TS.
Dopaminergic treatments
Tetrabenazine is commonly used to treat hyperkinetic movement disorders, including TS. Its mechanism of action is believed to involve the early metabolic degradation of monoamines, in particular DA. The classes of medications with the most proven efficacy in treating tics are typical and atypical antipsychotics (DA receptor antagonists) including risperidone, ziprasidone, haloperidol, pimozide, and fluphenazine.
Conduct disorder/oppositional defiant disorder
CD is defined by a behavioral pattern involving the violation of others’ rights and of societal rules along with antisocial behaviors before the age of 18 years, and ODD is characterized by recurrent patterns of defiant behaviors toward authority figures during childhood. These externalizing disorders, known collectively as disruptive behavior disorders, are often comorbid, and there is debate over whether they represent differences in severity of symptom expression or two distinct conditions. Prevalence estimates for both conditions are just over 3%. Although the preponderance of functional brain-imaging studies in these conditions has focused on cognitive switching and sustained attention, a significant subset of studies has focused on reward processing.
Clinical studies
Results of functional brain-imaging studies of response to rewards in CD/ODD are not wholly consistent. Rubia and colleagues reported reduced orbitofrontal activation during a rewarded continuous performance task in adolescents with CD, whereas Bjork et al. reported increased subgenual cortex activation in adolescents with externalizing disorders during a monetary incentive-delay task. Finally, Crowley and colleagues found that adolescents with CD and comorbid substance-use disorder displayed relative hypoactivation in the striatum and ACC during risky decision-making for rewards.
Despite evidence that the dopaminergic system plays a key role in aggression, only a small handful of molecular genetic studies implicate DA candidate genes, including DAT1, DRD2, and DRD4, in the development of conduct problems, and no molecular-imaging study to date has assessed striatal DA signaling in samples with CD/ODD who are not comorbid for other conditions.
Dopaminergic treatments
Atypical antipsychotics, psychostimulants, mood stabilizers, and α2 agonist agents are commonly used to treat CD/ODD) Divalproex was found it to be superior to placebo in treating explosive temper, mood lability, and CD in adolescents. There is initial evidence in the form of open-label or retrospective chart review studies, of the efficacy of olanzapine, quetiapine, and aripiprazole in treating aggressive behavior. Risperidone was found to be well-tolerated and superior to placebo in reducing aggressive behaviors in children with CD. Two large controlled trials found risperidone to be superior to placebo in ameliorating hostile and aggressive behavior in lower-functioning children with disruptive behavioral disorders.
Prader-Willi syndrome
PWS is characterized by infantile hypotonia, mental retardation, short stature, hypogonadism, hyperphagia and early-onset morbid obesity. It has an estimated prevalence of 1 in 10,000 to 1 in 30,000 births. Approximately 70% of cases are due to a genetic deletion on chromosome 15 (15q11–13), 25% of cases are due to a maternal uniparental disomy of chromosome 15, and the remaining cases result from imprinting defects. Although to date there are no preclinical models of PWS that clearly implicate the mesolimbic reward system, a linkage between PWS and reward-processing deficits is suggested by hyperphagia (abnormally increased appetite for and consumption of food) and the high incidence of obesity in affected individuals. PWS is the most commonly recognized genetic cause of childhood obesity, and obesity is the primary basis of morbidity and mortality for individuals with the syndrome. If given access, individuals with PWS will consume three to six times as much food as individuals without the syndrome, and show delayed meal termination, and earlier return of hunger after a previous meal. Children with PWS show enhanced behavioral responses to food cues, which do not diminish after receiving a favorite food, suggesting that the incentive salience of food is heightened in this population, and that this heightened motivation is not diminished with satiation. Appetite disturbance in PWS has been attributed to the hypothalamic dysfunction that characterizes the disorder, which also causes growth-hormone deficiency, hypogonadism, and temperature dysregulation.
The enhanced response to food that characterized PWS suggests that the brain reward-circuitry response to food may be hyperactive. Indeed, several research groups have found greater activation in the ventromedial prefrontal cortex, amygdala, and orbitofrontal cortex during reward anticipation for food cues in PWS. Miller and colleagues presented images of food, animals, and tools, and found that participants with PWS had relatively greater ventromedial prefrontal cortex activation to food compared with controls. Holsen and colleagues scanned participants with PWS while they viewed images of food and animals, both before and after eating a standard meal. They found a group × time interaction, reflecting the increased activation in orbitofrontal cortex, medial prefrontal cortex, and insula at post-meal relative to pre-meal in the PWS groups that was not evident in the control group. Dimitropoulos and Schultz reported increased activation in the hypothalamus and orbitofrontal cortex in PWS during high-calorie versus low-calorie food-reward outcomes.
These initial studies suggest that the hyperphagia in PWS may indeed be mediated by hyperactivation in brain-reward networks to food-related stimuli (but Hinton et al. failed to replicate this finding). In support of these findings, Shapira and colleagues showed that in patients with PWS that there was a temporal delay in response to glucose ingestion in the resting-state activity of a distributed network implicated in the regulation of hunger and satiation, namely the hypothalamus, insular cortex, ventral basal ganglia, and ventromedial prefrontal cortex.
To date there are no published molecular-imaging studies addressing striatal DA binding in PWS, and the first-line pharmacologic treatment for PWS is growth-hormone therapy, which does not regulate DA function.
Williams syndrome
WS (also known as Williams–Beuren syndrome), with a prevalence of about 1 in 7,500, is a neurodevelopmental condition caused by a hemizygous microdeletion on chromosome 7q11.23, and is characterized by hypersociality and being overly empathic. Although to date there are no preclinical models of WS that clearly implicate the mesolimbic reward system, the highly social phenotype of WS suggests a poorly modulated reward-system response to social cues.
There are currently three models of social function in WS: 1) heightened drive towards non-specific social interaction (for example, social interactions with strangers), 2) heightened emotional responsiveness, and 3) social fearlessness. Only two functional brain-imaging studies to date to have provided insight into reward processing in WS by assessing responses to happy and fearful faces. One such study found relations between amygdala responses to fearful faces specifically, and symptoms of social approach of strangers, supportive of the social fearlessness model. Another study found that individuals with WS show reduced amygdala activity in response to sad faces and comparable activity in the orbitofrontal cortex for happy and sad faces, whereas TS individuals show a heightened orbitofrontal cortex response to sad faces. However, both of these studies did not report responses to the happy-face conditions. In this regard, it is currently unknown if the phenotype of hypersociality in WS reflects a hyperactive neurobiological response to social rewards specifically, or if such behavior is but one exemplar of indiscriminant heightened approach behaviors to a wider range of social-emotional stimuli.
There are no published studies of striatal DAT function in WS. WS is typically treated by anxiolytic and antipsychotic agents, but to date there are no systematic data on efficacy of DA agents to treat WS.
Angelman syndrome
AS is characterized by intellectual disability, epilepsy, impaired coordination, and absence of speech. However, individuals with AS also commonly exhibit a characteristic happy demeanor with prominent smiling, non-specific laughing, a general exuberance, and an attraction to water and certain types of paper and plastics, suggesting that the reward-system function may be a candidate system for study in this syndrome. The syndrome is caused by mutations or deletions of the maternal copy of the gene Ube3a, an E3 ubquitin ligase enzyme that is involved in targeting proteins for degradation in cells. Although empirical evidence for altered reward-system function in individuals with AS is lacking, animal models suggest there may be some involvement. In elegant genetic studies using the fruit-fly Drosophila, overexpression or genetic knockout of the Drosophila homolog of Ube3a respectively increased or decreased DA levels, potentially due to changes in the expression of tetrahydrobiopterin, the rate-limiting cofactor in monoamine synthesis in flies. In addition, in a mouse model of AS, genetic loss of the Ube3a gene resulted in a loss of DA neurons in the substantia nigra, which may contribute to mechanisms that cause ataxia and motor deficits apparent in the mouse model of the disease. The severe developmental delay that characterizes the syndrome renders functional neuroimaging research challenging, and to date there are no functional brain-imaging data on responses to rewards or molecular brain-imaging studies in AS.
Rett syndrome
RS predominantly affects females and is caused by mutations in the gene encoding the methyl-CpG binding protein (MeCP)2, a transcriptional repressor involved in DNA remodeling and regulation of gene expression. In RS. both loss of function and gain in MeCP2 gene dosage lead to similar neurological phenotypes. MeCP2 mutations result in a number of pathologies including microencephaly, general growth retardation, motor clumsiness, ataxia, and autistic features, including social withdrawal, loss of language, and stereotypy.
Preclinical models
Although a connection between dysregulated mesolimbic DA reward systems and RS is not currently clear, several studies indicate altered DA levels and changes in the closely related nigrostriatal DA pathways in mouse models. It has been suggested that MeCP2 protein normally functions in the NAc to limit the rewarding properties of psychostimulants, and that psychostimulant or DA receptor-induced phosphorylation of MeCP2 may be involved in the rewarding properties of drugs of abuse such as amphetamines. In an engineered MeCP2-deficient mouse model, a postnatal reduction of DA and its metabolite homovanillic acid was seen in the caudate putamen, suggesting that MAO and/or COMT levels might be impaired. Loss of MeCP2 also compromises the nigrostriatal DA pathway in mice, where the number of DA-synthesizing neurons is significantly decreased in the substantia nigra of RS model mice. In addition, the DA neurons in the substantia nigra of MECP2 mutant mice have a decreased capacitance, total dendritic length, and resting membrane conductance as early as 4 weeks after birth, well before overt neurodevelopmental symptoms are seen in the mouse model. These studies suggest that nigrostriatal DA deficits may underlie the origin of motor dysfunctions in RS. Although further studies are required, there may also be similar deficits in the closely associated mesolimbic pathway in RS model mice.
Clinical studies
Because of the profound cognitive impairment associated with RS, there are no functional brain-imaging studies of individuals with this condition because of the cognitive demands of the functional brain-imaging environment. Molecular-imaging studies have indicated increased D2 receptor binding in the caudate and putamen, and in the striatum as a whole. No DA agents are first-line treatments for RS.
Fragile X syndrome
FXS is the most common inherited cause of intellectual disability, occurring in 1 in 4,000 males and 1 in 8,000 females, and is caused by a mutation of the FMR1 gene on the long arm of the X chromosome(locus Xq27.3;). The FMR1 full mutation affects cognition, adaptive behavior, social abilities, and motor skills. Specific areas of cognitive weaknesses include communication, mathematics, visual-spatial processing, executive function, and memory.
Preclinical models
Fragile X model mice have been developed that encode an engineered mutation in the FMR1 gene, recapitulating the human mutation, resulting in an absence of FMR1 expression. To identify potentially related neurochemical mechanisms affected by this mutation, Fulks and colleagues used fast-scanning cyclic voltammetry to measure electrically evoked DA release in striatal brain slices. In adult mice, a decrease in stimulated extracellular DA release and reuptake was seen in FMR1 mutant mice, which was also associated with decreased repetitive movements/stereotypy. FMR1 has been suggested as important for DA signaling in both the prefrontal cortex and striatum, where it may interact with G protein–coupled receptor kinase 2, which regulates DA receptor signaling cascades. In studies of FMR1 mutant mice, Zhuo and colleagues reported that cortical and striatal neurons from the mutant mice exhibit abnormal D1 receptor signaling and disrupted synaptic plasticity in response to D1 receptor activation. Remarkably, these neuronal deficits could be rescued by restoring the FMR1 gene to the mutant neurons. FMR1 is also suggested to be important for D1 receptor-mediated synthesis of SAPAP3 in prefrontal cortex neurons; SAPAP3 is a post-synaptic neuronal scaffolding protein that regulates glutamate receptor trafficking and function. Together, these studies indicate that FMR1 mutant mice have dysregulated striatal DA transmission and pre-frontal DA receptor function, and that these changes may contribute to the mechanisms underlying FXS.
Clinical studies
No functional brain-imaging studies to date have assessed responses to rewarding stimuli in FXS. Rather, given that individuals with FXS display social impairments that may be similar to those seen in ASD, it is not surprising that functional brain-imaging studies of FXS have focused almost exclusively on responses to social stimuli. To the extent that, in neurotypical development, social stimuli such as faces are rewarding, these studies may indirectly address the integrity of reward-circuitry function in FXS, although future studies designed to investigate striatal response to other rewards in FXS are needed.
Garret and colleagues reported relatively decreased activation of the fusiform gyrus and superior temporal sulcus and increased right insula activation to images of faces in FXS. The authors suggested that these results may reflect anxiety provoked by the face stimuli. Watson, Hoeft, Garrett et al. showed this same stimulus set to boys with FXS, and replicated the finding of greater insula activation (although on the left side) to direct gaze. Holsen et al. reported decreased cingulate and left insula activation in individuals with FXS in response to images of familiar fearful faces and inverse relations between social anxiety and activation in a number of regions, including a cluster in the left inferior frontal gyrus near the insula. These authors speculated that social anxiety in FXS has a cascading effect on multiple aspects of cognition. Finally, Dalton et al. compared responses in groups with FXS and with autism during the processing of emotional faces, and found that in response to faces, the FXS group had higher activation in the right insula (among other regions) compared with both the autism and control groups, a finding that the authors suggested may be linked to social anxiety.
The only published molecular-imaging study of striatal DAT binding is a small investigation of four patients with parkinsonism carrying the FXS permutation, which found initial evidence of decreased striatal binding. However, there is evidence that DA functioning may be atypical in FXS, as shown by high rates of comorbidity with tremor disorders, higher blink rates, and emerging preclinical models.
Dopaminergic treatments
Children and adults with FXS are regularly prescribed stimulants, antidepressants, anticonvulsants, and antipsychotics. Psychostimulants are the most often prescribed psychoactive medication to treat FXS, with initial randomized controlled trial data of response to methylphenidate and dextroamphetamine suggesting moderate response rates on attention and social skills. Preliminary studies of aripiprazole in FXS have also found evidence for an improvement in clinical symptoms and irritability.
Conclusions
The central tenet of this review is that multiple neurodevelopmental and psychiatric disorders and genetic syndromes share a common neurobiological characteristic, namely, altered functional output of striatal DA systems mediating the processing of rewards. This framework suggests the need for new methods of phenotypic assessment that cut across traditional symptom-based surveys developed to assess functioning based on traditional, category-based classification systems such as DSM and the International Classification of Diseases. Given that a significant portion of the disorders reviewed here respond favorably to treatment by psychopharmacologic agents that primarily affect DA systems, investigations of reward-circuitry functioning in psychopathology may have direct relevance not only for etiological models of disease mechanisms, but for the potential mechanisms of effective interventions and the development of treatment agents. Although treatment effects do not necessarily indicate pathophysiological etiologies, the efficacy of dopaminergic agents represents supportive preliminary evidence of a potential common etiology in a number of conditions.
However, we recognize that the one-to-one linking of mesolimbic DA function with reward response is clearly overly simplistic. The mesolimbic DA system represents only one component of a very complex and integrated set of circuits, and although DA is clearly a crucial neurotransmitter in the reward-processing system, non-DA systems clearly also modulate reward responsibility. Additionally, there are multiple brain regions not addressed in this review that contribute to reward processing, including the subthalamic nucleus and ventral pallidum, the subiculum, the lateral habenula, and the extended amygdala. Additionally, multiple non-DA compounds have shown efficacy in improving reward responses, such as agents that affect glutamate circuits involved in regulating monoamine systems. Consequently, the purpose of this review is to serve as a starting point for consideration of DA-mediated reward-system dysfunction as a potential common etiologic factor in a range of conditions. Future research aimed at understanding linkages between disease phenotype, reward function, and treatment response will clearly have to consider other interacting systems and neurotransmitters.
A host of unanswered questions remain about how ascending DA projections and their forebrain targets contribute to aspects of reward processing. For example, even within the context of DA systems, it is not clear whether increased and decreased reward-oriented motivation is a result of decreased or increased sensitivities of DA and associated systems. Moreover, the striatum and associated DA systems play a prominent role in processing aversive stimuli and processing rewards. Hence, the present review is intended to highlight initial evidence of the relevance of DA reward to neurodevelopmental and psychiatric disorders, but clearly future studies are needed to address other brain circuits, neurotransmitters, and motivating stimuli.
Another limitation of this line of research is that the majority of clinical studies summarized in this review assessed responses to standardized rewards, such as money or standard picture sets. This approach relies on the implicit assumption that standardized stimulus sets are a reasonable proxy for individual-specific stimuli. In the realm of nonclinical cognitive neuroscience, this assumption seems to be valid; however, the concordance of results using standardized versus individual-specific stimuli is largely unknown in clinical contexts. Additionally, there are a number of contexts in which reward-system dysfunction in a given disorder may be contingent on a particular class of stimuli (for example,, addiction cues in substance abuse, food images in eating disorders, and sad pictures in unipolar depression). Although this issue complicates cross-disorder comparisons, this variability in response-eliciting stimuli leads to distinct phenotypic expressions in different disorders.
Future research is needed to delineate linkages between laboratory measures of reward processing and real-life experiences of incentive motivation, positive affect, reward-seeking, and risk-taking tendencies. The few studies that have evaluated potential relations between mesolimbic neural activity and subjectively experienced reward or motivation to work for rewards have yielded promising initial results suggesting the external validity of laboratory-based measures of reward processes, but research on the ecological validity of reward-processing endophenotypic measures is needed. Additionally, the development of measures sensitive to reward-system integrity and suitably sensitive to change for intervention studies are also needed. Although self-report and behavioral measures of reward capacity have been developed, their association to neurobiological function has proven to be limited. As suggested by Treadway and Zald, an implication of clinical neurobiological research into reward-system dysfunction may be the modification of psychiatric interviews to frame and code questions to tap hedonic capacity and motivation towards certain classes of stimuli.
Another area in need of greater research is reward-circuitry function in comorbid disorders. Given that the conditions reviewed here share mesolimbic dysfunction, it is perhaps not surprising that there are high rates of comorbidity between these disorders. For example, there are high rates of comorbidity between substance abuse and other Axis I conditions, schizophrenia and bipolar disorder, and ASD and mood and anxiety disorders. A number of explanations for the high comorbidity rates have been suggested, including shared genetic etiology, self-medication of symptoms, and common socioenvironmental determinants, but only multi-group studies that directly compare cases with comorbid disorders will be able to distinguish the nature of reward-circuitry dysfunction in these contexts.
Finally, as previously noted, the vast majority of clinical research into reward-circuitry function is cross-sectional in nature, and has focused only on adults. Given the importance of brain development prior to adulthood, the study of reward-related processes during development will be crucial to disambiguate the proximal effects of altered reward-circuitry function from its more downstream effects on learning, motivation, and overall functioning. There may be critical periods during early development when mesolimbic dysfunction creates a predisposition to any number of disorders, and understanding the factors that mediate these processes will be essential for treatment and the prevention of symptom onset.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All three authors were major contributors in writing this manuscript, and have read and approved the final manuscript.
References 756
- 1.
American Psychiatric AssociationDiagnostic and statistical manual of mental disorders1994 4DSM-IV, Washington
Not in our library
- 2.
Aupperle RL Paulus MP Neural systems underlying approach and avoidance in anxiety disordersDialogues Clin Neurosci2010 124517531
Not in our library10.31887/dcns.2010.12.4/raupperle
- 3.
Murray EA Wise SP Drevets WC Localization of dysfunction in major depressive disorder: prefrontal cortex and amygdalaBiol Psychiatr2011 6912e43
Not in our library10.1016/j.biopsych.2010.09.041
- 4.
Kerns JG Cohen JD MacDonald AW Johnson MK Stenger VA Aizenstein H Carter CS Decreased conflict- and error-related activity in the anterior cingulate cortex in subjects with SchizophreniaAm J Psychiatr2005 1621018331839
Not in our library10.1176/appi.ajp.162.10.1833
- 5.
Pannu Hayes J Labar KS Petty CM McCarthy G Morey RA Alterations in the neural circuitry for emotion and attention associated with posttraumatic stress symptomatologyPsychiatr Res2009 1721715
Not in our library10.1016/j.pscychresns.2008.05.005
- 6.
NIMHThe National Institute of Mental Health Strategic Plan2008 National Institute of Mental Health (NIH Publication 08–6368), Bethesdahttp://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml
Not in our library
- 7.
Insel TR Cuthbert BN Endophenotypes: Bridging genomic complexity and disorder heterogeneityBiol Psychiatr2009 6611988989
Not in our library10.1016/j.biopsych.2009.10.008
- 8.
Miller G Psychiatry. Beyond DSM: Seeking a brain-based classification of mental illnessScience2010 32759721437
Not in our library10.1126/science.327.5972.1437
- 9.
Carter CS Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophreniaSchizophr Bull2005 314810815
Not in our library10.1093/schbul/sbi046
- 10.
Hasler G Drevets WC Manji HK Charney DS Discovering endophenotypes for major depressionNeuropsychopharmacology2004 291017651781
Not in our library10.1038/sj.npp.1300506
- 11.
Jacob S Landeros-Weisenberger A Leckman JF Autism spectrum and obsessive-compulsive disorders: OC behaviors, phenotypes and geneticsAutism Res2009 26293311
Not in our library10.1002/aur.108
- 12.
Charney DS Barlow DH Botteron KN Cohen JD Goldman D Gur RC Kupfer DJ, First MB, Regier DANeuroscience research agenda to guide development of a pathophysiologically based classification systemA Research Agenda for DSM-V2002 American Psychiatric Association, Washington3183
Not in our library
- 13.
Gottesman II Gould TD The endophenotype concept in psychiatry: etymology and strategic intentionsAm J Psychiatr2003 1604636645
Not in our library10.1176/appi.ajp.160.4.636
- 14.
Gottesman II Shields J Genetic theorizing and schizophreniaBr J Psychiatr1973 1225661530
Not in our library10.1192/bjp.122.1.15
- 15.
Ernst M Daniele T Frantz K New perspectives on adolescent motivated behavior: Attention and conditioningDeve Cognit Neurosci2011 14377389
Not in our library10.1016/j.dcn.2011.07.013
- 16.
Gladwin TE Figner B Crone EA Wiers RW Addiction, adolescence, and the integration of control and motivationDev Cognit Neurosci2011 14364376
Not in our library10.1016/j.dcn.2011.06.008
- 17.
Fairchild G The developmental psychopathology of motivation in adolescenceDeve Cognit Neurosci2011 14414429
Not in our library10.1016/j.dcn.2011.07.009
- 18.
Luman M Tripp G Scheres A Identifying the neurobiology of altered reinforcement sensitivity in ADHD: A review and research agendaNeurosci Biobehav Rev2010 345744754
Not in our library10.1016/j.neubiorev.2009.11.021
- 19.
Treadway MT Zald DH Reconsidering anhedonia in depression: lessons from translational neuroscienceNeurosci Biobehav Rev2011 353537555
Not in our library10.1016/j.neubiorev.2010.06.006
- 20.
Ernst M Fudge JL A developmental neurobiological model of motivated behavior: anatomy, connectivity and ontogeny of the triadic nodesNeurosci Biobehav Rev2009 333367382
Not in our library10.1016/j.neubiorev.2008.10.009
- 21.
Delgado MR Reward-related responses in the human striatumAnn N Y Acad Sci2007 11047088
Not in our library10.1196/annals.1390.002
- 22.
Smith KS Berridge KC Aldridge JW Disentangling pleasure from incentive salience and learning signals in brain reward circuitryProc Natl Acad Sci2011 10827E255
Not in our library10.1073/pnas.1101920108
- 23.
Barch DM Dowd EC Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactionsSchizophr Bull2010 365919934
Not in our library10.1093/schbul/sbq068
- 24.
Delgado MR Li J Schiller D Phelps EA The role of the striatum in aversive learning and aversive prediction errors. Philosophical Transactions of the Royal Society of LondonSer B Biol Sci2008 363151137873800
Not in our library10.1098/rstb.2008.0161
- 25.
Han S Huettel SA Raposo A Adcock RA Dobbins IG Functional significance of striatal responses during episodic decisions: recovery or goal attainment?J Neurosci2010 301347674775
Not in our library10.1523/jneurosci.3077-09.2010
- 26.
van der Schaaf ME Warmerdamc E Crone EA Cools R Distinct linear and non-linear trajectories of reward and punishment reversal learning during development: Relevance for dopamine’s role in adolescent decision makingDev Cognit Neurosci2011 1578590
Not in our library10.1016/j.dcn.2011.06.007
- 27.
Aarts E van Holstein M Cools R Striatal dopamine and the interface between motivation and cognitionFront Psychol2011 2163
Not in our library10.3389/fpsyg.2011.00163
- 28.
Knutson B Cooper JC Functional magnetic resonance imaging of reward predictionCurr Opin Neurol2005 184411417
Not in our library10.1097/01.wco.0000173463.24758.f6
- 29.
Schultz W Reward signaling by dopamine neuronsNeuroscientist2001 74293302
Not in our library10.1177/107385840100700406
- 30.
Kable JW Glimcher PW The neurobiology of decision: consensus and controversyNeuron2009 636733745
Not in our library10.1016/j.neuron.2009.09.003
- 31.
Platt ML Huettel SA Risky business: the neuroeconomics of decision making under uncertaintyNat Neurosci2008 114398403
Not in our library10.1038/nn2062
- 32.
Rangel A Camerer C Montague PR A framework for studying the neurobiology of value-based decision makingNat Rev Neurosci2008 97545556
Not in our library10.1038/nrn2357
- 33.
Hayes DJ Greenshaw AJ 5-HT receptors and reward-related behaviour: a reviewNeurosci Biobehav Rev2011 35614191449
Not in our library10.1016/j.neubiorev.2011.03.005
- 34.
Park J Wheeler RA Fontillas K Keithley RB Carelli RM Wightman RM Catecholamines in the bed nucleus of the stria terminalis reciprocally respond to reward and aversionBiol Psychiatr2011 714327334
Not in our library10.1016/j.biopsych.2011.10.017
- 35.
Cooper JR Bloom FE Roth RH The Biochemical Basis of Neuropharmacology2003 Oxford University Press, Oxford
Not in our library
- 36.
Enoch MA The role of GABA(A) receptors in the development of alcoholismPharmacol Biochem Behav2008 90195104
Not in our library10.1016/j.pbb.2008.03.007
- 37.
Grueter BA Rothwell PE Malenka RC Integrating synaptic plasticity and striatal circuit function in addictionCurr Opin Neurobiol2011 http://www.sciencedirect.com/science/article/pii/S095943881100153X.
Not in our library10.1016/j.conb.2011.09.009
- 38.
Russo SJ Dietz DM Dumitriu D Morrison JH Malenka RC Nestler EJ The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbensTrends Neurosci2011 336267276
Not in our library10.1016/j.tins.2010.02.002
- 39.
Berridge KC Kringelbach ML Affective neuroscience of pleasure: reward in humans and animalsPsychopharmacology (Berl)2008 1993457480
Not in our library10.1007/s00213-008-1099-6
- 40.
Berridge KC Robinson TE Parsing rewardTrends Neurosci2003 269507513
Not in our library10.1016/s0166-2236(03)00233-9
- 41.
Berridge KC Robinson TE Aldridge JW Dissecting components of reward: 'liking', 'wanting', and learningCurr Opin Pharmacol2009 916573
Not in our library10.1016/j.coph.2008.12.014
- 42.
Graybiel AM Habits, rituals, and the evaluative brainAnnu Rev Neurosci2008 31359387
Not in our library10.1146/annurev.neuro.29.051605.112851
- 43.
Salamone JD Functions of mesolimbic dopamine: changing concepts and shifting paradigmsPsychopharmacol Berl2007 1913389
Not in our library10.1007/s00213-006-0623-9
- 44.
Wise RA Dopamine and reward: The anhedonia hypothesis 30 years onNeurotoxicol Res2008 142–3169183
Not in our library10.1007/bf03033808
- 45.
Kringelbach ML Berridge KC Pleasures of the Brain2009 Oxford University Press, New York
Not in our library
- 46.
Rushworth MF Noonan MP Boorman ED Walton ME Behrens TE Frontal cortex and reward-guided learning and decision-makingNeuron2011 70610541069
Not in our library10.1016/j.neuron.2011.05.014
- 47.
Graybiel AM The basal gangliaCurr Biol2000 1014R509R511
Not in our library10.1016/s0960-9822(00)00593-5
- 48.
Yin HH Knowlton BJ The role of the basal ganglia in habit formationNat Rev Neurosci2006 76464476
Not in our library10.1038/nrn1919
- 49.
Hoebel BG Avena NM Rada P Accumbens dopamine-acetylcholine balance in approach and avoidanceCurr Opin Pharmacol2007 76617627
Not in our library10.1016/j.coph.2007.10.014
- 50.
vbIkemoto S Panksepp J The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seekingBrain Res Rev1999 311641
Not in our library10.1016/s0165-0173(99)00023-5
- 51.
Salamone JD Correa M Farrar AM Nunes EJ Pardo M Dopamine, behavioral economics, and effortFront Behav Neurosci2009 31315
Not in our library10.3389/neuro.08.013.2009
- 52.
Berridge KC Scherer K Davidson RJ, Goldsmith HHComparing the emotional brain of humans to other animalsHandbook of Affective Sciences2003 Oxford University Press, Oxford
Not in our library
- 53.
Davidson RJ Sutton SK Affective neuroscience: the emergence of a disciplineCurr Opin Neurobiol1995 52217224
Not in our library10.1016/0959-4388(95)80029-8
- 54.
Olds J Milner P Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brainJ Comp Physiol Psychol1954 476419427
Not in our library10.1037/h0058775
- 55.
Wise RA Addictive drugs and brain stimulation rewardAnnu Rev Neurosci1996 19319340
Not in our library10.1146/annurev.ne.19.030196.001535
- 56.
Haber SN The primate basal ganglia: Parallel and integrative networksJ Chem Neuroanat2003 264317330
Not in our library10.1016/j.jchemneu.2003.10.003
- 57.
McBride WJ Murphy JM Ikemoto S Localization of brain reinforcement mechanisms: Intracranial self-administration and intracranial place-conditioning studiesBehav Brain Res1999 1012129152
Not in our library10.1016/s0166-4328(99)00022-4
- 58.
Chau DT Roth RM Green AI The neural circuitry of reward and its relevance to psychiatric disordersCurr Psychiatr Rep2004 65391399
Not in our library10.1007/s11920-004-0026-8
- 59.
Lindvall O Bjorklund A Emson PCDopamine- and norepinephine-containing neuron systems: Their anatomy in the rat brainChemical Neuroanatomy1983 Raven, New York229255
Not in our library
- 60.
Swerdlow NR Koob GF Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic functionBehav Brain Sci1987 10197245
Not in our library
- 61.
Haber SN McFarland NR The concept of the ventral striatum in nonhuman primatesAnn N Y Acad Sci1999 8773348
Not in our library10.1111/j.1749-6632.1999.tb09259.x
- 62.
McGinty JF Advancing from the ventral striatum to the extended amygdala. Implications for neuropsychiatry and drug abuse. IntroductionAnn New York Acad Sci1999 877McGinty JFxiixv
Not in our library10.1111/j.1749-6632.1999.tb09257.x
- 63.
Kalivas PW Barnes CD Limbic Motor Circuits and Neuropsychiatry1993 CRC Press, Boca Raton
Not in our library
- 64.
Mogenson GJ Jones DL Yim CY From motivation to action: Functional interface between the limbic system and the motor systemProgr Neurobiol1980 142–36997
Not in our library10.1016/0301-0082(80)90018-0
- 65.
Beaulieu JM Gainetdinov RR The physiology, signaling, and pharmacology of dopamine receptorsPharmacol Rev2011 631182217
Not in our library10.1124/pr.110.002642
- 66.
Girault JA Greengard P The neurobiology of dopamine signalingArch Neurol2004 615641644
Not in our library10.1001/archneur.61.5.641
- 67.
Neve KA Seamans JK Trantham-Davidson H Dopamine receptor signalingJ Recept Signal Transduct Res2004 243165205
Not in our library10.1081/rrs-200029981
- 68.
Mogenson GJ Wu M Jones DL Locomotor activity elicited by injections of picrotoxin into the ventral tegmental area is attenuated by injections of GABA into the globus pallidusBrain Res1980 1912569571
Not in our library10.1016/0006-8993(80)91308-6
- 69.
Nicola SM Surmeier J Malenka RC Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbensAnnu Rev Neurosci2000 23185215
Not in our library10.1146/annurev.neuro.23.1.185
- 70.
Hopf FW Cascini MG Gordon AS Diamond I Bonci A Cooperative activation of dopamine D1 and D2 receptors increases spike firing of nucleus accumbens neurons via G-protein betagamma subunitsJ Neurosci2003 231250795087
Not in our library10.1523/jneurosci.23-12-05079.2003
- 71.
Cacciapaglia F Wightman RM Carelli RM Rapid dopamine signaling differentially modulates distinct microcircuits within the nucleus accumbens during sucrose-directed behaviorJ Neurosci2011 31391386013869
Not in our library10.1523/jneurosci.1340-11.2011
- 72.
Tsai HC Zhang F Adamantidis A Stuber GD Bonci A de Lecea L Deisseroth K Phasic firing in dopaminergic neurons is sufficient for behavioral conditioningScience2009 324593010801084
Not in our library10.1126/science.1168878
- 73.
Riddle EL Fleckenstein AE Hanson GR Role of monoamine transporters in mediating psychostimulant effectsAAPS J2005 74E847
Not in our library10.1208/aapsj070481
- 74.
Beveridge TJ Smith HR Nader MA Porrino LJ Abstinence from chronic cocaine self-administration alters striatal dopamine systems in rhesus monkeysNeuropsychopharmacology2009 34511621171
Not in our library10.1038/npp.2008.135
- 75.
Little KY Zhang L Desmond T Frey KA Dalack GW Cassin BJ Striatal dopaminergic abnormalities in human cocaine usersAm J Psychiatr1999 1562238245
Not in our library10.1176/ajp.156.2.238
- 76.
Seeman P Lee T Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neuronsScience1975 188419412171219
Not in our library10.1126/science.1145194
- 77.
Guillin O Abi-Dargham A Laruelle M Neurobiology of dopamine in schizophreniaInt Rev Neurobiol2007 78139
Not in our library10.1016/s0074-7742(06)78001-1
- 78.
Weinberger D Laruelle M Davis KL, Charney DS, Coyle JT, Nemeroff CNeurochemical and neuropharmachological imaging in schizophreniaNeuropsychopharmacology: The Fifth Generation of Progress2001 Lippincott, Williams, and Wilkins, New York833856
Not in our library
- 79.
Seeman P All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptorsCNS Neurosci Therapy2011 172118132
Not in our library10.1111/j.1755-5949.2010.00162.x
- 80.
Kellendonk C Simpson EH Polan HJ Malleret G Vronskaya S Winiger V Moore H Kandel ER Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioningNeuron2006 494603615
Not in our library10.1016/j.neuron.2006.01.023
- 81.
Kim KS Lee KW Im JY Yoo JY Kim SW Lee JK Nestler EJ Han PL Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine actionProc Natl Acad Sci2006 1031039083913
Not in our library10.1073/pnas.0508812103
- 82.
Greengard P The neurobiology of dopamine signalingBiosci Rep2001 213247269
Not in our library10.1023/a:1013205230142
- 83.
Gould TD Manji HK DARPP-32: A molecular switch at the nexus of reward pathway plasticityProc Natl Acad Sci2005 1022253254
Not in our library10.1073/pnas.0408700102
- 84.
Valjent E Pascoli V Svenningsson P Paul S Enslen H Corvol JC Stipanovich A Caboche J Lombroso PJ Nairn AC Greengard P Herve D Girault JA Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatumProc Natl Acad Sci2005 1022491496
Not in our library10.1073/pnas.0408305102
- 85.
Zachariou V Benoit-Marand M Allen PB Ingrassia P Fienberg AA Gonon F Greengard P Picciotto MR Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or Inhibitor 1Biol Psychiatr2002 518612620
Not in our library10.1016/s0006-3223(01)01318-x
- 86.
Nestler EJ Is there a common molecular pathway for addiction?Nat Neurosci2005 81114451449
Not in our library10.1038/nn1578
- 87.
Nestler EJ Barrot M Self DW DeltaFosB: a sustained molecular switch for addictionProc Natl Acad Sci2001 98201104211046
Not in our library10.1073/pnas.191352698
- 88.
McClung CA Nestler EJ Regulation of gene expression and cocaine reward by CREB and DeltaFosBNat Neurosci2003 61112081215
Not in our library10.1038/nn1143
- 89.
Barrot M Olivier JD Perrotti LI DiLeone RJ Berton O Eisch AJ Impey S Storm DR Neve RL Yin JC Zachariou V Nestler EJ CREB activity in the nucleus accumbens shell controls gating of behavioral responses to emotional stimuliProc Natl Acad Sci2002 99171143511440
Not in our library10.1073/pnas.172091899
- 90.
Walters CL Godfrey M Li X Blendy JA Alterations in morphine-induced reward, locomotor activity, and thermoregulation in CREB-deficient miceBrain Res2005 10321–2193199
Not in our library10.1016/j.brainres.2004.11.013
- 91.
Chen BT Hopf FW Bonci A Synaptic plasticity in the mesolimbic system: therapeutic implications for substance abuseAnn N Y Acad Sci2010 1187129139
Not in our library10.1111/j.1749-6632.2009.05154.x
- 92.
De Biasi M Dani JA Reward, addiction, withdrawal to nicotineAnnu Rev Neurosci2011 34105130
Not in our library10.1146/annurev-neuro-061010-113734
- 93.
Maze I Nestler EJ The epigenetic landscape of addictionAnn N Y Acad Sci2011 121699113
Not in our library10.1111/j.1749-6632.2010.05893.x
- 94.
Nestler EJ Hyman SE Animal models of neuropsychiatric disordersNat Neurosci2010 131011611169
Not in our library10.1038/nn.2647
- 95.
Nesse RM Evolutionary biology: a basic science for psychiatryWorld Psychiatr2002 1179
Not in our library
- 96.
Panksepp J Affective Neuroscience: the Foundations of Human and Animal Emotions1998 Oxford University Press, In. Oxford
Not in our library
- 97.
Hayden BY Parikh PC Deaner RO Platt ML Economic principles motivating social attention in humansProc R Soc Biol Sci2007 274161917511756
Not in our library10.1098/rspb.2007.0368
- 98.
Ernst M Nelson EE McClure EB Monk CS Munson S Eshel N Zarahn E Leibenluft E Zametkin A Towbin K Blair J Charney D Pine DS Choice selection and reward anticipation: an fMRI studyNeuropsychologia2004 421215851597
Not in our library10.1016/j.neuropsychologia.2004.05.011
- 99.
Knutson B Adams CM Fong GW Hommer D Anticipation of increasing monetary reward selectively recruits nucleus accumbensJ Neurosci2001 2116RC159
Not in our library10.1523/jneurosci.21-16-j0002.2001
- 100.
Zald DH Boileau I El-Dearedy W Gunn R McGlone F Dichter GS Dagher A Dopamine transmission in the human striatum during monetary reward tasksJ Neurosci2004 241741054112
Not in our library10.1523/jneurosci.4643-03.2004
- 101.
Kim H Shimojo S O'Doherty JP Overlapping responses for the expectation of juice and money rewards in human ventromedial prefrontal cortexCerebr Cortex2010 214769776
Not in our library10.1093/cercor/bhq145
- 102.
Kalivas PW Volkow ND The neural basis of addiction: a pathology of motivation and choiceAm J Psychiatr2005 162814031413
Not in our library10.1176/appi.ajp.162.8.1403
- 103.
Kessler RC Chiu WT Demler O Merikangas KR Walters EE Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey ReplicationArch Gen Psychiatr2005 626617627
Not in our library10.1001/archpsyc.62.6.617
- 104.
Bechara A Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspectiveNat Neurosci2005 81114581463
Not in our library10.1038/nn1584
- 105.
Bickel WK Miller ML Yi R Kowal BP Lindquist DM Pitcock JA Behavioral and neuroeconomics of drug addiction: competing neural systems and temporal discounting processesDrug Alcohol Depend2007 90Suppl 1S85S91
Not in our library10.1016/j.drugalcdep.2006.09.016
- 106.
Hommer DW Bjork JM Gilman JM Imaging brain response to reward in addictive disordersAnn N Y Acad Sci2011 121615061
Not in our library10.1111/j.1749-6632.2010.05898.x
- 107.
Parvaz MA Alia-Klein N Woicik PA Volkow ND Goldstein RZ Neuroimaging for drug addiction and related behaviorsRev Neurosci2011 226609624
Not in our library10.1515/rns.2011.055
- 108.
Jessor R Jessor SL: Problem Behavior and Psychosocial Development: A Longitudinal Study of Youth1977 Academic, New York
Not in our library
- 109.
Pihl RO Peterson J Finn P Inherited predisposition to alcoholism: characteristics of sons of male alcoholicsJ Abnorm Psychol1990 993291301
Not in our library10.1037//0021-843x.99.3.291
- 110.
Newman JP Wallace JF Diverse pathways to deficient self-regulation: implications for disinhibitory psychopathology in childrenClin Pschol Rev1993 13699720
Not in our library
- 111.
- 112.
Lane SD Cherek DR Risk taking by adolescents with maladaptive behavior historiesExp Clin Psychopharmacol2001 917482
Not in our library10.1037/1064-1297.9.1.74
- 113.
Di Chiara G Imperato A Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving ratsProc Nat Acad Sci1988 851452745278
Not in our library10.1073/pnas.85.14.5274
- 114.
Koob GF Bloom FE Cellular and molecular mechanisms of drug dependenceScience1988 2424879715723
Not in our library10.1126/science.2903550
- 115.
Drevets WC Gautier C Price JC Kupfer DJ Kinahan PE Grace AA Price JL Mathis CA Amphetamine-induced dopamine release in human ventral striatum correlates with euphoriaBiol Psychiatr2001 4928196
Not in our library10.1016/s0006-3223(00)01038-6
- 116.
Volkow ND Wang GJ Fowler JS Gatley SJ Ding YS Logan J Dewey SL Hitzemann R Lieberman J Relationship between psychostimulant-induced "high" and dopamine transporter occupancyProc Natl Acad Sci1996 93191038810392
Not in our library10.1073/pnas.93.19.10388
- 117.
Volkow ND Wang GJ Ma Y Fowler JS Zhu W Maynard L Telang F Vaska P Ding YS Wong C Swanson JM Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusersJ Neurosci2003 23361146111468
Not in our library10.1523/jneurosci.23-36-11461.2003
- 118.
Volkow ND Wang GJ Telang F Fowler JS Logan J Childress AR Jayne M Ma Y Wong C Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addictionJ Neurosci2006 262465836588
Not in our library10.1523/jneurosci.1544-06.2006
- 119.
Waelti P Dickinson A Schultz W Dopamine responses comply with basic assumptions of formal learning theoryNature2001 41268424348
Not in our library10.1038/35083500
- 120.
Volkow ND Fowler JS Wang GJ Baler R Telang F Imaging dopamine's role in drug abuse and addictionNeuropharmacology2009 56Suppl 138
Not in our library10.1016/j.neuropharm.2008.05.022
- 121.
Fibiger HC LePiane FG Jakubovic A Phillips AG The role of dopamine in intracranial self-stimulation of the ventral tegmental areaJ Neurosci1987 71238883896
Not in our library10.1523/jneurosci.07-12-03888.1987
- 122.
Willuhn I Wanat MJ Clark JJ Phillips PE Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuseCurr Top Behav Neurosci2010 32971
Not in our library10.1007/7854_2009_27
- 123.
Wise RA Bozarth MA A psychomotor stimulant theory of addictionPsychol Rev1987 944469492
Not in our library
- 124.
Koob GF Le Moal M Addiction and the brain antireward systemAnnu Rev Psychol2008 592953
Not in our library10.1146/annurev.psych.59.103006.093548
- 125.
Cheer JF Wassum KM Heien ML Phillips PE Wightman RM Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake ratsJ Neurosci2004 241843934400
Not in our library10.1523/jneurosci.0529-04.2004
- 126.
Cheer JF Wassum KM Sombers LA Heien ML Ariansen JL Aragona BJ Phillips PE Wightman RM Phasic dopamine release evoked by abused substances requires cannabinoid receptor activationJ Neurosci2007 274791795
Not in our library10.1523/jneurosci.4152-06.2007
- 127.
Stuber GD Wightman RM Carelli RM Extinction of cocaine self-administration reveals functionally and temporally distinct dopaminergic signals in the nucleus accumbensNeuron2005 464661669
Not in our library10.1016/j.neuron.2005.04.036
- 128.
Ritz MC Lamb RJ Goldberg SR Kuhar MJ Cocaine receptors on dopamine transporters are related to self-administration of cocaineScience1987 237481912191223
Not in our library10.1126/science.2820058
- 129.
Panlilio LV Goldberg SR Self-administration of drugs in animals and humans as a model and an investigative toolAddiction2007 1021218631870
Not in our library10.1111/j.1360-0443.2007.02011.x
- 130.
Yokel R Intravenous Self-Administration: Response Rates, the Effects of Pharmacological Challenges, and Drug Preference1987 Springer, New York
Not in our library
- 131.
Carlezon WA Devine DP Wise RA Habit-forming actions of nomifensine in nucleus accumbensPsychopharmacol Berl1995 1222194197
Not in our library10.1007/bf02246095
- 132.
Woolverton WL Goldberg LI Ginos JZ Intravenous self-administration of dopamine receptor agonists by rhesus monkeysJ Pharmacol Exp Therapy1984 2303678683
Not in our library
- 133.
Yokel RA Wise RA Amphetamine-type reinforcement by dopaminergic agonists in the ratPsychopharmacol Berl1978 583289296
Not in our library10.1007/bf00427393
- 134.
Caine SB Koob GF Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the ratJ Pharmacol Exp Ther1994 2701209218
Not in our library
- 135.
De Wit H Wise RA Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamineCan J Psychol1977 314195203
Not in our library10.1037/h0081662
- 136.
Ettenberg A Pettit HO Bloom FE Koob GF Heroin and cocaine intravenous self-administration in rats: Mediation by separate neural systemsPsychopharmacol Berl1982 783204209
Not in our library10.1007/bf00428151
- 137.
Roberts DC Koob GF Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in ratsPharmacol Biochem Behav1982 175901904
Not in our library10.1016/0091-3057(82)90469-5
- 138.
Xi ZX Stein EA Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine releaseJ Pharmacol Exp Therapy1999 290313691374
Not in our library
- 139.
Corrigall WA Franklin KB Coen KM Clarke PB The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotinePsychopharmacol Berl1992 1072–3285289
Not in our library10.1007/bf02245149
- 140.
Lyness WH Friedle NM Moore KE Destruction of dopaminergic nerve terminals in nucleus accumbens: Effect on d-amphetamine self-administrationPharmacol Biochem Behav1979 115553556
Not in our library10.1016/0091-3057(79)90040-6
- 141.
Pettit HO Ettenberg A Bloom FE Koob GF Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in ratsPsychopharmacol Berl1984 842167173
Not in our library10.1007/bf00427441
- 142.
Roberts DC Koob GF Klonoff P Fibiger HC Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbensPharmacol Biochem Behav1980 125781787
Not in our library10.1016/0091-3057(80)90166-5
- 143.
Shoaib M Swanner LS Beyer CE Goldberg SR Schindler CW The GABAB agonist baclofen modifies cocaine self-administration in ratsBehav Pharmacol1998 93195206
Not in our library
- 144.
Wexler BE Gottschalk CH Fulbright RK Prohovnik I Lacadie CM Rounsaville BJ Gore JC Functional magnetic resonance imaging of cocaine cravingAm J Psychiatr2001 15818695
Not in our library10.1176/appi.ajp.158.1.86
- 145.
Buhler M Vollstadt-Klein S Kobiella A Budde H Reed LJ Braus DF Buchel C Smolka MN Nicotine Dependence Is Characterized by Disordered Reward Processing in a Network Driving MotivationBiol Psychiatry2009
Not in our library10.1016/j.biopsych.2009.10.029
- 146.
Myrick H Anton RF Li X Henderson S Drobes D Voronin K George MS Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to cravingNeuropsychopharmacology2004 292393402
Not in our library10.1038/sj.npp.1300295
- 147.
Oberlin BG Dzemidzic M Bragulat V Lehigh CA Talavage T O'Connor SJ Kareken DA Limbic responses to reward cues correlate with antisocial trait density in heavy drinkersNeuroimage2011 601644652
Not in our library10.1016/j.neuroimage.2011.12.043
- 148.
Filbey FM Schacht JP Myers US Chavez RS Hutchison KE Marijuana craving in the brainProc Natl Acad Sci2009 106311301613021
Not in our library10.1073/pnas.0903863106
- 149.
Volkow ND Wang GJ Kollins SH Wigal TL Newcorn JH Telang F Fowler JS Zhu W Logan J Ma Y Pradhan K Wong C Swanson JM Evaluating dopamine reward pathway in ADHD: Clinical implicationsJAMA2009 3021010841091
Not in our library10.1001/jama.2009.1308
- 150.
Bozarth MA New perspectives on cocaine addiction: recent findings from animal researchCan J Physiol Pharmacol1989 67911581167
Not in our library10.1139/y89-185
- 151.
Comings DE Blum K Reward deficiency syndrome: genetic aspects of behavioral disordersProgr Brain Res2000 126325341
Not in our library10.1016/s0079-6123(00)26022-6
- 152.
Asensio S Romero MJ Palau C Sanchez A Senabre I Morales JL Carcelen R Romero FJ Altered neural response of the appetitive emotional system in cocaine addiction: An fMRI StudyAddict Biol2010 154504516
Not in our library10.1111/j.1369-1600.2010.00230.x
- 153.
Gilman JM Hommer DW Modulation of brain response to emotional images by alcohol cues in alcohol-dependent patientsAddiction Biol2008 133–4423434
Not in our library10.1111/j.1369-1600.2008.00111.x
- 154.
Bühler M Vollstadt-Klein S Kobiella A Budde H Reed LJ Braus DF Buchel C Smolka MN Nicotine dependence is characterized by disordered reward processing in a network driving motivationBiol Psychiatr2010 678745752
Not in our library10.1016/j.biopsych.2009.10.029
- 155.
Andrews MM Meda SA Thomas AD Potenza MN Krystal JH Worhunsky P Stevens MC O'Malley S Book GA Reynolds B Pearlson GD Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factorsBiol Psychiatr2011 698675683
Not in our library10.1016/j.biopsych.2010.09.049
- 156.
Lubman DI Yucel M Kettle JW Scaffidi A Mackenzie T Simmons JG Allen NB Responsiveness to drug cues and natural rewards in opiate addiction: Associations with later heroin useArch Gen Psychiatr2009 662205212
Not in our library10.1001/archgenpsychiatry.2008.522
- 157.
Luo S Ainslie G Giragosian L Monterosso JR Striatal hyposensitivity to delayed rewards among cigarette smokersDrug Alcohol Depend2011 1161–31823
Not in our library10.1016/j.drugalcdep.2010.11.012
- 158.
Jia Z Worhunsky PD Carroll KM Rounsaville BJ Stevens MC Pearlson GD Potenza MN An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependenceBiol Psychiatr2011 706553560
Not in our library10.1016/j.biopsych.2011.05.008
- 159.
Schneider S Peters J Bromberg U Brassen S Miedl SF Banaschewski T Barker GJ Conrod P Flor H Garavan H Risk taking and the adolescent reward system: A potential common link to Substance abuseAm J Psychiatr2011 16913946
Not in our library10.1176/appi.ajp.2011.11030489
- 160.
Peters J Bromberg U Schneider S Brassen S Menz M Banaschewski T Conrod PJ Flor H Gallinat J Garavan H Lower ventral striatal activation during reward anticipation in adolescent smokersAm J Psychiatr2011 1685540
Not in our library10.1176/appi.ajp.2010.10071024
- 161.
Nestor L Hester R Garavan H Increased ventral striatal BOLD activity during non-drug reward anticipation in cannabis usersNeuroimage2010 49111331143
Not in our library10.1016/j.neuroimage.2009.07.022
- 162.
Koob GF Le Moal M Plasticity of reward neurocircuitry and the 'dark side' of drug addictionNat Neurosci2005 81114421444
Not in our library10.1038/nn1105-1442
- 163.
Martinez D Narendran R Imaging neurotransmitter release by drugs of abuseCurr Top Behav Neurosci2010 3219245
Not in our library10.1007/7854_2009_34
- 164.
Martinez D Broft A Foltin RW Slifstein M Hwang DR Huang Y Perez A Frankle WG Cooper T Kleber HD Fischman MW Laruelle M Cocaine dependence and d2 receptor availability in the functional subdivisions of the striatum: Relationship with cocaine-seeking behaviorNeuropsychopharmacology2004 29611901202
Not in our library10.1038/sj.npp.1300420
- 165.
Volkow ND Fowler JS Wang GJ Hitzemann R Logan J Schlyer DJ Dewey SL Wolf AP Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusersSynapse1993 142169177
Not in our library10.1002/syn.890140210
- 166.
Volkow ND Fowler JS Wolf AP Schlyer D Shiue CY Alpert R Dewey SL Logan J Bendriem B Christman D Effects of chronic cocaine abuse on postsynaptic dopamine receptorsAm J Psychiatr1990 1476719724
Not in our library10.1176/ajp.147.6.719
- 167.
Volkow ND Wang GJ Fowler JS Logan J Gatley SJ Hitzemann R Chen AD Dewey SL Pappas N Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjectsNature1997 3866627830833
Not in our library10.1038/386830a0
- 168.
Wang GJ Volkow ND Fowler JS Logan J Abumrad NN Hitzemann RJ Pappas NS Pascani K Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawalNeuropsychopharmacology1997 162174182
Not in our library10.1016/s0893-133x(96)00184-4
- 169.
Hietala J West C Syvalahti E Nagren K Lehikoinen P Sonninen P Ruotsalainen U Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependencePsychopharmacol (Berl)1994 1163285290
Not in our library10.1007/bf02245330
- 170.
Volkow ND Wang GJ Fowler JS Logan J Hitzemann R Ding YS Pappas N Shea C Piscani K Decreases in dopamine receptors but not in dopamine transporters in alcoholicsAlcoholism Clin Exp Res1996 20915941598
Not in our library10.1111/j.1530-0277.1996.tb05936.x
- 171.
Volkow ND Chang L Wang GJ Fowler JS Ding YS Sedler M Logan J Franceschi D Gatley J Hitzemann R Gifford A Wong C Pappas N Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortexAm J Psychiatr2001 1581220152021
Not in our library10.1176/appi.ajp.158.12.2015
- 172.
Volkow ND Wang G Fowler JS Logan J Gerasimov M Maynard L Ding Y Gatley SJ Gifford A Franceschi D Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brainJ Neurosci2001 212RC121
Not in our library10.1523/jneurosci.21-02-j0001.2001
- 173.
Melis M Spiga S Diana M The dopamine hypothesis of drug addiction: Hypodopaminergic stateInt Rev Neurobiol2005 63101154
Not in our library10.1016/s0074-7742(05)63005-x
- 174.
Volkow ND Fowler JS Wang GJ Role of dopamine in drug reinforcement and addiction in humans: results from imaging studiesBehav Pharmacol2002 135–6355366
Not in our library10.1097/00008877-200209000-00008
- 175.
Volkow ND Wang GJ Fowler JS Thanos PP Logan J Gatley SJ Gifford A Ding YS Wong C Pappas N Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication studySynapse2002 4627982
Not in our library10.1002/syn.10137
- 176.
Schott BH Minuzzi L Krebs RM Elmenhorst D Lang M Winz OH Seidenbecher CI Coenen HH Heinze HJ Zilles K Duzel E Bauer A Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlates with reward-related ventral striatal dopamine releaseJ Neurosci2008 28521431114319
Not in our library10.1523/jneurosci.2058-08.2008
- 177.
Karila L Weinstein A Aubin HJ Benyamina A Reynaud M Batki SL Pharmacological approaches to methamphetamine dependence: A focused reviewBr J Clin Pharmacol2010 696578592
Not in our library10.1111/j.1365-2125.2010.03639.x
- 178.
Anderson AL Reid MS Li SH Holmes T Shemanski L Slee A Smith EV Kahn R Chiang N Vocci F Ciraulo D Dackis C Roache JD Salloum IM Somoza E Urschel HC Elkashef AM Modafinil for the treatment of cocaine dependenceDrug Alcohol Depend2009 1041–2133139
Not in our library10.1016/j.drugalcdep.2009.04.015
- 179.
McElhiney MC Rabkin JG Rabkin R Nunes EV Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV + gay men: a pilot studyAm J Drug Alcohol Abuse2009 3513437
Not in our library10.1080/00952990802342907
- 180.
Garrett BE Rose CA Henningfield JE Tobacco addiction and pharmacological interventionsExpet Opin Pharmacother2001 21015451555
Not in our library10.1517/14656566.2.10.1545
- 181.
Grabowski J Rhoades H Schmitz J Stotts A Daruzska LA Creson D Moeller FG Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trialJ Clin Psychopharmacol2001 215522526
Not in our library10.1097/00004714-200110000-00010
- 182.
Meredith CW Jaffe C Yanasak E Cherrier M Saxon AJ An open-label pilot study of risperidone in the treatment of methamphetamine dependenceJ Psychoactive Drugs2007 392167172
Not in our library10.1080/02791072.2007.10399875
- 183.
Stoops WW Lile JA Glaser PE Rush CR A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamineDrug Alcohol Depend2006 842206209
Not in our library10.1016/j.drugalcdep.2006.02.004
- 184.
Brent DA Maalouf FT Pediatric depression: is there evidence to improve evidence-based treatments?J Child Psychol Psychiatr2009 501–2143152
Not in our library10.1111/j.1469-7610.2008.02037.x
- 185.
Kovacs M Presentation and course of major depressive disorder during childhood and later years of the life spanJ Am Acad Child Adolesc Psychiatr1996 356705715
Not in our library10.1097/00004583-199606000-00010
- 186.
Rohde P Beevers CG Stice E O'Neil K Major and minor depression in female adolescents: Onset, course, symptom presentation, and demographic associationsJ Clin Psychol2009 651213391349
Not in our library10.1002/jclp.20629
- 187.
- 188.
Davidson RJ Affective style and affective disorders: Perspectives from affective neuroscienceCognit Emot1998 123307330
Not in our library
- 189.
Willner P Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMSNeuropsychobiology2005 52290110
Not in our library10.1159/000087097
- 190.
Willner P Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluationPsychopharmacol Berl1997 1344319329
Not in our library10.1007/s002130050456
- 191.
Willner P Towell A Sampson D Sophokleous S Muscat R Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressantPsychopharmacol Berl1987 933358364
Not in our library10.1007/bf00187257
- 192.
Muscat R Papp M Willner P Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotilinePsychopharmacol (Berl)1992 1094433438
Not in our library10.1007/bf02247719
- 193.
Papp M Muscat R Willner P Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stressPsychopharmacol Berl1993 1101–2152158
Not in our library10.1007/bf02246965
- 194.
Papp M Willner P Muscat R Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedoniaPsychopharmacol Berl1993 1101–2159164
Not in our library10.1007/bf02246966
- 195.
- 196.
Bekris S Antoniou K Daskas S Papadopoulou-Daifoti Z Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strainsBehav Brain Res2005 16114559
Not in our library10.1016/j.bbr.2005.01.005
- 197.
Imperato A Angelucci L Casolini P Zocchi A Puglisi-Allegra S Repeated stressful experiences differently affect limbic dopamine release during and following stressBrain Res1992 5772194199
Not in our library10.1016/0006-8993(92)90274-d
- 198.
Mangiavacchi S Masi F Scheggi S Leggio B De Montis MG Gambarana C Long-term behavioral and neurochemical effects of chronic stress exposure in ratsJ Neurochem2001 79611131121
Not in our library10.1046/j.1471-4159.2001.00665.x
- 199.
Ossowska G Nowa G Kata R Klenk-Majewska B Danilczuk Z Zebrowska-Lupina I Brain monoamine receptors in a chronic unpredictable stress model in ratsJ Neural Transm2001 1083311319
Not in our library10.1007/s007020170077
- 200.
Dunlop BW Nemeroff CB The role of dopamine in the pathophysiology of depressionArch Gen Psychiatr2007 643327337
Not in our library10.1001/archpsyc.64.3.327
- 201.
Eshel N Roiser JP Reward and punishment processing in depressionBiol Psychiatr2010 682118124
Not in our library10.1016/j.biopsych.2010.01.027
- 202.
Hasler G Northoff G Discovering imaging endophenotypes for major depressionMol Psychiatr2011 166604619
Not in our library10.1038/mp.2011.23
- 203.
Henriques JB Davidson RJ Decreased responsiveness to reward in depressionCognit Emot2000 145711724
Not in our library
- 204.
McFarland BR Klein DN Emotional reactivity in depression: diminished responsiveness to anticipated reward but not to anticipated punishment or to nonreward or avoidanceDepress Anxiety2009 262117122
Not in our library10.1002/da.20513
- 205.
Pizzagalli DA Iosifescu D Hallett LA Ratner KG Fava M Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward taskJ Psychiatr Res2008 4317687
Not in our library10.1016/j.jpsychires.2008.03.001
- 206.
Robinson OJ Cools R Carlisi CO Sahakian BJ Drevets WC Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorderAm J Psychiatr2011 1692152159
Not in our library10.1176/appi.ajp.2011.11010137
- 207.
Liu W Chan RCK Wang L Huang J Cheung EFC Gong Q Gollan JK Deficits in sustaining reward responses in subsyndromal and syndromal major depressionProgr Neuro Psychopharmacol Biol Psychiatr2011 35410451052
Not in our library10.1016/j.pnpbp.2011.02.018
- 208.
Tremblay LK Naranjo CA Cardenas L Herrmann N Busto UE Probing brain reward system function in major depressive disorder: Altered response to dextroamphetamineArch Gen Psychiatr2002 595409416
Not in our library10.1001/archpsyc.59.5.409
- 209.
- 210.
Epstein J Pan H Kocsis JH Yang Y Butler T Chusid J Hochberg H Murrough J Strohmayer E Stern E Silbersweig DA Lack of ventral striatal response to positive stimuli in depressed versus normal subjectsAm J Psychiatr2006 1631017841790
Not in our library10.1176/ajp.2006.163.10.1784
- 211.
Keedwell PA Andrew C Williams SC Brammer MJ Phillips ML The neural correlates of anhedonia in major depressive disorderBiol Psychiatr2005 58843853
Not in our library10.1016/j.biopsych.2005.05.019
- 212.
Kumar P Waiter G Ahearn T Milders M Reid I Steele JD Abnormal temporal difference reward-learning signals in major depressionBrain2008 131820842093
Not in our library10.1093/brain/awn136
- 213.
Mitterschiffthaler MT Kumari V Malhi GS Brown RG Giampietro VP Brammer MJ Suckling J Poon L Simmons A Andrew C Sharma T Neural response to pleasant stimuli in anhedonia: an fMRI studyNeuroreport2003 142177182
Not in our library10.1097/00001756-200302100-00003
- 214.
Schaefer HS Putnam KM Benca RM Davidson RJ Event-related functional magnetic resonance imaging measures of neural activity to positive social stimuli in pre- and post-treatment depressionBiol Psychiatr2006 609974986
Not in our library10.1016/j.biopsych.2006.03.024
- 215.
Kumari V Mitterschiffthaler MT Teasdale JD Malhi GS Brown RG Giampietro V Brammer MJ Poon L Simmons A Williams SC Checkley SA Sharma T Neural abnormalities during cognitive generation of affect in treatment-resistant depressionBiol Psychiatr2003 548777791
Not in our library10.1016/s0006-3223(02)01785-7
- 216.
Ochsner KN Ray RD Cooper JC Robertson ER Chopra S Gabrieli JD Gross JJ For better or for worse: neural systems supporting the cognitive down- and up-regulation of negative emotionNeuroimage2004 232483499
Not in our library10.1016/j.neuroimage.2004.06.030
- 217.
Keedwell PA Andrew C Williams SCR Brammer MJ Zelaya F Phillips ML The neural correlates of depressionBiol Psychiatr2003 53171S
Not in our library
- 218.
Liotti M Mayberg HS McGinnis S Brannan SL Jerabek P Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depressionAm J Psychiatr2002 1591118301840
Not in our library10.1176/appi.ajp.159.11.1830
- 219.
Forbes EE Christopher May J Siegle GJ Ladouceur CD Ryan ND Carter CS Birmaher B Axelson DA Dahl RE Reward-related decision-making in pediatric major depressive disorder: An fMRI studyJ Child Psychol Psychiatr2006 471010311040
Not in our library10.1111/j.1469-7610.2006.01673.x
- 220.
Forbes EE Hariri AR Martin SL Silk JS Moyles DL Fisher PM Brown SM Ryan ND Birmaher B Axelson DA Dahl RE Altered striatal activation predicting real-world positive affect in adolescent major depressive disorderAm J Psychiatr2009 16616473
Not in our library10.1176/appi.ajp.2008.07081336
- 221.
Forbes EE Olino TM Ryan ND Birmaher B Axelson D Moyles DL Dahl RE Reward-related brain function as a predictor of treatment response in adolescents with major depressive disorderCognit Affect Behav Neurosci2010 101107118
Not in our library10.3758/cabn.10.1.107
- 222.
Olino TM McMakin DL Dahl RE Ryan ND Silk JS Birmaher B Axelson DA Forbes EE "I won, but I'm not getting my hopes up": depression moderates the relationship of outcomes and reward anticipationPsychiatr Res2011 1943393395
Not in our library10.1016/j.pscychresns.2011.04.009
- 223.
Osuch EA Bluhm RL Williamson PC Theberge J Densmore M Neufeld RW Brain activation to favorite music in healthy controls and depressed patientsNeuroreport2009 201312041208
Not in our library10.1097/wnr.0b013e32832f4da3
- 224.
Pizzagalli DA Holmes AJ Dillon DG Goetz EL Birk JL Bogdan R Dougherty DD Iosifescu DV Rauch SL Fava M Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorderAm J Psychiatr2009 1666702710
Not in our library10.1176/appi.ajp.2008.08081201
- 225.
Steele J Kumar P Ebmeier K Blunted response to feedback information in depressive illnessBrain2007 13092367
Not in our library10.1093/brain/awm150
- 226.
Tremblay LK Naranjo CA Graham SJ Herrmann N Mayberg HS Hevenor S Busto UE Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probeArch Gen Psychiatr2005 62111228
Not in our library10.1001/archpsyc.62.11.1228
- 227.
Wacker J Dillon DG Pizzagalli DA The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: Integration of resting EEG, fMRI, and volumetric techniquesNeuroimage2009 461327337
Not in our library10.1016/j.neuroimage.2009.01.058
- 228.
Smoski MJ Felder J Bizzell J Green SR Ernst M Lynch TR Dichter GS fMRI of alterations in reward selection, anticipation, and feedback in major depressive disorderJ Affect Disord2009 1181–36978
Not in our library10.1016/j.jad.2009.01.034
- 229.
Knutson B Bhanji JP Cooney RE Atlas LY Gotlib IH Neural responses to monetary incentives in major depressionBiol Psychiatr2008 637686692
Not in our library10.1016/j.biopsych.2007.07.023
- 230.
Dichter GS Felder JN Petty C Bizzell J Ernst M Smoski MJ The effects of psychotherapy on neural responses to rewards in major depressionBiol Psychiatr2009 669886897
Not in our library10.1016/j.biopsych.2009.06.021
- 231.
Forbes EE Ryan ND Phillips ML Manuck SB Worthman CM Moyles DL Tarr JA Sciarrillo SR Dahl RE Healthy adolescents' neural response to reward: associations with puberty, positive affect, and depressive symptomsJ Am Acad Child Adolesc Psychiatr2010 492162172
Not in our library10.1097/00004583-201002000-00010
- 232.
Smoski MJ Rittenberg A Dichter GS Major depressive disorder is characterized by greater reward network activation to monetary than pleasant image rewardsPsychiatr Res Neuroimaging2011 1943263270
Not in our library10.1016/j.pscychresns.2011.06.012
- 233.
Alloy LB Ambramson LY Raniere D Dyller IM Kendall PC, Butcher JN, Holmbeck GNResearch methods in adult psychopathologyHandbook of Research Methods in Clinical Psychology1999 2Wiley, New York466498
Not in our library
- 234.
Mednick SA McNeil TF Current methodology in research on the etiology of schizophrenia: serious difficulties which suggest the use of the high-risk-group methodPsychol Bull1968 706681693
Not in our library10.1037/h0026836
- 235.
McCabe C Cowen PJ Harmer CJ Neural representation of reward in recovered depressed patientsPsychopharmacol (Berl)2009 2054667677
Not in our library10.1007/s00213-009-1573-9
- 236.
Dichter GS Kozink RV McClernon FJ Smoski MJ Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomesJ Affect Disord2012 136311261134
Not in our library10.1016/j.jad.2011.09.048
- 237.
Kerestes R Ladouceur CD Meda S Nathan PJ Blumberg HP Maloney K Ruf B Saricicek A Pearlson GD Bhagwagar Z Phillips ML Abnormal prefrontal activity subserving attentional control of emotion in remitted depressed patients during a working memory task with emotional distractersPsychol Med2012 422940
Not in our library10.1017/s0033291711001097
- 238.
- 239.
Etkin A Egner T Kalisch R Emotional processing in anterior cingulate and medial prefrontal cortexTrends Cognit Sci2011 1528593
Not in our library10.1016/j.tics.2010.11.004
- 240.
Liu X Hairston J Schrier M Fan J Common and distinct networks underlying reward valence and processing stages: a meta-analysis of functional neuroimaging studiesNeurosci Biobehav Rev2011 35512191236
Not in our library10.1016/j.neubiorev.2010.12.012
- 241.
Wallis JD Kennerley SW Heterogeneous reward signals in prefrontal cortexCurr Opin Neurobiol2010 202191198
Not in our library10.1016/j.conb.2010.02.009
- 242.
Ebert D Feistel H Barocka A Effects of sleep deprivation on the limbic system and the frontal lobes in affective disorders: a study with Tc-99 m-HMPAO SPECTPsychiatr Res1991 404247251
Not in our library10.1016/0925-4927(91)90016-j
- 243.
Ebert D Feistel H Kaschka W Barocka A Pirner A Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation–preliminary resultsBiol Psychiatr1994 3511880885
Not in our library10.1016/0006-3223(94)90024-8
- 244.
Wu J Buchsbaum MS Gillin JC Tang C Cadwell S Wiegand M Najafi A Klein E Hazen K Bunney WE Fallon JH Keator D Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortexAm J Psychiatr1999 156811491158
Not in our library10.1176/ajp.156.8.1149
- 245.
Wu JC Gillin JC Buchsbaum MS Hershey T Johnson JC Bunney WE Effect of sleep deprivation on brain metabolism of depressed patientsAm J Psychiatr1992 1494538543
Not in our library10.1176/ajp.149.4.538
- 246.
Brody AL Saxena S Mandelkern MA Fairbanks LA Ho ML Baxter LR Brain metabolic changes associated with symptom factor improvement in major depressive disorderBiol Psychiatr2001 503171178
Not in our library10.1016/s0006-3223(01)01117-9
- 247.
Brody AL Saxena S Silverman DH Alborzian S Fairbanks LA Phelps ME Huang SC Wu HM Maidment K Baxter LR Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetinePsychiatr Res1999 913127139
Not in our library10.1016/s0925-4927(99)00034-7
- 248.
Mayberg HS Limbic-cortical dysregulation: a proposed model of depressionJ Neuropsychiatr Clin Neurosci1997 93471481
Not in our library10.1176/jnp.9.3.471
- 249.
Mayberg HS Brannan SK Tekell JL Silva JA Mahurin RK McGinnis S Jerabek PA Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical responseBiol Psychiatr2000 488830843
Not in our library10.1016/s0006-3223(00)01036-2
- 250.
Pizzagalli D Pascual-Marqui RD Nitschke JB Oakes TR Larson CL Abercrombie HC Schaefer SM Koger JV Benca RM Davidson RJ Anterior cingulate activity as a predictor of degree of treatment response in major depression: Evidence from brain electrical tomography analysisAm J Psychiatr2001 1583405415
Not in our library10.1176/appi.ajp.158.3.405
- 251.
Kennedy SH Evans KR Kruger S Mayberg HS Meyer JH McCann S Arifuzzman AI Houle S Vaccarino FJ Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depressionAm J Psychiatr2001 1586899905
Not in our library10.1176/appi.ajp.158.6.899
- 252.
Smith GS Reynolds CF Pollock B Derbyshire S Nofzinger E Dew MA Houck PR Milko D Meltzer CC Kupfer DJ Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depressionAm J Psychiatr1999 1565683689
Not in our library10.1176/ajp.156.5.683
- 253.
Lawrence NS Williams AM Surguladze S Giampietro V Brammer MJ Andrew C Frangou S Ecker C Phillips ML Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depressionBiol Psychiatr2004 556578587
Not in our library10.1016/j.biopsych.2003.11.017
- 254.
Meyer JH Ginovart N Boovariwala A Sagrati S Hussey D Garcia A Young T Praschak-Rieder N Wilson AA Houle S Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depressionArch Gen Psychiatr2006 631112091216
Not in our library10.1001/archpsyc.63.11.1209
- 255.
Meltzer CC Price JC Mathis CA Greer PJ Cantwell MN Houck PR Mulsant BH Ben-Eliezer D Lopresti B DeKosky ST Reynolds CF PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disordersAm J Psychiatr1999 1561218711878
Not in our library10.1176/ajp.156.12.1871
- 256.
Meyer JH Kapur S Houle S DaSilva J Owczarek B Brown GM Wilson AA Kennedy SH Prefrontal cortex 5-HT2 receptors in depression: An [18 F]setoperone PET imaging studyAm J Psychiatr1999 156710291034
Not in our library10.1176/ajp.156.7.1029
- 257.
D'Haenen HA Bossuyt A Dopamine D2 receptors in depression measured with single photon emission computed tomographyBiol Psychiatr1994 352128132
Not in our library10.1016/0006-3223(94)91202-5
- 258.
Brunswick DJ Amsterdam JD Mozley PD Newberg A Greater availability of brain dopamine transporters in major depression shown by [99 m Tc]TRODAT-1 SPECT imagingAm J Psychiatr2003 1601018361841
Not in our library10.1176/appi.ajp.160.10.1836
- 259.
Parsey RV Oquendo MA Zea-Ponce Y Rodenhiser J Kegeles LS Pratap M Cooper TB Van Heertum R Mann JJ Laruelle M Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depressionBiol Psychiatr2001 505313322
Not in our library10.1016/s0006-3223(01)01089-7
- 260.
Meyer JH McNeely HE Sagrati S Boovariwala A Martin K Verhoeff NP Wilson AA Houle S Elevated putamen D(2) receptor binding potential in major depression with motor retardation: An [11 C]raclopride positron emission tomography studyAm J Psychiatr2006 163915941602
Not in our library10.1176/ajp.2006.163.9.1594
- 261.
Meyer JH Kruger S Wilson AA Christensen BK Goulding VS Schaffer A Minifie C Houle S Hussey D Kennedy SH Lower dopamine transporter binding potential in striatum during depressionNeuroreport2001 121841214125
Not in our library10.1097/00001756-200112210-00052
- 262.
Ebert D Feistel H Loew T Pirner A Dopamine and depression–striatal dopamine D2 receptor SPECT before and after antidepressant therapyPsychopharmacol Berl1996 12619194
Not in our library10.1007/bf02246416
- 263.
Klimke A Larisch R Janz A Vosberg H Muller-Gartner HW Gaebel W Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECTPsychiatr Res1999 90291101
Not in our library10.1016/s0925-4927(99)00009-8
- 264.
Perala J Suvisaari J Saarni SI Kuoppasalmi K Isometsa E Pirkola S Partonen T Tuulio-Henriksson A Hintikka J Kieseppa T Harkanen T Koskinen S Lonnqvist J Lifetime prevalence of psychotic and bipolar I disorders in a general populationArch Gen Psychiatr2007 6411928
Not in our library10.1001/archpsyc.64.1.19
- 265.
Gruber J A review and synthesis of positive emotion and reward disturbance in bipolar disorderClin Psychol Psychother2011 185356365
Not in our library10.1002/cpp.776
- 266.
Johnson SL Mania and dysregulation in goal pursuit: A reviewClin Psychol Rev2005 252241262
Not in our library10.1016/j.cpr.2004.11.002
- 267.
Gorrindo T Blair RJ Budhani S Dickstein DP Pine DS Leibenluft E Deficits on a probabilistic response-reversal task in patients with pediatric bipolar disorderAm J Psychiatr2005 1621019751977
Not in our library10.1176/appi.ajp.162.10.1975
- 268.
Farmer A Lam D Sahakian B Roiser J Burke A O'Neill N Keating S Smith GP McGuffin P A pilot study of positive mood induction in euthymic bipolar subjects compared with healthy controlsPsychol Med2006 36912131218
Not in our library10.1017/s0033291706007835
- 269.
Meyer B Johnson S Winters R Responsiveness to threat and incentive in bipolar disorder: relations of the BIS/BAS scales with symptomsJ Psychopathol Behav Assess2001 233133143
Not in our library10.1023/a:1010929402770
- 270.
Mueller SC Ng P Temple V Hardin MG Pine DS Leibenluft E Ernst M Perturbed reward processing in pediatric bipolar disorder: An antisaccade studyJ Psychopharmacol2010 24121779
Not in our library10.1177/0269881109353462
- 271.
Blumberg HP Martin A Kaufman J Leung HC Skudlarski P Lacadie C Fulbright RK Gore JC Charney DS Krystal JH Peterson BS Frontostriatal abnormalities in adolescents with bipolar disorder: Preliminary observations from functional MRIAm J Psychiatr2003 160713451347
Not in our library10.1176/appi.ajp.160.7.1345
- 272.
Cerullo MA Adler CM Delbello MP Strakowski SM The functional neuroanatomy of bipolar disorderInt Rev Psychiatr2009 214314322
Not in our library10.1080/09540260902962107
- 273.
Marchand WR Yurgelun-Todd D Striatal structure and function in mood disorders: a comprehensive reviewBipolar Disord2010 128764785
Not in our library10.1111/j.1399-5618.2010.00874.x
- 274.
Strakowski SM Delbello MP Adler CM The functional neuroanatomy of bipolar disorder: a review of neuroimaging findingsMol Psychiatr2005 101105116
Not in our library10.1038/sj.mp.4001585
- 275.
Yurgelun-Todd DA Ross AJ Functional magnetic resonance imaging studies in bipolar disorderCNS Spectr2006 114287297
Not in our library10.1017/s1092852900020782
- 276.
Hwang J Lyoo IK Dager SR Friedman SD Oh JS Lee JY Kim SJ Dunner DL Renshaw PF Basal ganglia shape alterations in Bipolar disorderAm J Psychiatr2006 1632276285
Not in our library10.1176/appi.ajp.163.2.276
- 277.
Liu IY Howe M Garrett A Karchemskiy A Kelley R Alegria D Reiss A Chang K Striatal volumes in pediatric bipolar patients with and without comorbid ADHDPsychiatr Res Neuroimaging2011 19411420
Not in our library10.1016/j.pscychresns.2011.06.008
- 278.
Strakowski SM Adler CM DelBello MP Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder?Bipolar Disorder2002 428088
Not in our library10.1034/j.1399-5618.2002.01160.x
- 279.
Abler B Greenhouse I Ongur D Walter H Heckers S Abnormal reward system activation in maniaNeuropsychopharmacology2008 33922172227
Not in our library10.1038/sj.npp.1301620
- 280.
Jogia J Dima D Kumari V Frangou S Frontopolar cortical inefficiency may underpin reward and working memory dysfunction in bipolar disorderWorld J Biol Psychiatr2011 http://informahealthcare.com/doi/abs/10.3109/15622975.2011.585662.
Not in our library10.3109/15622975.2011.585662
- 281.
Miller R Striatal dopamine in reward and attention: a system for understanding the symptomatology of acute schizophrenia and maniaInt Rev Neurobiol1993 35161278
Not in our library10.1016/s0074-7742(08)60571-1
- 282.
Suhara T Nakayama K Inoue O Fukuda H Shimizu M Mori A Tateno Y D1 dopamine receptor binding in mood disorders measured by positron emission tomographyPsychopharmacol Berl1992 10611418
Not in our library10.1007/bf02253582
- 283.
Amsterdam JD Newberg AB A preliminary study of dopamine transporter binding in bipolar and unipolar depressed patients and healthy controlsNeuropsychobiology2007 553–4167170
Not in our library10.1159/000106476
- 284.
Chang TT Yeh TL Chiu NT Chen PS Huang HY Yang YK Lee IH Lu RB Higher striatal dopamine transporters in euthymic patients with bipolar disorder: A SPECT study with [Tc] TRODAT-1Bipolar Disord2010 121102106
Not in our library10.1111/j.1399-5618.2009.00771.x
- 285.
Anand A Barkay G Dzemidzic M Albrecht D Karne H Zheng QH Hutchins GD Normandin MD Yoder KK Striatal dopamine transporter availability in unmedicated bipolar disorderBipolar Disord2011 134406413
Not in our library10.1111/j.1399-5618.2011.00936.x
- 286.
Pearlson GD Wong DF Tune LE Ross CA Chase GA Links JM Dannals RF Wilson AA Ravert HT Wagner HN In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorderArch Gen Psychiatr1995 526471477
Not in our library10.1001/archpsyc.1995.03950180057008
- 287.
Wong DF Pearlson GD Tune LE Young LT Meltzer CC Dannals RF Ravert HT Reith J Kuhar MJ Gjedde A Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illnessJ Cerebr Blood Metabol1997 173331342
Not in our library10.1097/00004647-199703000-00010
- 288.
Anand A Verhoeff P Seneca N Zoghbi SS Seibyl JP Charney DS Innis RB Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patientsAm J Psychiatr2000 157711081114
Not in our library10.1176/appi.ajp.157.7.1108
- 289.
Yatham LN Liddle PF Shiah IS Lam RW Ngan E Scarrow G Imperial M Stoessl J Sossi V Ruth TJ PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodiumAm J Psychiatr2002 1595768774
Not in our library10.1176/appi.ajp.159.5.768
- 290.
Thase ME Haight BR Richard N Rockett CB Mitton M Modell JG VanMeter S Harriett AE Wang Y Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trialsJ Clin Psychiatr2005 668974981
Not in our library10.4088/jcp.v66n0803
- 291.
Dichter GS Tomarken AJ Shelton RC Freid C Addington S Effects of Bupropion SR on dimensions of mood2001 Poster presented at the annual meeting of The American Psychiatric Association, New Orleans, Louisiana
Not in our library
- 292.
Ostow M Pramipexole for depressionAm J Psychiatr2002 1592320321
Not in our library10.1176/appi.ajp.159.2.320-a
- 293.
Post RM Gerner RH Carman JS Gillin JC Jimerson DC Goodwin FK Bunney WE Effects of a dopamine agonist piribedil in depressed patients: Relationship of pretreatment homovanillic acid to antidepressant responseArch Gen Psychiatr1978 355609615
Not in our library10.1001/archpsyc.1978.01770290091008
- 294.
Moroz G Magni G Fava M Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder"J Clin Psychopharmacol2000 202285
Not in our library10.1097/00004714-200004000-00035
- 295.
Montgomery SA Dopaminergic deficit and the role of amisulpride in the treatment of mood disordersInt Clin Psychopharmacol2002 17Suppl 4discussion S16-17
Not in our library
- 296.
Corrigan MH Denahan AQ Wright CE Ragual RJ Evans DL Comparison of pramipexole, fluoxetine, and placebo in patients with major depressionDepress Anxiety2000 1125865
Not in our library10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
- 297.
Weihs KL Settle EC Batey SR Houser TL Donahue RM Ascher JA Bupropion sustained release versus paroxetine for the treatment of depression in the elderlyJ Clin Psychiatr2000 613196202
Not in our library10.4088/jcp.v61n0309
- 298.
Bodkin JA Lasser RA Wines JD Gardner DM Baldessarini RJ Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapyJ Clin Psychiatr1997 584137145
Not in our library10.4088/jcp.v58n0401
- 299.
Jamerson BD Krishnan KR Roberts J Krishen A Modell JG Effect of bupropion SR on specific symptom clusters of depression: Analysis of the 31-item Hamilton Rating Scale for depressionPsychopharmacol Bull2003 3726778
Not in our library
- 300.
Tomarken AJ Dichter GS Freid C Addington S Shelton RC Assessing the effects of Bupropion SR on mood dimensions of depressionJ Affect Disord2004 783235241
Not in our library10.1016/s0165-0327(02)00306-3
- 301.
Zhou QY Palmiter RD Dopamine-deficient mice are severely hypoactive, adipsic, and aphagicCell1995 83711971209
Not in our library10.1016/0092-8674(95)90145-0
- 302.
Szczypka MS Mandel RJ Donahue BA Snyder RO Leff SE Palmiter RD Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient miceNeuron1999 221167178
Not in our library10.1016/s0896-6273(00)80688-1
- 303.
- 304.
Szczypka MS Kwok K Brot MD Marck BT Matsumoto AM Donahue BA Palmiter RD Dopamine production in the caudate putamen restores feeding in dopamine-deficient miceNeuron2001 303819828
Not in our library10.1016/s0896-6273(01)00319-1
- 305.
Szczypka MS Rainey MA Palmiter RD Dopamine is required for hyperphagia in Lep(ob/ob) miceNat Genet2000 251102104
Not in our library10.1038/75484
- 306.
Kelley AE Functional specificity of ventral striatal compartments in appetitive behaviorsAnn N Y Acad Sci1999 8777190
Not in our library10.1111/j.1749-6632.1999.tb09262.x
- 307.
Koob GF Drugs of abuse: anatomy, pharmacology and function of reward pathwaysTrends Pharmacol Sci1992 135177184
Not in our library10.1016/0165-6147(92)90060-j
- 308.
Phillips AG Atkinson LJ Blackburn JR Blaha CD Increased extracellular dopamine in the nucleus accumbens of the rat elicited by a conditional stimulus for food: an electrochemical studyCan J Physiol Pharmacol1993 715–6387393
Not in our library10.1139/y93-059
- 309.
Schultz W Dickinson A Neuronal coding of prediction errorsAnnu Rev Neurosci2000 23473500
Not in our library10.1146/annurev.neuro.23.1.473
- 310.
Wilson C Nomikos GG Collu M Fibiger HC Dopaminergic correlates of motivated behavior: importance of driveJ Neurosci1995 157 Pt 251695178
Not in our library10.1523/jneurosci.15-07-05169.1995
- 311.
Phillips GD Robbins TW Everitt BJ Bilateral intra-accumbens self-administration of d-amphetamine: antagonism with intra-accumbens SCH-23390 and sulpiridePsychopharmacol Berl1994 1143477485
Not in our library10.1007/bf02249339
- 312.
Pecina S Berridge KC Opioid site in nucleus accumbens shell mediates eating and hedonic 'liking' for food: Map based on microinjection Fos plumesBrain Res2000 8631–27186
Not in our library10.1016/s0006-8993(00)02102-8
- 313.
Stratford TR Kelley AE GABA in the nucleus accumbens shell participates in the central regulation of feeding behaviorJ Neurosci1997 171144344440
Not in our library10.1523/jneurosci.17-11-04434.1997
- 314.
White NM Control of sensorimotor function by dopaminergic nigrostriatal neurons: influence on eating and drinkingNeurosci Biobehav Rev1986 1011536
Not in our library10.1016/0149-7634(86)90030-8
- 315.
Zigmond MJ Stricker EM Deficits in feeding behavior after intraventricular injection of 6-hydroxydopamine in ratsScience1972 177405512111214
Not in our library10.1126/science.177.4055.1211
- 316.
Fairburn CG Harrison PJ Eating disordersLancet2003 3619355407416
Not in our library10.1016/s0140-6736(03)12378-1
- 317.
Volkow ND Wang GJ Fowler JS Telang F Overlapping neuronal circuits in addiction and obesity: evidence of systems pathologyPhilosophical Transactions of the Royal Society of London. Ser B Biol Sci2008 363150731913200
Not in our library10.1098/rstb.2008.0107
- 318.
Hoebel BG Hernandez L Schwartz DH Mark GP Hunter GA Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implicationsAnn N Y Acad Sci1989 575171191
Not in our library10.1111/j.1749-6632.1989.tb53242.x
- 319.
Broft AI Berner LA Martinez D Walsh BT Bulimia nervosa and evidence for striatal dopamine dysregulation: a conceptual reviewPhysiol Behav2011 1041122127
Not in our library10.1016/j.physbeh.2011.04.028
- 320.
Huebner HF Endorphins, Eating Disorders, and Other Addictive Behaviors1993 1Norton, New York
Not in our library
- 321.
Joos AAB Saum B van Elst LT Perlov E Glauche V Hartmann A Freyer T Tüscher O Zeeck A Amygdala hyperreactivity in restrictive anorexia nervosaPsychiatr Res Neuroimaging2011 1913189195
Not in our library10.1016/j.pscychresns.2010.11.008
- 322.
Bohon C Stice E Reward abnormalities among women with full and subthreshold bulimia nervosa: a functional magnetic resonance imaging studyInt J Eat Disord2011 447585595
Not in our library10.1002/eat.20869
- 323.
Wagner A Aizenstein H Venkatraman VK Bischoff-Grethe A Fudge J May JC Frank GK Bailer UF Fischer L Putnam K Kaye WH Altered striatal response to reward in bulimia nervosa after recoveryInt J Eat Disord2010 434289294
Not in our library10.1002/eat.20699
- 324.
Frank GK Wagner A Achenbach S McConaha C Skovira K Aizenstein H Carter CS Kaye WH Altered brain activity in women recovered from bulimic-type eating disorders after a glucose challenge: a pilot studyInt J Eat Disord2006 3917679
Not in our library10.1002/eat.20210
- 325.
Uher R Murphy T Brammer MJ Dalgleish T Phillips ML Ng VW Andrew CM Williams SCR Campbell IC Treasure J Medial prefrontal cortex activity associated with symptom provocation in eating disordersAm J Psychiatr2004 161712381246
Not in our library10.1176/appi.ajp.161.7.1238
- 326.
Schienle A Schafer A Hermann A Vaitl D Binge-eating disorder: Reward sensitivity and brain activation to images of foodBiol Psychiatr2009 658654661
Not in our library10.1016/j.biopsych.2008.09.028
- 327.
- 328.
Davis C Levitan RD Kaplan AS Carter J Reid C Curtis C Patte K Kennedy JL Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case–control study of binge eating disorderNeuropsychopharmacology2007 321021992206
Not in our library10.1038/sj.npp.1301348
- 329.
Kaplan AS Levitan RD Yilmaz Z Davis C Tharmalingam S Kennedy JL A DRD4/BDNF gene-gene interaction associated with maximum BMI in women with bulimia nervosaInt J Eat Disord2008 4112228
Not in our library10.1002/eat.20474
- 330.
Nisoli E Brunani A Borgomainerio E Tonello C Dioni L Briscini L Redaelli G Molinari E Cavagnini F Carruba MO D2 dopamine receptor (DRD2) gene Taq1A polymorphism and the eating-related psychological traits in eating disorders (Anorexia Nervosa and Bulimia) and obesityEat Weight Disord2007 1229196
Not in our library10.1007/bf03327583
- 331.
Tauscher J Pirker W Willeit M de Zwaan M Bailer U Neumeister A Asenbaum S Lennkh C Praschak-Rieder N Brucke T Kasper S [123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosaBiol Psychiatr2001 494326332
Not in our library10.1016/s0006-3223(00)00951-3
- 332.
Alexander W Prozac wins new indication for bulimia nervosaDrug Topics1997 141634
Not in our library
- 333.
Jackson CW Cates M Lorenz R Pharmacotherapy of eating disordersNutr Clin Pract2010 252143159
Not in our library10.1177/0884533610362239
- 334.
Watson KK Werling DM Zucker NL Platt ML Altered social reward and attention in anorexia nervosaFront Psychol2010 136
Not in our library10.3389/fpsyg.2010.00036
- 335.
Kringelbach ML O'Doherty J Rolls ET Andrews C Activation of the human orbitofrontal cortex to a liquid food stimulus is correlated with its subjective pleasantnessCerebr Cortex2003 131010641071
Not in our library10.1093/cercor/13.10.1064
- 336.
O'Doherty J Winston J Critchley H Perrett D Burt DM Dolan RJ Beauty in a smile: The role of medial orbitofrontal cortex in facial attractivenessNeuropsychologia2003 412147155
Not in our library10.1016/s0028-3932(02)00145-8
- 337.
Zucker NL Losh M Bulik CM LaBar KS Piven J Pelphrey KA Anorexia nervosa and autism spectrum disorders: guided investigation of social cognitive endophenotypesPsychol Bull2007 13369761006
Not in our library10.1037/0033-2909.133.6.976
- 338.
Jappe LM Frank GKW Shott ME Rollin MDH Pryor T Hagman JO Yang TT Davis E Heightened sensitivity to reward and punishment in anorexia nervosaInt J Eat Disord2011 444317324
Not in our library10.1002/eat.20815
- 339.
Fladung AK Gron G Grammer K Herrnberger B Schilly E Grasteit S Wolf RC Walter H von Wietersheim J A neural signature of anorexia nervosa in the ventral striatal reward systemAm J Psychiatr2010 1672206212
Not in our library10.1176/appi.ajp.2009.09010071
- 340.
Joos AAB Saum B Zeeck A Perlov E Glauche V Hartmann A Freyer T Sandholz A Unterbrink T van Elst LT Tüscher O Frontocingular dysfunction in Bulimia Nervosa when confronted with disease-specific stimuliEur Eat Disord Rev2011 195447453
Not in our library10.1002/erv.1150
- 341.
Wagner A Aizenstein H Venkatraman VK Fudge J May JC Mazurkewicz L Frank GK Bailer UF Fischer L Nguyen V Carter C Putnam K Kaye WH Altered reward processing in women recovered from anorexia nervosaAm J Psychiatr2007 1641218421849
Not in our library10.1176/appi.ajp.2007.07040575
- 342.
Burger KS Stice E Relation of dietary restraint scores to activation of reward-related brain regions in response to food intake, anticipated intake, and food picturesNeuroimage2011 551233239
Not in our library10.1016/j.neuroimage.2010.12.009
- 343.
Frank GK Bailer UF Henry SE Drevets W Meltzer CC Price JC Mathis CA Wagner A Hoge J Ziolko S Barbarich-Marsteller N Weissfeld L Kaye WH Increased dopamine D2/D3 receptor binding after recovery from anorexia nervosa measured by positron emission tomography and [11c]racloprideBiol Psychiatr2005 5811908912
Not in our library10.1016/j.biopsych.2005.05.003
- 344.
Bergen AW Yeager M Welch RA Haque K Ganjei JK van den Bree MB Mazzanti C Nardi I Fichter MM Halmi KA Kaplan AS Strober M Treasure J Woodside DB Bulik CM Bacanu SA Devlin B Berrettini WH Goldman D Kaye WH Association of multiple DRD2 polymorphisms with anorexia nervosaNeuropsychopharmacology2005 30917031710
Not in our library10.1038/sj.npp.1300719
- 345.
Brambilla F Garcia CS Fassino S Daga GA Favaro A Santonastaso P Ramaciotti C Bondi E Mellado C Borriello R Monteleone P Olanzapine therapy in anorexia nervosa: Psychobiological effectsInt Clin Psychopharmacol2007 224197204
Not in our library10.1097/yic.0b013e328080ca31
- 346.
Brambilla F Monteleone P Maj M Olanzapine-induced weight gain in anorexia nervosa: Involvement of leptin and ghrelin secretion?Psychoneuroendocrinology2007 324402406
Not in our library10.1016/j.psyneuen.2007.02.005
- 347.
Mondraty N Birmingham CL Touyz S Sundakov V Chapman L Beumont P Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosaAust New Zeal J Psychiatr2005 1317275
Not in our library10.1080/j.1440-1665.2004.02154.x
- 348.
McGrath J Saha S Chant D Welham J Schizophrenia: A concise overview of incidence, prevalence, and mortalityEpidemiol Rev2008 306776
Not in our library10.1093/epirev/mxn001
- 349.
Blanchard JJ Mueser KT Bellack AS Anhedonia, positive and negative affect, and social functioning in schizophreniaSchizophr Bull1998 243413424
Not in our library10.1093/oxfordjournals.schbul.a033336
- 350.
Meehl P Schizotaxia, schizotypy, and schizophreniaAm Psychol1962 17827838
Not in our library
- 351.
Rado S Psychoanalysis of Behavior: The Collected Papers of Sandor Rado (Vol. 2)1962 Grune & Stratton, New York
Not in our library
- 352.
Kwapil TR Social anhedonia as a predictor of the development of schizophrenia-spectrum disordersJ Abnorm Psychol1998 1074558565
Not in our library10.1037//0021-843x.107.4.558
- 353.
Broome MR Woolley JB Tabraham P Johns LC Bramon E Murray GK Pariante C McGuire PK Murray RM What causes the onset of psychosis?Schizophr Res2005 7912334
Not in our library10.1016/j.schres.2005.02.007
- 354.
- 355.
Stone JM Morrison PD Pilowsky LS Glutamate and dopamine dysregulation in schizophrenia–a synthesis and selective reviewJ Psychopharmacol2007 214440452
Not in our library10.1177/0269881106073126
- 356.
Ziauddeen H Murray GK The relevance of reward pathways for schizophreniaCurr Opin Psychiatr2010 2329196
Not in our library10.1097/yco.0b013e328336661b
- 357.
Meltzer HY Stahl SM The dopamine hypothesis of schizophrenia: A reviewSchizophr Bull1976 211976
Not in our library10.1093/schbul/2.1.19
- 358.
Creese I Burt DR Snyder SH Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugsScience1976 1924238481483
Not in our library10.1126/science.3854
- 359.
Allen JA Roth BL Strategies to discover unexpected targets for drugs active at G protein-coupled receptorsAnnu Rev Pharmacol Toxicol2011 51117144
Not in our library10.1146/annurev-pharmtox-010510-100553
- 360.
Roth BL Sheffler DJ Kroeze WK Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophreniaNat Rev Drug Discov2004 34353359
Not in our library10.1038/nrd1346
- 361.
Gejman PV Sanders AR Kendler KS Genetics of schizophrenia: new findings and challengesAnnu Rev Genom Hum Genet2011 12121144
Not in our library10.1146/annurev-genom-082410-101459
- 362.
Allen JA Yadav PN Setola V Farrell M Roth BL Schizophrenia risk gene CAV1 is both pro-psychotic and required for atypical antipsychotic drug actions in vivoTranslational Psychiatr2011 1e33
Not in our library10.1038/tp.2011.35
- 363.
Brandon NJ Millar JK Korth C Sive H Singh KK Sawa A Understanding the role of DISC1 in psychiatric disease and during normal developmentJ Neurosci2009 29411276812775
Not in our library10.1523/jneurosci.3355-09.2009
- 364.
Marder SR Roth B Sullivan PF Scolnick EM Nestler EJ Geyer MA Welnberger DR Karayiorgou M Guidotti A Gingrich J Akbarian S Buchanan RW Lieberman JA Conn PJ Haggarty SJ Law AJ Campbell B Krystal JH Moghaddam B Saw A Caron MG George SR Allen JA Solis M Advancing drug discovery for schizophreniaAnn N Y Acad Sci2011 123613043
Not in our library10.1111/j.1749-6632.2011.06216.x
- 365.
Powell SB Zhou X Geyer MA Prepulse inhibition and genetic mouse models of schizophreniaBehav Brain Res2009 2042282294
Not in our library10.1016/j.bbr.2009.04.021
- 366.
Geyer MA Krebs-Thomson K Braff DL Swerdlow NR Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in reviewPsychopharmacol (Berl)2001 1562–3117154
Not in our library10.1007/s002130100811
- 367.
Braff DL Geyer MA Light GA Sprock J Perry W Cadenhead KS Swerdlow NR Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophreniaSchizophr Res2001 491–2171178
Not in our library10.1016/s0920-9964(00)00139-0
- 368.
Swerdlow NR Weber M Qu Y Light GA Braff DL Realistic expectations of prepulse inhibition in translational models for schizophrenia researchPsychopharmacol Berl2008 1993331388
Not in our library10.1007/s00213-008-1072-4
- 369.
Ralph-Williams RJ Lehmann-Masten V Geyer MA Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in miceNeuropsychopharmacology2003 281108118
Not in our library10.1038/sj.npp.1300017
- 370.
Ralph RJ Varty GB Kelly MA Wang YM Caron MG Rubinstein M Grandy DK Low MJ Geyer MA The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in miceJ Neurosci1999 191146274633
Not in our library10.1523/jneurosci.19-11-04627.1999
- 371.
Kozikowski AP Cho SJ Jensen NH Allen JA Svennebring AM Roth BL HTS and rational drug design to generate a class of 5-HT(2 C)-selective ligands for possible use in schizophreniaChemMedChem2010 5812211225
Not in our library10.1002/cmdc.201000186
- 372.
Castagne V Moser PC Porsolt RD Preclinical behavioral models for predicting antipsychotic activityAdv Pharmacol2009 57381418
Not in our library10.1016/s1054-3589(08)57010-4
- 373.
Giros B Jaber M Jones SR Wightman RM Caron MG Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporterNature1996 3796566606612
Not in our library10.1038/379606a0
- 374.
Gainetdinov RR Wetsel WC Jones SR Levin ED Jaber M Caron MG Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivityScience1999 2835400397401
Not in our library10.1126/science.283.5400.397
- 375.
Barr AM Lehmann-Masten V Paulus M Gainetdinov RR Caron MG Geyer MA The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout miceNeuropsychopharmacology2004 292221228
Not in our library10.1038/sj.npp.1300343
- 376.
Ralph RJ Paulus MP Fumagalli F Caron MG Geyer MA Prepulse inhibition deficits and perseverative motor patterns in dopamine transporter knock-out mice: differential effects of D1 and D2 receptor antagonistsJ Neurosci2001 211305313
Not in our library10.1523/jneurosci.21-01-00305.2001
- 377.
Powell SB Young JW Ong JC Caron MG Geyer MA Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout miceBehav Pharmacol2008 195–6562565
Not in our library10.1097/fbp.0b013e32830dc110
- 378.
Yamashita M Fukushima S Shen HW Hall FS Uhl GR Numachi Y Kobayashi H Sora I Norepinephrine transporter blockade can normalize the prepulse inhibition deficits found in dopamine transporter knockout miceNeuropsychopharmacology2006 311021322139
Not in our library10.1038/sj.npp.1301009
- 379.
Li YC Kellendonk C Simpson EH Kandel ER Gao WJ D2 receptor overexpression in the striatum leads to a deficit in inhibitory transmission and dopamine sensitivity in mouse prefrontal cortexProc Natl Acad Sci2011 108291210712112
Not in our library10.1073/pnas.1109718108
- 380.
Kellendonk C Modeling excess striatal D2 receptors in miceProgr Brain Res2009 1795965
Not in our library10.1016/s0079-6123(09)17907-4
- 381.
Simpson EH Kellendonk C Kandel E A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophreniaNeuron2010 655585596
Not in our library10.1016/j.neuron.2010.02.014
- 382.
Kellendonk C Simpson EH Kandel ER Modeling cognitive endophenotypes of schizophrenia in miceTrends Neurosci2009 326347358
Not in our library10.1016/j.tins.2009.02.003
- 383.
Maia TV Frank MJ From reinforcement learning models to psychiatric and neurological disordersNat Neurosci2011 142154162
Not in our library10.1038/nn.2723
- 384.
Ward RD Simpson EH Kandel ER Balsam PD Modeling motivational deficits in mouse models of schizophrenia: Behavior analysis as a guide for neuroscienceBehav Process2011 871149156
Not in our library10.1016/j.beproc.2011.02.004
- 385.
Young JW Zhou X Geyer MA Animal models of schizophreniaCurr Top Behav Neurosci2010 4391433
Not in our library10.1007/7854_2010_62
- 386.
Trémeau F Antonius D Cacioppo JT Ziwich R Butler P Malaspina D Javitt DC Anticipated, on-line and remembered positive experience in schizophreniaSchizophr Res2009 1221–3199205
Not in our library10.1016/j.schres.2009.10.019
- 387.
Earnst KS Kring AM Emotional responding in deficit and non-deficit schizophreniaPsychiatr Res1999 883191207
Not in our library10.1016/s0165-1781(99)00083-9
- 388.
Berenbaum H Oltmanns TF Emotional experience and expression in schizophrenia and depressionJ Abnorm Psychol1992 10113744
Not in our library10.1037//0021-843x.101.1.37
- 389.
Aghevli MA Blanchard JJ Horan WP The expression and experience of emotion in schizophrenia: A study of social interactionsPsychiatr Res2003 1193261270
Not in our library10.1016/s0165-1781(03)00133-1
- 390.
Kring AM Moran EK Emotional response deficits in schizophrenia: Insights from affective scienceSchizophr Bull2008 345819834
Not in our library10.1093/schbul/sbn071
- 391.
Trémeau F A review of emotion deficits in schizophreniaDialogues Clin Neurosci2006 815970
Not in our library10.31887/dcns.2006.8.1/ftremeau
- 392.
Cohen AS Minor KS Emotional experience in patients with schizophrenia revisited: Meta-analysis of laboratory studiesSchizophr Bull2008 361143150
Not in our library10.1093/schbul/sbn061
- 393.
Kring AM Kerr SL Smith DA Neale JM Flat affect in schizophrenia does not reflect diminished subjective experience of emotionJ Abnorm Psychol1993 1024507517
Not in our library10.1037//0021-843x.102.4.507
- 394.
Burbridge JA Barch DM Anhedonia and the experience of emotion in individuals with schizophreniaJ Abnorm Psychol2007 11613042
Not in our library10.1037/0021-843x.116.1.30
- 395.
Berlin I Givry-Steiner L Lecrubier Y Puech AJ Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjectsEur Psychiatr1998 136303309
Not in our library10.1016/s0924-9338(98)80048-5
- 396.
Schneider F Habel U Reske M Toni I Falkai P Shah NJ Neural substrates of olfactory processing in schizophrenia patients and their healthy relativesPsychiatr Res2007 1552103112
Not in our library10.1016/j.pscychresns.2006.12.004
- 397.
Earnst KS Kring AM Kadar MA Salem JE Shepard DA Loosen PT Facial expression in schizophreniaBiol Psychiatr1996 406556558
Not in our library10.1016/0006-3223(96)00171-0
- 398.
Kring AM Kerr SL Earnst KS Schizophrenic patients show facial reactions to emotional facial expressionsPsychophysiology1999 362186192
Not in our library
- 399.
Kring AM Neale JM Do schizophrenic patients show a disjunctive relationship among expressive, experiential, and psychophysiological components of emotion?J Abnorm Psychol1996 1052249257
Not in our library10.1037//0021-843x.105.2.249
- 400.
Venables PH Wing JK Level of arousal and the subclassification of schizophreniaArch Gen Psychiatr1962 7114119
Not in our library10.1001/archpsyc.1962.01720020038006
- 401.
Curtis CE Lebow B Lake DS Katsanis J Iacono WG Acoustic startle reflex in schizophrenia patients and their first-degree relatives: evidence of normal emotional modulationPsychophysiology1999 364469475
Not in our library10.1017/s0048577299980757
- 402.
Schlenker R Cohen R Hopmann G Affective modulation of the startle reflex in Schizophrenic patientsEur Arch Psychiatr Clin Neurosci1995 2456309318
Not in our library10.1007/bf02191873
- 403.
Chan RCK Wang Y Huang J Shi Y Hong X Ma Z Li Z Lai M Kring AM Anticipatory and consummatory components of the experience of pleasure in schizophrenia: Cross-cultural validation and extensionPsychiatr Res2010 1751–2181183
Not in our library10.1016/j.psychres.2009.01.020
- 404.
Gard DE Kring AM Gard MG Horan WP Green MF Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasureSchizophr Res2007 931–3253260
Not in our library10.1016/j.schres.2007.03.008
- 405.
Loas G Monestes JL Ameller A Bubrovszky M Yon V Wallier J Berthoz S Corcos M Thomas P Gard D Loas G Monestes JL Ameller A Bubrovszky M Yon V Wallier J Berthoz S Corcos M Thomas P Gard D Traduction et étude de validation de la version française de l'échelle d'expérience temporelle du plaisir (EETP, Temporal Experience of Pleasure Scale [TEPS], Gard et al., 2006): étude chez 125 étudiants et chez 162 sujets présentant un trouble psychiatriqueTraduction et étude de validation2009 1679641648
Not in our library
- 406.
Waltz JA Frank MJ Wiecki TV Gold JM Altered probabilistic learning and response biases in schizophrenia: Behavioral evidence and neurocomputational modelingNeuropsychology2011 25186
Not in our library10.1037/a0020882
- 407.
Wynn JK Horan WP Kring AM Simons RF Green MF Impaired anticipatory event-related potentials in schizophreniaInt J Psychophysiol2010 772141149
Not in our library10.1016/j.ijpsycho.2010.05.009
- 408.
Strauss GP Wilbur RC Warren KR August SM Gold JM Anticipatory vs. consummatory pleasure: What is the nature of hedonic deficits in schizophrenia?Psychiatr Res2011 1871–23641
Not in our library10.1016/j.psychres.2011.01.012
- 409.
Elliott R McKenna PJ Robbins TW Sahakian BJ Neuropsychological evidence for frontostriatal dysfunction in schizophreniaPsychol Med1995 253619630
Not in our library10.1017/s0033291700033523
- 410.
Gold JM Waltz JA Prentice KJ Morris SE Heerey EA Reward processing in schizophrenia: a deficit in the representation of valueSchizophr Bull2008 345835
Not in our library10.1093/schbul/sbn068
- 411.
Koch K Schachtzabel C Wagner G Schikora J Schultz C Reichenbach JR Sauer H Schlösser RGM Altered activation in association with reward-related trial-and-error learning in patients with schizophreniaNeuroimage2010 501223232
Not in our library10.1016/j.neuroimage.2009.12.031
- 412.
Strauss MM Makris N Aharon I Vangel MG Goodman J Kennedy DN Gasic GP Breiter HC fMRI of sensitization to angry facesNeuroimage2005 262389413
Not in our library10.1016/j.neuroimage.2005.01.053
- 413.
Waltz JA Gold JM Probabilistic reversal learning impairments in schizophrenia: Further evidence of orbitofrontal dysfunctionSchizophr Res2007 931–3296303
Not in our library10.1016/j.schres.2007.03.010
- 414.
Somlai Z Moustafa AA Kéri S Myers CE Gluck MA General functioning predicts reward and punishment learning in schizophreniaSchizophr Res2011 1271–3131136
Not in our library10.1016/j.schres.2010.07.028
- 415.
Yarkoni T Gray JR Chrastil ER Barch DM Green L Braver TS Sustained neural activity associated with cognitive control during temporally extended decision makingBrain Res Cognit Brain Res2005 2317184
Not in our library10.1016/j.cogbrainres.2005.01.013
- 416.
Simon JJ Biller A Walther S Roesch-Ely D Stippich C Weisbrod M Kaiser S Neural correlates of reward processing in schizophrenia–Relationship to apathy and depressionSchizophr Res2009 1181–3154161
Not in our library10.1016/j.schres.2009.11.007
- 417.
Juckel G Schlagenhauf F Koslowski M Filonov D Wustenberg T Villringer A Knutson B Kienast T Gallinat J Wrase J Heinz A Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neurolepticsPsychopharmacol Berl2006 1872222228
Not in our library10.1007/s00213-006-0405-4
- 418.
Kirsch P Ronshausen S Mier D Gallhofer B The influence of antipsychotic treatment on brain reward system reactivity in Schizophrenia patientsPharmacopsychiatry2007 405196198
Not in our library10.1055/s-2007-984463
- 419.
Waltz JA Schweitzer JB Gold JM Kurup PK Ross TJ Salmeron BJ Rose EJ McClure SM Stein EA Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcersNeuropsychopharmacology2009 34615671577
Not in our library10.1038/npp.2008.214
- 420.
Waltz JA Schweitzer JB Ross TJ Kurup PK Salmeron BJ Rose EJ Gold JM Stein EA Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophreniaNeuropsychopharmacology2010 3524272439
Not in our library10.1038/npp.2010.126
- 421.
Morris R Vercammen A Lenroot R Moore L Langton J Short B Kulkarni J Curtis J O'Donnell M Weickert C Disambiguating ventral striatum fMRI-related bold signal during reward prediction in schizophreniaMol Psychiatr2011 17280289
Not in our library10.1038/mp.2011.75
- 422.
Juckel G Schlagenhauf F Koslowski M Wustenberg T Villringer A Knutson B Wrase J Heinz A Dysfunction of ventral striatal reward prediction in schizophreniaNeuroimage2006 292409416
Not in our library10.1016/j.neuroimage.2005.07.051
- 423.
Schlagenhauf F Juckel G Koslowski M Kahnt T Knutson B Dembler T Kienast T Gallinat J Wrase J Heinz A Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapinePsychopharmacol Berl2008 1964673684
Not in our library10.1007/s00213-007-1016-4
- 424.
Grimm O Vollstadt-Klein S Krebs L Zink M Smolka MN Reduced striatal activation during reward anticipation due to appetite-provoking cues in chronic schizophrenia: A fMRI studySchizophr Res2011 1342–3151157
Not in our library10.1016/j.schres.2011.11.027
- 425.
Kegeles LS Abi-Dargham A Frankle WG Gil R Cooper TB Slifstein M Hwang D-R Huang Y Haber SN Laruelle M Increased synaptic dopamine function in associative regions of the striatum in schizophreniaArch Gen Psychiatr2010 673231239
Not in our library10.1001/archgenpsychiatry.2010.10
- 426.
Lieberman JA Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and developmentBr J Psychiatr1993 22718Suppl
Not in our library
- 427.
Mailman RB Murthy V Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?Curr Pharm Des2010 165488501
Not in our library10.2174/138161210790361461
- 428.
Stahl SM Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptorsJ Clin Psychiatr2001 6211841842
Not in our library10.4088/jcp.v62n1101
- 429.
Froehlich TE Lanphear BP Epstein JN Barbaresi WJ Katusic SK Kahn RS Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US childrenArch Pediatr Adolesc Med2007 1619857864
Not in our library10.1001/archpedi.161.9.857
- 430.
Kessler RC Adler L Barkley R Biederman J Conners CK Demler O Faraone SV Greenhill LL Howes MJ Secnik K Spencer T Ustun TB Walters EE Zaslavsky AM The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey ReplicationAm J Psychiatr2006 1634716723
Not in our library10.1176/appi.ajp.163.4.716
- 431.
Visser SN Lesesne CA Perou R National estimates and factors associated with medication treatment for childhood Attention-Deficit/Hyperactivity disorderPediatrics2007 119Suppl 1S99S106
Not in our library10.1542/peds.2006-2089o
- 432.
Spencer TJ Biederman J Mick E Attention-deficit/hyperactivity disorder: Diagnosis, lifespan, comorbidities, and neurobiologyJ Pediatr Psychol2007 326631642
Not in our library10.1093/jpepsy/jsm005
- 433.
Biederman J Faraone SV Attention-deficit hyperactivity disorderLancet2005 3669481237248
Not in our library10.1016/s0140-6736(05)66915-2
- 434.
Donnelly M Haby MM Carter R Andrews G Vos T Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorderAust New Zeal J Psychiatr2004 388592601
Not in our library10.1080/j.1440-1614.2004.01422.x
- 435.
Secnik K Swensen A Lage MJ Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorderPharmacoeconomics2005 23193102
Not in our library10.2165/00019053-200523010-00008
- 436.
Taylor E Chadwick O Heptinstall E Danckaerts M Hyperactivity and conduct problems as risk factors for adolescent developmentJ Am Acad Adolesc Psychiatr1996 35912131226
Not in our library10.1097/00004583-199609000-00019
- 437.
Sagvolden T Johansen EB Aase H Russell VA A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypesBehav Brain Sci2005 283397418
Not in our library10.1017/s0140525x05000075
- 438.
Tripp G Wickens JR Research review: Dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHDJ Child Psychol Psychiatr2008 497691704
Not in our library10.1111/j.1469-7610.2007.01851.x
- 439.
Tripp G Wickens JR Neurobiology of ADHDNeuropharmacology2009 577–8579589
Not in our library10.1016/j.neuropharm.2009.07.026
- 440.
Gizer IR Ficks C Waldman ID Candidate gene studies of ADHD: a meta-analytic reviewHum Genet2009 12615190
Not in our library10.1007/s00439-009-0694-x
- 441.
Khan SA Faraone SV The genetics of ADHD: a literature review of 2005Curr Psychiatr Rep2006 85393397
Not in our library10.1007/s11920-006-0042-y
- 442.
Arime Y Kubo Y Sora I Animal models of attention-deficit/hyperactivity disorderBiol Pharmacol Bull2011 34913731376
Not in our library10.1248/bpb.34.1373
- 443.
Gainetdinov RR Strengths and limitations of genetic models of ADHDAttention Deficit Hyperactive Disord2010 212130
Not in our library10.1007/s12402-010-0021-3
- 444.
Trinh JV Nehrenberg DL Jacobsen JP Caron MG Wetsel WC Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type miceNeuroscience2003 118297310
Not in our library10.1016/s0306-4522(03)00165-9
- 445.
Hironaka N Ikeda K Sora I Uhl GR Niki H Food-reinforced operant behavior in dopamine transporter knockout mice: Enhanced resistance to extinctionAnn N Y Acad Sci2004 1025140145
Not in our library10.1196/annals.1316.018
- 446.
Gainetdinov RR Caron MG Genetics of childhood disorders: XXIV. ADHD, Part 8: hyperdopaminergic mice as an animal model of ADHDJ Am Acad Child Adolesc Psychiatr2001 40380382
Not in our library10.1097/00004583-200103000-00020
- 447.
Jucaite A Fernell E Halldin C Forssberg H Farde L Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: Association between striatal dopamine markers and motor hyperactivityBiol Psychiatr2005 57229238
Not in our library10.1016/j.biopsych.2004.11.009
- 448.
Dougherty DD Bonab AA Spencer TJ Rauch SL Madras BK Fischman AJ Dopamine transporter density in patients with attention deficit hyperactivity disorderLancet1999 354919621322133
Not in our library10.1016/s0140-6736(99)04030-1
- 449.
Krause KH Dresel SH Krause J Kung HF Tatsch K Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomographyNeurosci Lett2000 2852107110
Not in our library10.1016/s0304-3940(00)01040-5
- 450.
Russell VA Overview of animal models of attention deficit hyperactivity disorder (ADHD)Curr Protoc Neurosci2011 54
Not in our library10.1002/0471142301.ns0935s54
- 451.
Johansen EB Killeen PR Sagvolden T Behavioral variability, elimination of responses, and delay-of-reinforcement gradients in SHR and WKY ratsBehav Brain Funct2007 360
Not in our library10.1186/1744-9081-3-60
- 452.
Sagvolden T Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD)Neurosci Biobehav Rev2000 243139
Not in our library10.1016/s0149-7634(99)00058-5
- 453.
Sagvolden T Russell VA Aase H Johansen EB Farshbaf M Rodent models of attention-deficit/hyperactivity disorderBiol Psychiatr2005 5712391247
Not in our library10.1016/j.biopsych.2005.02.002
- 454.
Bull E Reavill C Hagan JJ Overend P Jones DN Evaluation of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder: acquisition and performance of the DRL-60s testBehav Brain Res2000 1092735
Not in our library10.1016/s0166-4328(99)00156-4
- 455.
Mill J Sagvolden T Asherson P Sequence analysis of Drd2, Drd4, and Dat1 in SHR and WKY rat strainsBehav Brain Funct2005 124
Not in our library10.1186/1744-9081-1-24
- 456.
Cook EH Stein MA Krasowski MD Cox NJ Olkon DM Kieffer JE Leventhal BL Association of attention-deficit disorder and the dopamine transporter geneAm J Hum Genet1995 56993998
Not in our library
- 457.
Watanabe Y Fujita M Ito Y Okada T Kusuoka H Nishimura T Brain dopamine transporter in spontaneously hypertensive ratsJ Nucl Med1997 38470474
Not in our library
- 458.
Leo D Sorrentino E Volpicelli F Eyman M Greco D Viggiano D Di PU Perrone-Capano C Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHDNeurosci Biobehav Rev2003 27661669
Not in our library10.1016/j.neubiorev.2003.08.009
- 459.
Johansen EB Killeen PR Russell VA Tripp G Wickens JR Tannock R Williams J Sagvolden T Origins of altered reinforcement effects in ADHDBehav Brain Funct2009 57
Not in our library10.1186/1744-9081-5-7
- 460.
Luman M Oosterlaan J Sergeant JA The impact of reinforcement contingencies on AD/HD: A review and theoretical appraisalClin Psychol Rev2005 252183213
Not in our library10.1016/j.cpr.2004.11.001
- 461.
Drechsler R Rizzo P Steinhausen HC Decision-making on an explicit risk-taking task in preadolescents with attention-deficit/hyperactivity disorderJ Neural Transm2008 1152201209
Not in our library10.1007/s00702-007-0814-5
- 462.
Sonuga-Barke EJ Taylor E Sembi S Smith J Hyperactivity and delay aversion–. The effect of delay on choice.IJ Psychol Psychiatr1992 332387398
Not in our library10.1111/j.1469-7610.1992.tb00874.x
- 463.
Luman M Oosterlaan J Hyde C van Meel CS Sergeant JA Heart rate and reinforcement sensitivity in ADHDJ Psychol Psychiatr2007 489890898
Not in our library10.1111/j.1469-7610.2007.01769.x
- 464.
Brennan AR Arnsten AF Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical functionAnn N Y Acad Sci2008 1129236245
Not in our library10.1196/annals.1417.007
- 465.
Brocki K Fan J Fossella J Placing neuroanatomical models of executive function in a developmental context: Imaging and imaging–genetic strategiesAnn N Y Acad Sci2008 1129246255
Not in our library10.1196/annals.1417.025
- 466.
Prince J Catecholamine dysfunction in attention-deficit/hyperactivity disorder: An updateJ Clin Psychopharmacol2008 283 Suppl 2S39
Not in our library10.1097/jcp.0b013e318174f92a
- 467.
Wilens TE Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorderJ Clin Psychopharmacol2008 283 Suppl 2S46S53
Not in our library10.1097/jcp.0b013e318173312f
- 468.
Kollins SH Lane SD Shapiro SK The experimental analysis of childhood psychopathologyPsychol Record1997 4712544
Not in our library
- 469.
Bitsakou P Psychogiou L Thompson M Sonuga-Barke EJ Delay aversion in Attention Deficit/Hyperactivity Disorder: An empirical investigation of the broader phenotypeNeuropsychologia2009 472446456
Not in our library10.1016/j.neuropsychologia.2008.09.015
- 470.
Kuntsi J Oosterlaan J Stevenson J Psychological mechanisms in hyperactivity: I. Response inhibition deficit, working memory impairment, delay aversion, or something else?J Child Psychol Psychiatr2001 422199210
Not in our library
- 471.
Marco R Miranda A Schlotz W Melia A Mulligan A Muller U Andreou P Butler L Christiansen H Gabriels I Medad S Albrecht B Uebel H Asherson P Banaschewski T Gill M Kuntsi J Mulas F Oades R Roeyers H Steinhausen HC Rothenberger A Faraone SV Sonuga-Barke EJ Delay and reward choice in ADHD: An experimental test of the role of delay aversionNeuropsychology2009 233367380
Not in our library10.1037/a0014914
- 472.
Neef NA Bicard DF Endo S Assessment of impulsivity and the development of self-control in students with attention deficit hyperactivity disorderJ Appl Behav Anal2001 344397408
Not in our library10.1901/jaba.2001.34-397
- 473.
Rapport MD Tucker SB DuPaul GJ Merlo M Stoner G Hyperactivity and frustration: The influence of control over and size of rewards in delaying gratificationJ Abnorm Child Psychol1986 142191204
Not in our library10.1007/bf00915440
- 474.
Tripp G Alsop B Sensitivity to reward delay in children with Attention Deficit Hyperactivity disorder (ADHD)J Child Psychol Psychiatr2001 425691698
Not in our library
- 475.
Solanto MV Abikoff H Sonuga-Barke E Schachar R Logan GD Wigal T Hechtman L Hinshaw S Turkel E The ecological validity of delay aversion and response inhibition as measures of impulsivity in AD/HD: A supplement to the NIMH multimodal treatment study of AD/HDJ Abnorm Child Psychol2001 293215228
Not in our library10.1023/a:1010329714819
- 476.
Scheres A Tontsch C Thoeny AL Kaczkurkin A Temporal reward discounting in attention-deficit/hyperactivity disorder: The contribution of symptom domains, reward magnitude, and session lengthBiol psychiatr2010 677641648
Not in our library10.1016/j.biopsych.2009.10.033
- 477.
Johansen EB Aase H Meyer A Sagvolden T Attention-deficit/hyperactivity disorder (ADHD) behaviour explained by dysfunctioning reinforcement and extinction processesBehav Brain Res2002 1301–23745
Not in our library10.1016/s0166-4328(01)00434-x
- 478.
Luman M van Meel CS Oosterlaan J Geurts HM Reward and punishment sensitivity in children with ADHD: validating the sensitivity to punishment and sensitivity to reward questionnaire for children (SPSRQ-C)J Abnorm Child Psychol2011 40113
Not in our library10.1007/s10802-011-9547-x
- 479.
Drechsler R Rizzo P Steinhausen HC Decision making with uncertain reinforcement in children with attention deficit/hyperactivity disorder (ADHD)Child Neuropsychol2010 162145161
Not in our library10.1080/09297040903190774
- 480.
Demurie E Roeyers H Baeyens D Sonuga Barke E Common alterations in sensitivity to type but not amount of reward in ADHD and autism spectrum disordersJ Child Psychol Psychiatr2011 5211641173
Not in our library10.1111/j.1469-7610.2010.02374.x
- 481.
Rubia K Overmeyer S Taylor E Brammer M Williams SC Simmons A Bullmore ET Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: A study with functional MRIAm J Psychiatr1999 1566891896
Not in our library10.1176/ajp.156.6.891
- 482.
Vaidya CJ Austin G Kirkorian G Ridlehuber HW Desmond JE Glover GH Gabrieli JD Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance studyProc Natl Acad Sci1998 95241449414499
Not in our library10.1073/pnas.95.24.14494
- 483.
Zang YF Jin Z Weng XC Zhang L Zeng YW Yang L Wang YF Seidman LJ Faraone SV Functional MRI in attention-deficit hyperactivity disorder: Evidence for hypofrontalityBrain Dev2005 278544550
Not in our library10.1016/j.braindev.2004.11.009
- 484.
Carmona S Hoekzema E Ramos Quiroga JA Richarte V Canals C Bosch R Rovira M Carlos Soliva J Bulbena A Tobeña A Response inhibition and reward anticipation in medication naïve adults with attention deficit/hyperactivity disorder: A within subject case control neuroimaging studyHum Brain Mapp2011 http://onlinelibrary.wiley.com/doi/10.1002/hbm.21368/abstract.
Not in our library10.1002/hbm.21368
- 485.
Plichta MM Vasic N Wolf RC Lesch K-P Brummer D Jacob C Fallgatter AJ Grön G Neural hyporesponsiveness and hyperresponsiveness during immediate and delayed reward processing in adult Attention-Deficit/Hyperactivity DisorderBiol Psychiatr2009 651714
Not in our library10.1016/j.biopsych.2008.07.008
- 486.
Scheres A Milham MP Knutson B Castellanos FX Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorderBiol Psychiatr2007 615720724
Not in our library10.1016/j.biopsych.2006.04.042
- 487.
Strohle A Stoy M Wrase J Schwarzer S Schlagenhauf F Huss M Hein J Nedderhut A Neumann B Gregor A Juckel G Knutson B Lehmkuhl U Bauer M Heinz A Reward anticipation and outcomes in adult males with Attention-Deficit/Hyperactivity disorderNeuroimage2008 393966972
Not in our library10.1016/j.neuroimage.2007.09.044
- 488.
Cubillo A Halari R Smith A Taylor E Rubia K Attention Deficit Hyperactivity Disorder (ADHD) and new evidence for dysfunction in adults with ADHD during motivation and attentionCortex2011 482194215
Not in our library10.1016/j.cortex.2011.04.007
- 489.
Paloyelis Y Mehta MA Kuntsi J Asherson P Functional MRI in ADHD: a systematic literature reviewExpet Rev Neurotherapy2007 71013371356
Not in our library10.1586/14737175.7.10.1337
- 490.
Stoy M Schlagenhauf F Schlochtermeier L Wrase J Knutson B Lehmkuhl U Huss M Heinz A Strohle A Reward processing in male adults with childhood ADHD–a comparison between drug-naive and methylphenidate-treated subjectsPsychopharmacol Berl2011 2153467481
Not in our library10.1007/s00213-011-2166-y
- 491.
Hahn T Heinzel S Dresler T Plichta MM Renner TJ Markulin F Jakob PM Lesch KP Fallgatter AJ Association between reward-related activation in the ventral striatum and trait reward sensitivity is moderated by dopamine transporter genotypeHum Brain Mapp2011 321015571565
Not in our library10.1002/hbm.21127
- 492.
Stark R Bauer E Merz CJ Zimmermann M Reuter M Plichta MM Kirsch P Lesch KP Fallgatter AJ Vaitl D Herrmann MJ ADHD related behaviors are associated with brain activation in the reward systemNeuropsychologia2011 493426434
Not in our library10.1016/j.neuropsychologia.2010.12.012
- 493.
Wilbertz G van Elst LT Delgado MR Maier S Feige B Philipsen A Blechert J Orbitofrontal reward sensitivity and impulsivity in adult attention deficit hyperactivity disorderNeuroimage2011 601353361
Not in our library10.1016/j.neuroimage.2011.12.011
- 494.
Ernst M Zametkin AJ Matochik JA Pascualvaca D Jons PH Cohen RM High midbrain [18 F]DOPA accumulation in children with attention deficit hyperactivity disorderAm J Psychiatr1999 156812091215
Not in our library10.1176/ajp.156.8.1209
- 495.
Volkow N Wang G Newcorn J Kollins S Wigal T Telang F Fowler J Goldstein R Klein N Logan J Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathwayMol Psychiatr2010 1611471154
Not in our library10.1038/mp.2010.97
- 496.
Madras BK Miller GM Fischman AJ The dopamine transporter and attention-deficit/hyperactivity disorderBiol Psychiatr2005 571113971409
Not in our library10.1016/j.biopsych.2004.10.011
- 497.
Yano M Steiner H Methylphenidate and cocaine: The same effects on gene regulation?Trends Pharmacol Sci2007 2811588596
Not in our library10.1016/j.tips.2007.10.004
- 498.
Heal DJ Cheetham SC Smith SL The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safetyNeuropharmacology2009 577–8608618
Not in our library10.1016/j.neuropharm.2009.08.020
- 499.
Conners CK Casat CD Gualtieri CT Weller E Reader M Reiss A Weller RA Khayrallah M Ascher J Bupropion hydrochloride in attention deficit disorder with hyperactivityJ Am Acad Child Adolesc Psychiatr1996 351013141321
Not in our library10.1097/00004583-199610000-00018
- 500.
Kuperman S Perry PJ Gaffney GR Lund BC Bever-Stille KA Arndt S Holman TL Moser DJ Paulsen JS Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adultsAnn Clin Psychiatr2001 133129134
Not in our library10.1023/a:1012239823148
- 501.
Ruscio AM Stein DJ Chiu WT Kessler RC The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey ReplicationMol Psychiatr2010 1515363
Not in our library10.1038/mp.2008.94
- 502.
Cavedini P Gorini A Bellodi L Understanding obsessive-compulsive disorder: Focus on decision makingNeuropsychol Rev2006 161315
Not in our library10.1007/s11065-006-9001-y
- 503.
Denys D Zohar J Westenberg HG The role of dopamine in obsessive-compulsive disorder: Preclinical and clinical evidenceJ Clin Psychiatr2004 65Suppl 141117
Not in our library
- 504.
Holden C Psychiatry. Behavioral addictions debut in proposed DSM-VScience2010 3275968935
Not in our library10.1126/science.327.5968.935
- 505.
Geller DA Biederman J Faraone S Agranat A Cradock K Hagermoser L Kim G Frazier J Coffey BJ Developmental aspects of obsessive compulsive disorder: findings in children, adolescents, and adultsJ Nerv Ment Dis2001 189471477
Not in our library10.1097/00005053-200107000-00009
- 506.
Yang XW Lu XH Molecular and cellular basis of obsessive-compulsive disorder-like behaviors: Emerging view from mouse modelsCurr Opin Neurol2011 242114118
Not in our library10.1097/wco.0b013e32834451fb
- 507.
Feusner JD Hembacher E Phillips KA The mouse who couldn't stop washing: Pathologic grooming in animals and humansCNS Spectr2009 149503513
Not in our library10.1017/s1092852900023567
- 508.
- 509.
Welch JM Lu J Rodriguiz RM Trotta NC Peca J Ding JD Feliciano C Chen M Adams JP Luo J Dudek SM Weinberg RJ Calakos N Wetsel WC Feng G Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant miceNature2007 4487156894900
Not in our library10.1038/nature06104
- 510.
Shmelkov SV Hormigo A Jing D Proenca CC Bath KG Milde T Shmelkov E Kushner JS Baljevic M Dincheva I Murphy AJ Valenzuela DM Gale NW Yancopoulos GD Ninan I Lee FS Rafii S Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in miceNat Med2010 165598602
Not in our library10.1038/nm.2125
- 511.
Nielen MM den Boer JA Smid HG Patients with obsessive-compulsive disorder are impaired in associative learning based on external feedbackPsychol Med2009 39915191526
Not in our library10.1017/s0033291709005297
- 512.
Cavedini P Riboldi G D'Annucci A Belotti P Cisima M Bellodi L Decision-making heterogeneity in obsessive-compulsive disorder: Ventromedial prefrontal cortex function predicts different treatment outcomesNeuropsychologia2002 402205211
Not in our library10.1016/s0028-3932(01)00077-x
- 513.
Saxena S Brody AL Schwartz JM Baxter LR Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorderBr J Psychiatr1998 352637Suppl
Not in our library
- 514.
Fontenelle LF Oostermeijer S Harrison BJ Pantelis C Yucel M Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatmentsDrugs2011 717827840
Not in our library10.2165/11591790-000000000-00000
- 515.
Jung WH Kang DH Han JY Jang JH Gu BM Choi JS Jung MH Choi CH Kwon JS Aberrant ventral striatal responses during incentive processing in unmedicated patients with obsessive-compulsive disorderActa Psychiatr Scand2010 1235376386
Not in our library10.1111/j.1600-0447.2010.01659.x
- 516.
Figee M Vink M de Geus F Vulink N Veltman DJ Westenberg H Denys D Dysfunctional reward circuitry in obsessive-compulsive disorderBiol Psychiatr2011 699867874
Not in our library10.1016/j.biopsych.2010.12.003
- 517.
Pena-Garijo J Barros-Loscertales A Ventura-Campos N Ruiperez-Rodriguez M Edo-Villamon S Avila C Involvement of the thalamic-cortical-striatal circuit in patients with obsessive-compulsive disorder during an inhibitory control task with reward and punishment contingenciesRev Neurol2011 53277
Not in our library
- 518.
Whiteside SP Port JD Abramowitz JS A meta-analysis of functional neuroimaging in obsessive-compulsive disorderPsychiatr Res2004 13216979
Not in our library10.1016/j.pscychresns.2004.07.001
- 519.
Menzies L Chamberlain SR Laird AR Thelen SM Sahakian BJ Bullmore ET Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: The orbitofronto-striatal model revisitedNeurosci Biobehav Rev2008 323525549
Not in our library10.1016/j.neubiorev.2007.09.005
- 520.
Nikolaus S Antke C Beu M Muller HW Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders–results from in vivo imaging studiesRev Neurosci2010 212119139
Not in our library10.1515/revneuro.2010.21.2.119
- 521.
Pallanti S Quercioli L Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic linesProgr Neuropsychopharmacol Biol Psychiatr2006 303400412
Not in our library10.1016/j.pnpbp.2005.11.028
- 522.
Bystritsky A Ackerman DL Rosen RM Vapnik T Gorbis E Maidment KM Saxena S Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trialJ Clin Psychiatr2004 654565568
Not in our library10.4088/jcp.v65n0418
- 523.
Carey PD Vythilingum B Seedat S Muller JE van Ameringen M Stein DJ Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled studyBMC Psychiatr2005 55
Not in our library10.1186/1471-244x-5-5
- 524.
Hollander E Baldini Rossi N Sood E Pallanti S Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled studyInt J Neuropsychopharmacol2003 64397401
Not in our library10.1017/s1461145703003730
- 525.
Komossa K Depping AM Meyer M Kissling W Leucht S Second-generation antipsychotics for obsessive compulsive disorderCochrane Database Sys Rev2010 12CD008141
Not in our library10.1002/14651858.cd008141.pub2
- 526.
Denys D Mantione M Figee M van den Munckhof P Koerselman F Westenberg H Bosch A Schuurman R Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorderArch Gen Psychiatr2010 671010611068
Not in our library10.1001/archgenpsychiatry.2010.122
- 527.
Huff W Lenartz D Schormann M Lee SH Kuhn J Koulousakis A Mai J Daumann J Maarouf M Klosterkotter J Sturm V Unilateral deep brain stimulation of the nucleus accumbens in patients with treatment-resistant obsessive-compulsive disorder: Outcomes after one yearClin Neurol Neurosurg2010 1122137143
Not in our library10.1016/j.clineuro.2009.11.006
- 528.
Sturm V Lenartz D Koulousakis A Treuer H Herholz K Klein JC Klosterkotter J The nucleus accumbens: A target for deep brain stimulation in obsessive-compulsive- and anxiety-disordersJ Chem Neuroanat2003 264293299
Not in our library10.1016/j.jchemneu.2003.09.003
- 529.
Kogan MD Blumberg SJ Schieve LA Boyle CA Perrin JM Ghandour RM Singh GK Strickland BB Trevathan E van Dyck PC Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the USPediatrics2009 124513951403
Not in our library10.1542/peds.2009-1522
- 530.
Moy SS Nadler JJ Perez A Barbaro RP Johns JM Magnuson TR Piven J Crawley JN Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in miceGene Brain Behav2004 35287302
Not in our library10.1111/j.1601-1848.2004.00076.x
- 531.
Moy SS Nadler JJ Young NB Nonneman RJ Grossman AW Murphy DL D'Ercole AJ Crawley JN Magnuson TR Lauder JM Social approach in genetically engineered mouse lines relevant to autismGene Brain Behav2009 82129142
Not in our library10.1111/j.1601-183x.2008.00452.x
- 532.
Smith SE Zhou YD Zhang G Jin Z Stoppel DC Anderson MP Increased gene dosage of Ube3a results in autism traits and decreased glutamate synaptic transmission in miceSci Translational Med2011 3103103ra197103ra197
Not in our library10.1126/scitranslmed.3002627
- 533.
Nair HP Young LJ Vasopressin and pair-bond formation: Genes to brain to behaviorPhysiol (Bethesda)2006 21146152
Not in our library10.1152/physiol.00049.2005
- 534.
Young KA Gobrogge KL Liu Y Wang Z The neurobiology of pair bonding: Insights from a socially monogamous rodentFront Neuroendocrinol2010 3215369
Not in our library10.1016/j.yfrne.2010.07.006
- 535.
Bishop SL Lahvis GP The autism diagnosis in translation: shared affect in children and mouse models of ASDAutism Res2011 45317335
Not in our library10.1002/aur.216
- 536.
Carter CS Getz LL Monogamy and the prairie voleSci Am Am1993 2686100106
Not in our library10.1038/scientificamerican0693-100
- 537.
Curtis JT Wang Z Ventral tegmental area involvement in pair bonding in male prairie volesPhysiol Behav2005 863338346
Not in our library10.1016/j.physbeh.2005.08.022
- 538.
Aragona BJ Liu Y Yu YJ Curtis JT Detwiler JM Insel TR Wang Z Nucleus accumbens dopamine differentially mediates the formation and maintenance of monogamous pair bondsNat Neurosci2006 91133139
Not in our library10.1038/nn1613
- 539.
Gingrich B Liu Y Cascio C Wang Z Insel TR Dopamine D2 receptors in the nucleus accumbens are important for social attachment in female prairie voles (Microtus ochrogaster)Behav Neurosci2000 1141173183
Not in our library10.1037//0735-7044.114.1.173
- 540.
Aragona BJ Wang Z Opposing regulation of pair bond formation by cAMP signaling within the nucleus accumbens shellJ Neurosci2007 27481335213356
Not in our library10.1523/jneurosci.3216-07.2007
- 541.
Curtis JT Wang Z Amphetamine effects in microtine rodents: A comparative study using monogamous and promiscuous vole speciesNeuroscience2007 1484857866
Not in our library10.1016/j.neuroscience.2007.07.011
- 542.
Hostetler CM Harkey SL Krzywosinski TB Aragona BJ Bales KL Neonatal exposure to the D1 agonist SKF38393 inhibits pair bonding in the adult prairie voleBehav Pharmacol2011 227703710
Not in our library10.1097/fbp.0b013e32834affd2
- 543.
Liu H Dong F Meng Z Zhang B Tan J Wang Y Evaluation of Tourette's syndrome by (99 m) Tc-TRODAT-1 SPECT/CT imagingAnn Nucl Med2010 247515521
Not in our library10.1007/s12149-010-0389-3
- 544.
Liu Y Young KA Curtis JT Aragona BJ Wang Z Social bonding decreases the rewarding properties of amphetamine through a dopamine D1 receptor-mediated mechanismJ Neurosci2011 312279607966
Not in our library10.1523/jneurosci.1006-11.2011
- 545.
Lim MM Liu Y Ryabinin AE Bai Y Wang Z Young LJ CRF receptors in the nucleus accumbens modulate partner preference in prairie volesHorm Behav2007 514508515
Not in our library10.1016/j.yhbeh.2007.01.006
- 546.
Olazabal DE Young LJ Oxytocin receptors in the nucleus accumbens facilitate "spontaneous" maternal behavior in adult female prairie volesNeuroscience2006 1412559568
Not in our library10.1016/j.neuroscience.2006.04.017
- 547.
Young LJ Lim MM Gingrich B Insel TR Cellular mechanisms of social attachmentHorm Behav2001 402133138
Not in our library10.1006/hbeh.2001.1691
- 548.
Insel TR The challenge of translation in social neuroscience: A review of oxytocin, vasopressin, and affiliative behaviorNeuron2010 656768779
Not in our library10.1016/j.neuron.2010.03.005
- 549.
Hammock EA Young LJ Oxytocin, vasopressin and pair bonding: implications for autismPhilosophical Transactions of the Royal Society of London. Ser B Biol Sci2006 361147621872198
Not in our library10.1098/rstb.2006.1939
- 550.
Dawson G Meltzoff AN Osterling J Rinaldi J Brown E Children with autism fail to orient to naturally occurring social stimuliJ Autism Dev Disord1998 286479485
Not in our library10.1023/a:1026043926488
- 551.
Dawson G Webb SJ McPartland J Understanding the nature of face processing impairment in autism: Insights from behavioral and electrophysiological studiesDev Neuropsychol2005 273403424
Not in our library10.1207/s15326942dn2703_6
- 552.
Schultz RT Developmental deficits in social perception in autism: The role of the amygdala and fusiform face areaInt J Dev Neurosci2005 232–3125141
Not in our library10.1016/j.ijdevneu.2004.12.012
- 553.
Kuhl PK Coffey-Corina S Padden D Dawson G Links between social and linguistic processing of speech in preschool children with autism: Behavioral and electrophysiological measuresDev Sci2005 8F1F12
Not in our library10.1111/j.1467-7687.2004.00384.x
- 554.
Schultz RT Gauthier I Klin A Fulbright RK Anderson AW Volkmar F Skudlarski P Lacadie C Cohen DJ Gore JC Abnormal ventral temporal cortical activity during face discrimination among individuals with autism and Asperger syndromeArch Gen Psychiatr2000 574331340
Not in our library10.1001/archpsyc.57.4.331
- 555.
Klin A Lin DJ Gorrindo P Ramsay G Jones W Two-year-olds with autism orient to non-social contingencies rather than biological motionNature2009 4597244257261
Not in our library10.1038/nature07868
- 556.
Klin A Jones W Schultz R Volkmar F Cohen D Visual fixation patterns during viewing of naturalistic social situations as predictors of social competence in individuals with autismArch Gen Psychiatr2002 599809816
Not in our library10.1001/archpsyc.59.9.809
- 557.
Chevallier C Grèzes J Molesworth C Berthoz S Happé F Brief report: Selective social anhedonia in high functioning autismJ Autism Dev Disord2012 http://www.springerlink.com/content/q83152232p71m363/.
Not in our library10.1007/s10803-011-1364-0
- 558.
Sasson N Tsuchiya N Hurley R Couture SM Penn DL Adolphs R Piven J Orienting to social stimuli differentiates social cognitive impairment in autism and schizophreniaNeuropsychologia2007 451125802588
Not in our library10.1016/j.neuropsychologia.2007.03.009
- 559.
Sasson N Turner-Brown L Holtzclaw T Lam KS Bodfish J Children with autism demonstrate circumscribed attention during passive viewing of complex social and nonsocial picture arraysAutism Res2008 13142
Not in our library10.1002/aur.4
- 560.
Sasson NJ Elison JT Turner-Brown LM Dichter GS Bodfish JW Brief report: Circumscribed attention in young children with autismJ Autism Dev Disord2011 412242247
Not in our library10.1007/s10803-010-1038-3
- 561.
Soderstrom H Rastam M Gillberg C Temperament and character in adults with Asperger syndromeAutism2002 63287290
Not in our library10.1177/1362361302006003006
- 562.
Johnson SA Yechiam E Murphy RR Queller S Stout JC Motivational processes and autonomic responsivity in Asperger's disorder: Evidence from the Iowa Gambling TaskJ Int Neuropsychol Soc2006 1205668676
Not in our library10.1017/s1355617706060802
- 563.
Schmitz N Rubia K van Amelsvoort T Daly E Smith A Murphy DG Neural correlates of reward in autismBr J Psychiatr2008 1921924
Not in our library10.1192/bjp.bp.107.036921
- 564.
Scott-Van Zeeland AA Dapretto M Ghahremani DG Poldrack RA Bookheimer SY Reward processing in autismAutism Res2010 325367
Not in our library10.1002/aur.122
- 565.
Garretson HB Fein D Waterhouse L Sustained attention in children with autismJ Autism Dev Disord1990 201101114
Not in our library10.1007/bf02206860
- 566.
Ingersoll B Schreibman L Tran QH Effect of sensory feedback on immediate object imitation in children with autismJ Autism Dev Disord2003 336673683
Not in our library10.1023/b:jadd.0000006003.26667.f8
- 567.
Ozonoff S Reliability and Validity of the Wisconsin Card Sorting Test in Studies of AutismNeuropsychology1995 94491500
Not in our library
- 568.
Pascualvaca DM Fantie BD Papageorgiou M Mirsky AF Attentional capacities in children with autism: Is there a general deficit in shifting focus?J Autism Dev Disord1998 286467478
Not in our library10.1023/a:1026091809650
- 569.
Dichter GS Richey JA Rittenberg AM Sabatino A Bodfish JW Reward circuitry function in autism during face anticipation and outcomesJ Autism Dev Disord2012 422147160
Not in our library10.1007/s10803-011-1221-1
- 570.
Kohls G Schulte-Rüther M Nehrkorn B Müller K Fink GR Kamp-Becker I Herpertz-Dahlmann B Schultz RT Konrad K Reward system dysfunction in spectrum disordersSoc Cognit Affect Neurosci2011 4115231533
Not in our library10.1093/scan/nss033
- 571.
Kylliainen A Wallace S Coutanche MN Leppanen JM Cusack J Bailey AJ Hietanen JK Affective-motivational brain responses to direct gaze in children with autism spectrum disorderJ Child Psychol Psychiatr2012 53790797
Not in our library10.1111/j.1469-7610.2011.02522.x
- 572.
Sutton SK Burnette CP Mundy PC Meyer J Vaughan A Sanders C Yale M Resting cortical brain activity and social behavior in higher functioning children with autismJ Child Psychol Psychiatr2005 462211222
Not in our library10.1111/j.1469-7610.2004.00341.x
- 573.
Larson MJ South M Krauskopf E Clawson A Crowley MJ Feedback and reward processing in high-functioning autismPsychiatr Res2011 1871–2198203
Not in our library10.1016/j.psychres.2010.11.006
- 574.
Lewis MH Bodfish JW Repetitive behavior disorders in autismMent Retard Dev Disabil Res Rev1998 48089
Not in our library
- 575.
Dichter GS Felder JN Green SR Rittenberg AM Sasson NJ Bodfish JW Reward circuitry function in autism spectrum disordersSoc Cognit Affect Neurosci2012 7160172
Not in our library10.1093/scan/nsq095
- 576.
Dawson G Rogers S Munson J Smith M Winter J Greenson J Donaldson A Varley J Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver ModelPediatrics2010 1251e17
Not in our library10.1542/peds.2009-0958
- 577.
Lovaas OI Behavioral treatment and normal educational and intellectual functioning in young autistic childrenJ Consult Clin Psychol1987 5513
Not in our library10.1037//0022-006x.55.1.3
- 578.
Mesibov GB Shea V The TEACCH program in the era of evidence-based practiceJ Autism Dev Disord2010 405570579
Not in our library10.1007/s10803-009-0901-6
- 579.
Kasari C Assessing change in early intervention programs for children with autismJ Autism Dev Disord2002 325447461
Not in our library10.1023/a:1020546006971
- 580.
Sherer MR Schreibman L Individual behavioral profiles and predictors of treatment effectiveness for children with autismJ Consult Clin Psychol2005 733525
Not in our library10.1037/0022-006x.73.3.525
- 581.
Smith T Groen AD Wynn JW Randomized trial of intensive early intervention for children with pervasive developmental disorderAm J Ment Retard2000 1054269285
Not in our library10.1352/0895-8017(2000)105<0269:rtoiei>2.0.co;2
- 582.
Spreckley M Boyd R Efficacy of applied behavioral intervention in preschool children with autism for improving cognitive, language, and adaptive behavior: A systematic review and meta-analysisJ Pediatr2009 1543338344
Not in our library10.1016/j.jpeds.2008.09.012
- 583.
McDougle CJ Posey DJ Potenza MN Hollander ENeurobiology of serotonin function in autismAutism Spectrum Disorders2003 Marcel Dekker, New York199220
Not in our library
- 584.
Makkonen I Riikonen R Kokki H Airaksinen MM Kuikka JT Serotonin and dopamine transporter binding in children with autism determined by SPECTDev Med Child Neurol2008 508593597
Not in our library10.1111/j.1469-8749.2008.03027.x
- 585.
Sun X Yue J Zheng C Study of dopamine transporter imaging on the brain of children with autismSheng Wu Yi Xue Gong Cheng Xue Za Zhi2008 252327330
Not in our library
- 586.
Nakamura K Sekine Y Ouchi Y Tsujii M Yoshikawa E Futatsubashi M Tsuchiya KJ Sugihara G Iwata Y Suzuki K Matsuzaki H Suda S Sugiyama T Takei N Mori N Brain serotonin and dopamine transporter bindings in adults with high-functioning autismArch Gen Psychiatr2010 6715968
Not in our library10.1001/archgenpsychiatry.2009.137
- 587.
Ernst M Zametkin AJ Matochik JA Pascualvaca D Cohen RM Low medial prefrontal dopaminergic activity in autistic childrenLancet1997 3509078638
Not in our library10.1016/s0140-6736(05)63326-0
- 588.
Nieminen-von Wendt TS Metsahonkala L Kulomaki TA Aalto S Autti TH Vanhala R Eskola O Bergman J Hietala JA von Wendt LO Increased presynaptic dopamine function in Asperger syndromeNeuroreport2004 155757760
Not in our library10.1097/00001756-200404090-00003
- 589.
Makkonen I Kokki H Kuikka J Turpeinen U Riikonen R Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-1 in children with autismNeuropediatrics2011 42207209
Not in our library10.1055/s-0031-1291242
- 590.
Buchsbaum MS Hollander E Haznedar MM Tang C Spiegel-Cohen J Wei TC Solimando A Buchsbaum BR Robins D Bienstock C Cartwright C Mosovich S Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot studyInt J Neuropsychopharmacol2001 42119125
Not in our library10.1017/s1461145701002280
- 591.
Hollander E Phillips A Chaplin W Zagursky K Novotny S Wasserman S Iyengar R A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autismNeuropsychopharmacology2005 303582589
Not in our library10.1038/sj.npp.1300627
- 592.
McDougle CJ Naylor ST Cohen DJ Volkmar FR Heninger GR Price LH A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorderArch Gen Psychiatr1996 531110011008
Not in our library10.1001/archpsyc.1996.01830110037005
- 593.
Namerow LB Thomas P Bostic JQ Prince J Monuteaux MC Use of citalopram in pervasive developmental disordersJ Dev Behav Pediatr2003 242104108
Not in our library10.1097/00004703-200304000-00005
- 594.
Owley T Walton L Salt J Guter SJ Winnega M Leventhal BL Cook EH An open-label trial of escitalopram in pervasive developmental disordersJ Am Acad Child Adolesc Psychiatr2005 444343348
Not in our library10.1097/01.chi.0000153229.80215.a0
- 595.
King BH Hollander E Sikich L McCracken JT Scahill L Bregman JD Donnelly CL Anagnostou E Dukes K Sullivan L Hirtz D Wagner A Ritz L Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autismArch Gen Psychiatr2009 666583590
Not in our library10.1001/archgenpsychiatry.2009.30
- 596.
Aman MG Hollway JA McDougle CJ Scahill L Tierney E McCracken JT Arnold LE Vitiello B Ritz L Gavaletz A Cognitive effects of risperidone in children with autism and irritable behaviorJ Child Adolesc Psychopharmacol2008 183227236
Not in our library10.1089/cap.2007.0133
- 597.
Aman MG Lam KSL Van Bourgondien ME Medication patterns in patients with autism: Temporal, regional, and demographic influencesJ Child Adolesc Psychopharmacol2005 151116126
Not in our library10.1089/cap.2005.15.116
- 598.
Arnold LE Farmer C Kraemer HC Davies M Witwer A Chuang S DiSilvestro R McDougle CJ McCracken J Vitiello B Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritabilityJ Child Adolesc Psychopharmacol2010 2028393
Not in our library10.1089/cap.2009.0022
- 599.
Pandina GJ Bossie CA Youssef E Zhu Y Dunbar F Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trialJ Autism Dev Disord2007 372367373
Not in our library10.1007/s10803-006-0234-7
- 600.
Williams H Clarke R Bouras N Martin J Holt G Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disabilityJ Intellect Disabil Res2000 442164169
Not in our library10.1046/j.1365-2788.2000.00284.x
- 601.
McCracken JT McGough J Shah B Cronin P Hong D Aman MG Arnold LE Lindsay R Nash P Hollway J Risperidone in children with autism and serious behavioral problemsNew Engl J Med2002 3475314321
Not in our library10.1056/nejmoa013171
- 602.
McDougle CJ Stigler KA Erickson CA Posey DJ Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disordersJ Clin Psychiatr2008 6915
Not in our library
- 603.
Nagaraj R Singhi P Malhi P Risperidone in children with autism: Randomized, placebo-controlled, double-blind studyJ Child Neurol2006 216450
Not in our library10.1177/08830738060210060801
- 604.
Owen R Sikich L Marcus RN Corey-Lisle P Manos G McQuade RD Carson WH Findling RL Aripiprazole in the treatment of irritability in children and adolescents with autistic disorderPediatrics2009 12461533
Not in our library10.1542/peds.2008-3782
- 605.
Marcus RN Owen R Manos G Mankoski R Kamen L McQuade RD Carson WH Corey-Lisle PK Aman MG Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with Autistic Disorder: Results from a 52-week, open-label studyJ Child Adolesc Psychopharmacol2011 213229236
Not in our library10.1089/cap.2009.0121
- 606.
Akhondzadeh S Erfani S Mohammadi M Tehrani Doost M Amini H Gudarzi S Yasamy M Cyproheptadine in the treatment of autistic disorder: a double blind placebo controlled trialJ Clin Pharm Ther2004 292145150
Not in our library10.1111/j.1365-2710.2004.00546.x
- 607.
Parikh MS Kolevzon A Hollander E Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerabilityJ Child Adolesc Psychopharmacol2008 182157178
Not in our library10.1089/cap.2007.0041
- 608.
Stigler KA Erickson CA Mullett JE Posey DJ McDougle CJ Paliperidone for irritability in autistic disorderJ Child Adolesc Psychopharmacol2010 2017578
Not in our library10.1089/cap.2009.0019
- 609.
Handen BL Johnson CR Lubetsky M Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorderJ Autism Dev Disord2000 303245255
Not in our library10.1023/a:1005548619694
- 610.
Posey DJ Stigler KA Erickson CA McDougle CJ Antipsychotics in the treatment of autismJ Clin Investig2008 11816
Not in our library10.1172/jci32483
- 611.
McCracken JT Safety issues with drug therapies for autism spectrum disordersJ Clin Psychiatr2005 66Suppl 103237
Not in our library
- 612.
McNaught KS Mink JW Advances in understanding and treatment of Tourette syndromeNat Rev Neurol2011 712667676
Not in our library10.1038/nrneurol.2011.167
- 613.
Karagiannidis I Rizzo R Tarnok Z Wolanczyk T Hebebrand J Nothen MM Lehmkuhl G Farkas L Nagy P Barta C Szymanska U Panteloglou G Miranda DM Feng Y Sandor P Barr C Paschou P Replication of association between a SLITRK1 haplotype and Tourette Syndrome in a large sample of familiesMol Psychiatr2011 http://www.nature.com/mp/journal/vaop/ncurrent/full/mp2011151a.html.
Not in our library10.1038/mp.2011.151
- 614.
O'Rourke JA Scharf JM Yu D Pauls DL The genetics of Tourette syndrome: A reviewJ Psychosom Res2009 676533545
Not in our library10.1016/j.jpsychores.2009.06.006
- 615.
Katayama K Yamada K Ornthanalai VG Inoue T Ota M Murphy NP Aruga J Slitrk1-deficient mice display elevated anxiety-like behavior and noradrenergic abnormalitiesMol Psychiatr2008 152177184
Not in our library10.1038/mp.2008.97
- 616.
Stillman AA Krsnik Z Sun J Rasin MR State MW Sestan N Louvi A Developmentally regulated and evolutionarily conserved expression of SLITRK1 in brain circuits implicated in Tourette syndromeJ Comp Neurol2009 51312137
Not in our library10.1002/cne.21919
- 617.
Singer HS Butler IJ Tune LE Seifert WF Coyle JT Dopaminergic dysfunction in Tourette syndromeAnn Neurol1982 12361366
Not in our library10.1002/ana.410120408
- 618.
Singer HS Hahn IH Moran TH Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndromeAnn Neurol1991 304558562
Not in our library10.1002/ana.410300408
- 619.
Wong DF Brasic JR Singer HS Schretlen DJ Kuwabara H Zhou Y Nandi A Maris MA Alexander M Ye W Rousset O Kumar A Szabo Z Gjedde A Grace AA Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: Clues from an in vivo neurochemistry study with PETNeuropsychopharmacology2008 33612391251
Not in our library10.1038/sj.npp.1301528
- 620.
Grace AA Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophreniaNeuroscience1991 411124
Not in our library10.1016/0306-4522(91)90196-u
- 621.
Palminteri S Lebreton M Worbe Y Hartmann A Lehéricy S Vidailhet M Grabli D Pessiglione M Dopamine-dependent reinforcement of motor skill learning: Evidence from Gilles de la Tourette syndromeBrain2011 134822872301
Not in our library10.1093/brain/awr147
- 622.
Mazzone L Yu S Blair C Gunter BC Wang Z Marsh R Peterson BS An fMRI study of frontostriatal circuits during the inhibition of eye blinking in persons with Tourette SyndromeAm J Psychiatr2010 1673341349
Not in our library10.1176/appi.ajp.2009.08121831
- 623.
Peterson BS Skudlarski P Anderson AW Zhang H Gatenby JC Lacadie CM Leckman JF Gore JC A functional magnetic resonance imaging study of tic suppression in Tourette syndromeArch Gen Psychiatr1998 554326333
Not in our library10.1001/archpsyc.55.4.326
- 624.
Leckman JF Zhang H Vitale A Lahnin F Lynch K Bondi C Kim YS Peterson BS Course of tic severity in Tourette syndrome: The first two decadesPediatrics1998 10211419
Not in our library10.1542/peds.102.1.14
- 625.
Spessot AL Plessen KJ Peterson BS Neuroimaging of developmental psychopathologies: The importance of self-regulatory and neuroplastic processes in adolescenceAnn N Y Acad Sci2004 102186104
Not in our library10.1196/annals.1308.010
- 626.
Comings DE Comings BG Muhleman D Dietz G Shahbahrami B Tast D Knell E Kocsis P Baumgarten R Kovacs BW The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disordersJAMA1991 266131793
Not in our library
- 627.
Herzberg I Valencia-Duarte AV Kay VA White DJ Müller H Rivas IC Mesa SC Cuartas M García J Bedoya G Cornejo W Ruiz-Linares A Kremeyer B Association of DRD2 variants and Gilles de la Tourette syndrome in a family-based sample from a South American population isolatePsychiatr Genet2010 204179183
Not in our library10.1097/ypg.0b013e32833a215a
- 628.
Lee CC Chou I Dopamine receptor D2 gene polymorphisms are associated in Taiwanese children with Tourette syndromePediatr Neurol2005 334272276
Not in our library10.1016/j.pediatrneurol.2005.05.005
- 629.
Diaz-Anzaldua A Joober R Riviere J Dion Y Lesperance P Richer F Chouinard S Rouleau G Tourette syndrome and dopaminergic genes: a family-based association study in the French Canadian founder populationMol Psychiatr2004 93272277
Not in our library10.1038/sj.mp.4001411
- 630.
Díaz Anzaldúa A Rivière JB Dubé MP Joober R Saint Onge J Dion Y Lespérance P Richer F Chouinard S Rouleau GA Chromosome 11 q24 region in Tourette syndrome: Association and linkage disequilibrium study in the French Canadian populationAm J Med Genet A2005 1383225228
Not in our library10.1002/ajmg.a.30928
- 631.
Gelernter J Pakstis AJ Pauls DL Kurlan R Gancher ST Civelli O Grandy D Kidd KK Gilles de la Tourette syndrome is not linked to D2-dopamine receptorArch Gen Psychiatr1990 47111073
Not in our library10.1001/archpsyc.1990.01810230089014
- 632.
Gelernter J Pauls DL Leckman J Kidd KK Kurlan R D2 dopamine receptor alleles do not influence severity of Tourette's Syndrome: Results from four large kindredsArch Neurol1994 514397
Not in our library10.1001/archneur.1994.00540160099012
- 633.
Nöthen MM Hebebrand J Knapp M Hebebrand K Camps A von Gontard A Wettke Schäfer R Lisch S Cichon S Poustka F Association analysis of the dopamine D2 receptor gene in Tourette's syndrome using the haplotype relative risk methodAm J Med Genet1994 543249252
Not in our library10.1002/ajmg.1320540311
- 634.
Wolf SS Jones DW Knable MB Gorey JG Lee KS Hyde TM Coppola R Weinberger DR Tourette syndrome: Prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor bindingScience1996 273527912251227
Not in our library10.1126/science.273.5279.1225
- 635.
Yeh CB Lee CS Ma KH Lee MS Chang CJ Huang WS Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with 99mTc TRODAT-1 imagingPsychiatr Res2007 15617582
Not in our library10.1016/j.pscychresns.2007.01.003
- 636.
Albin RL Koeppe RA Bohnen NI Nichols TE Meyer P Wernette K Minoshima S Kilbourn MR Frey KA Increased ventral striatal monoaminergic innervation in Tourette syndromeNeurology2003 613310315
Not in our library10.1212/01.wnl.0000076181.39162.fc
- 637.
Liu Y Aragona BJ Young KA Dietz DM Kabbaj M Mazei-Robison M Nestler EJ Wang Z Nucleus accumbens dopamine mediates amphetamine-induced impairment of social bonding in a monogamous rodent speciesProc Natl Acad Sci2010 107312171222
Not in our library10.1073/pnas.0911998107
- 638.
Muller-Vahl KR Berding G Brucke T Kolbe H Meyer GJ Hundeshagen H Dengler R Knapp WH Emrich HM Dopamine transporter binding in Gilles de la Tourette syndromeJ Neurol2000 2477514520
Not in our library10.1007/pl00007806
- 639.
Serra-Mestres J Ring HA Costa DC Gacinovic S Walker Z Lees AJ Robertson MM Trimble MR Dopamine transporter binding in Gilles de la Tourette syndrome: A [123I]FP-CIT/SPECT studyActa Psychiatr Scand2004 1092140146
Not in our library10.1111/j.0001-690x.2004.00214.x
- 640.
Singer HS Szymanski S Giuliano J Yokoi F Dogan AS Brasic JR Zhou Y Grace AA Wong DF Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PETAm J Psychiatr2002 159813291336
Not in our library10.1176/appi.ajp.159.8.1329
- 641.
Cheon KA Ryu YH Namkoong K Kim CH Kim JJ Lee JD Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorderPsychiatr Res2004 13018595
Not in our library10.1016/j.pscychresns.2003.06.001
- 642.
Hwang WJ Yao WJ Fu YK Yang AS [99mTc]TRODAT-1/[123I]IBZM SPECT studies of the dopaminergic system in Tourette syndromePsychiatr Res2008 1622159166
Not in our library10.1016/j.pscychresns.2007.04.006
- 643.
Stamenkovic M Schindler SD Asenbaum S Neumeister A Willeit M Willinger U de Zwaan M Riederer F Aschauer HN Kasper S No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette's disorder patients: A [(123)I]-beta-CIT SPECt-studyEur Neuropsychopharmacol2001 1116974
Not in our library10.1016/s0924-977x(00)00134-6
- 644.
Yeh CB Lee CH Chou YH Chang CJ Ma KH Huang WS Evaluating dopamine transporter activity with 99mTc-TRODAT-1 SPECT in drug-naive Tourette's adultsNucl Med Comm2006 2710779784
Not in our library10.1097/01.mnm.0000239485.53780.16
- 645.
Fasano A Bentivoglio AR TetrabenazineExpet Opin Pharmacother2009 101728832896
Not in our library10.1517/14656560903386292
- 646.
Zheng G Dwoskin LP Crooks PA Vesicular monoamine transporter 2: role as a novel target for drug developmentAAPS J2006 84E682
Not in our library10.1208/aapsj080478
- 647.
Scahill L Erenberg G Berlin CM Budman C Coffey BJ Jankovic J Kiessling L King RA Kurlan R Lang A Mink J Murphy T Zinner S Walkup J Contemporary assessment and pharmacotherapy of Tourette syndromeNeuroRx2006 32192206
Not in our library10.1016/j.nurx.2006.01.009
- 648.
Rubia K "Cool" inferior frontostriatal dysfunction in attention-deficit/hyperactivity disorder versus "hot" ventromedial orbitofrontal-limbic dysfunction in conduct disorder: a reviewBiol Psychiatr2011 6912e69
Not in our library10.1016/j.biopsych.2010.09.023
- 649.
Canino G Polanczyk G Bauermeister JJ Rohde LA Frick PJ Does the prevalence of CD and ODD vary across cultures?Soc Psychiatr Psychiatr Epidemiol2010 457695704
Not in our library10.1007/s00127-010-0242-y
- 650.
Banaschewski T Hollis C Oosterlaan J Roeyers H Rubia K Willcutt E Taylor E Towards an understanding of unique and shared pathways in the psychopathophysiology of ADHDDev Sci2005 82132140
Not in our library10.1111/j.1467-7687.2005.00400.x
- 651.
Rubia K Smith AB Halari R Matsukura F Mohammad M Taylor E Brammer MJ Disorder-specific dissociation of orbitofrontal dysfunction in boys with pure conduct disorder during reward and ventrolateral prefrontal dysfunction in boys with pure ADHD during sustained attentionAm J Psychiatr2009 16618394
Not in our library10.1176/appi.ajp.2008.08020212
- 652.
Bjork JM Chen G Smith AR Hommer DW Incentive-elicited mesolimbic activation and externalizing symptomatology in adolescentsJ Child Psychol Psychiatr2010 517827837
Not in our library10.1111/j.1469-7610.2009.02201.x
- 653.
Crowley TJ Dalwani MS Mikulich-Gilbertson SK Du YP Lejuez CW Raymond KM Banich MT Risky decisions and their consequences: Neural processing by boys with antisocial substance disorderPLoS One2010 59e12835
Not in our library10.1371/journal.pone.0012835
- 654.
de Almeida RM Ferrari PF Parmigiani S Miczek KA Escalated aggressive behavior: Dopamine, serotonin and GABAEur J Pharmacol2005 5261–35164
Not in our library10.1016/j.ejphar.2005.10.004
- 655.
Laakso A Wallius E Kajander J Bergman J Eskola O Solin O Ilonen T Salokangas RK Syvalahti E Hietala J Personality traits and striatal dopamine synthesis capacity in healthy subjectsAm J Psychiatr2003 1605904910
Not in our library10.1176/appi.ajp.160.5.904
- 656.
Beaver KM Wright JP DeLisi M Walsh A Vaughn MG Boisvert D Vaske J A gene x gene interaction between DRD2 and DRD4 is associated with conduct disorder and antisocial behavior in malesBehav Brain Functions2007 330
Not in our library10.1186/1744-9081-3-30
- 657.
Burt SA Mikolajewski AJ Preliminary evidence that specific candidate genes are associated with adolescent-onset antisocial behaviorAggress Behav2008 344437445
Not in our library10.1002/ab.20251
- 658.
Lahey BB Rathouz PJ Lee SS Chronis-Tuscano A Pelham WE Waldman ID Cook EH Interactions between early parenting and a polymorphism of the child's dopamine transporter gene in predicting future child conduct disorder symptomsJ Abnorm Psychol2011 12013345
Not in our library10.1037/a0021133
- 659.
Sonuga-Barke EJ Oades RD Psychogiou L Chen W Franke B Buitelaar J Banaschewski T Ebstein RP Gil M Anney R Miranda A Roeyers H Rothenberger A Sergeant J Steinhausen HC Thompson M Asherson P Faraone SV Dopamine and serotonin transporter genotypes moderate sensitivity to maternal expressed emotion: The case of conduct and emotional problems in attention deficit/hyperactivity disorderJ Child Psychol Psychiatr2009 50910521063
Not in our library10.1111/j.1469-7610.2009.02095.x
- 660.
- 661.
Donovan SJ Stewart JW Nunes EV Quitkin FM Parides M Daniel W Susser E Klein DF Divalproex treatment for youth with explosive temper and mood lability: A double-blind, placebo-controlled crossover designAm J Psychiatr2000 1575818820
Not in our library10.1176/appi.ajp.157.5.818
- 662.
Steiner H Petersen ML Saxena K Ford S Matthews Z Divalproex sodium for the treatment of conduct disorder: A randomized controlled clinical trialJ Clin Psychiatr2003 641011831191
Not in our library10.4088/jcp.v64n1007
- 663.
Cheng-Shannon J McGough JJ Pataki C McCracken JT Second-generation antipsychotic medications in children and adolescentsJ Child Adolesc Psychopharmacol2004 143372394
Not in our library10.1089/cap.2004.14.372
- 664.
Findling RL Aman MG Eerdekens M Derivan A Lyons B Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQAm J Psychiatr2004 1614677684
Not in our library10.1176/appi.ajp.161.4.677
- 665.
Findling RL McNamara NK Branicky LA Schluchter MD Lemon E Blumer JL A double-blind pilot study of risperidone in the treatment of conduct disorderJ Am Acad Child Adolesc Psychiatr2000 394509516
Not in our library10.1097/00004583-200004000-00021
- 666.
Turgay A Binder C Snyder R Fisman S Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQsPediatrics2002 1103e34
Not in our library10.1542/peds.110.3.e34
- 667.
Aman MG De Smedt G Derivan A Lyons B Findling RL Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligenceAm J Psychiatry2002 159813371346
Not in our library10.1176/appi.ajp.159.8.1337
- 668.
Snyder R Turgay A Aman M Binder C Fisman S Carroll A Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQsJ Am Acad Child Adolesc Psychiatr2002 41910261036
Not in our library10.1097/00004583-200209000-00002
- 669.
Holm VA Cassidy SB Butler MG Hanchett JM Greenswag LR Whitman BY Greenberg F Prader-Willi syndrome: Consensus diagnostic criteriaPediatrics1993 912398402
Not in our library
- 670.
Whittington JE Holland AJ Webb T Butler J Clarke D Boer H Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health RegionJ Med Genet2001 3811792798
Not in our library10.1136/jmg.38.11.792
- 671.
Glenn CC Driscoll DJ Yang TP Nicholls RD Genomic imprinting: Potential function and mechanisms revealed by the Prader-Willi and Angelman syndromesMol Hum Reprod1997 34321332
Not in our library10.1093/molehr/3.4.321
- 672.
Nicholls RD Knepper JL Genome organization, function, and imprinting in Prader-Willi and Angelman syndromesAnnu Rev Genom Hum Genet2001 2153175
Not in our library10.1146/annurev.genom.2.1.153
- 673.
Fieldstone A Zipf WB Sarter MF Berntson GG Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine receptor agonistObes Res1998 612933
Not in our library10.1002/j.1550-8528.1998.tb00311.x
- 674.
Holland AJ Treasure J Coskeran P Dallow J Milton N Hillhouse E Measurement of excessive appetite and metabolic changes in Prader-Willi syndromeInt J Obes Relat Metab Disord1993 179527532
Not in our library
- 675.
von Deneen KM Gold MS Liu Y Food addiction and cues in Prader-Willi syndromeJ Addiction Med2009 311925
Not in our library10.1097/adm.0b013e31819a6e5f
- 676.
Hinton EC Isles AR Williams NM Parkinson JA Excessive appetitive arousal in Prader–Willi syndromeAppetite2010 541225228
Not in our library10.1016/j.appet.2009.12.002
- 677.
Swaab DF Prader-Willi syndrome and the hypothalamusActa Paediatr Suppl1997 4235054
Not in our library10.1111/j.1651-2227.1997.tb18369.x
- 678.
Miller JL James GA Goldstone AP Couch JA He G Driscoll DJ Liu Y Enhanced activation of reward mediating prefrontal regions in response to food stimuli in Prader-Willi syndromeJ Neurol Neurosurg Psychiatr2007 786615619
Not in our library10.1136/jnnp.2006.099044
- 679.
Holsen LM Zarcone JR Brooks WM Butler MG Thompson TI Ahluwalia JS Nollen NL Savage CR Neural mechanisms underlying hyperphagia in Prader-Willi SyndromeObesity2006 14610281037
Not in our library10.1038/oby.2006.118
- 680.
Dimitropoulos A Schultz R Food-related neural circuitry in Prader-Willi Syndrome: Response to high-versus low-calorie foodsJ Autism Dev Disord2008 38916421653
Not in our library10.1007/s10803-008-0546-x
- 681.
Hinton EC Holland AJ Gellatly MS Soni S Owen AM An investigation into food preferences and the neural basis of food-related incentive motivation in Prader-Willi syndromeJ Intellect Disabil Res2006 50633642
Not in our library10.1111/j.1365-2788.2006.00812.x
- 682.
Shapira NA Lessig MC He AG James GA Driscoll DJ Liu Y Satiety dysfunction in Prader-Willi syndrome demonstrated by fMRIJ Neurol Neurosurg Psychiatr2005 762260262
Not in our library10.1136/jnnp.2004.039024
- 683.
Stromme P Bjornstad PG Ramstad K Prevalence estimation of Williams syndromeJ Child Neurol2002 174269271
Not in our library10.1177/088307380201700406
- 684.
Bellugi U Adolphs R Cassady C Chiles M Towards the neural basis for hypersociability in a genetic syndromeNeuroreport1999 10816531657
Not in our library10.1097/00001756-199906030-00006
- 685.
Klein-Tasman BP Mervis CB Distinctive personality characteristics of 8-, 9-, and 10-year-olds with Williams syndromeDev Neuropsychol2003 231–2269290
Not in our library10.1080/87565641.2003.9651895
- 686.
Doyle TF Bellugi U Korenberg JR Graham J "Everybody in the world is my friend" hypersociability in young children with Williams syndromeAm J Med Genet2004 124A3263273
Not in our library10.1002/ajmg.a.20416
- 687.
Einfeld SL Tonge BJ Florio T Behavioral and emotional disturbance in individuals with Williams syndromeAm J Ment Retard1997 10214553
Not in our library10.1352/0895-8017(1997)102<0045:baedii>2.0.co;2
- 688.
Meyer-Lindenberg A Mervis CB Berman KF Neural mechanisms in Williams syndrome: A unique window to genetic influences on cognition and behaviourNat Rev Neurosci2006 75380393
Not in our library10.1038/nrn1906
- 689.
Haas BW Hoeft F Searcy YM Mills D Bellugi U Reiss A Individual differences in social behavior predict amygdala response to fearful facial expressions in Williams syndromeNeuropsychologia2009 48512831288
Not in our library10.1016/j.neuropsychologia.2009.12.030
- 690.
Mimura M Hoeft F Kato M Kobayashi N Sheau K Piggot J Mills D Galaburda A Korenberg JR Bellugi U A preliminary study of orbitofrontal activation and hypersociability in Williams SyndromeJ Neurodev Disord2010 229398
Not in our library10.1007/s11689-009-9041-8
- 691.
Pober BR Williams-Beuren syndromeNew Engl J Med2010 3623239252
Not in our library10.1056/nejmra0903074
- 692.
Philpot BD Thompson CE Franco L Williams CA Angelman syndrome: Advancing the research frontier of neurodevelopmental disordersJ Neurodev Disord2011 315056
Not in our library10.1007/s11689-010-9066-z
- 693.
Harting I Seitz A Rating D Sartor K Zschocke J Janssen B Ebinger F Wolf NI Abnormal myelination in Angelman syndromeEur J Paediatr Neurol2009 133271276
Not in our library10.1016/j.ejpn.2008.04.005
- 694.
Didden R Korzilius H Sturmey P Lancioni GE Curfs LM Preference for water-related items in Angelman syndrome, Down syndrome and non-specific intellectual disabilityJ Intellect Dev Disabil2008 3315964
Not in our library10.1080/13668250701872126
- 695.
Pelc K Cheron G Dan B Behavior and neuropsychiatric manifestations in Angelman syndromeNeuropsychiatr Dis Treat2008 43577584
Not in our library10.2147/ndt.s2749
- 696.
Ferdousy F Bodeen W Summers K Doherty O Wright O Elsisi N Hilliard G O'Donnell JM Reiter LT Drosophila Ube3a regulates monoamine synthesis by increasing GTP cyclohydrolase I activity via a non-ubiquitin ligase mechanismNeurobiol Dis2011 413669677
Not in our library10.1016/j.nbd.2010.12.001
- 697.
Mulherkar SA Jana NR Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndromeNeurobiol Dis2010 403586592
Not in our library10.1016/j.nbd.2010.08.002
- 698.
Chahrour M Zoghbi HY The story of Rett syndrome: From clinic to neurobiologyNeuron2007 563422437
Not in our library10.1016/j.neuron.2007.10.001
- 699.
Percy AK Rett syndrome: exploring the autism linkArch Neurol2011 688985989
Not in our library10.1001/archneurol.2011.149
- 700.
Hutchinson AN Deng JV Aryal DK Wetsel WC West AE Differential regulation of MeCP2 phosphorylation in the CNS by dopamine and serotoninNeuropsychopharmacology2012 37321337
Not in our library10.1038/npp.2011.190
- 701.
- 702.
Panayotis N Pratte M Borges-Correia A Ghata A Villard L Roux JC Morphological and functional alterations in the substantia nigra pars compacta of the Mecp2-null mouseNeurobiol Dis2011 412385397
Not in our library10.1016/j.nbd.2010.10.006
- 703.
Gantz SC Ford CP Neve KA Williams JT Loss of Mecp2 in substantia nigra dopamine neurons compromises the nigrostriatal pathwayJ Neurosci2011 31351262912637
Not in our library10.1523/jneurosci.0684-11.2011
- 704.
Dunn HG Stoessl AJ Ho HH MacLeod PM Poskitt KJ Doudet DJ Schulzer M Blackstock D Dobko T Koop B de Amorim GV Rett syndrome: Investigation of nine patients, including PET scanCan J Neurol Sci2002 294345357
Not in our library10.1017/s0317167100002213
- 705.
Chiron C Bulteau C Loc'h C Raynaud C Garreau B Syrota A Maziere B Dopaminergic D2 receptor SPECT imaging in Rett syndrome: Increase of specific binding in striatumJ Nucl Med1993 341017171721
Not in our library
- 706.
Crawford DC Acuna JM Sherman SL FMR1 and the fragile X syndrome: Human genome epidemiology reviewGenet Med2001 35359371
Not in our library10.1097/00125817-200109000-00006
- 707.
Verkerk AJ Pieretti M Sutcliffe JS Fu YH Kuhl DP Pizzuti A Reiner O Richards S Victoria MF Zhang FP Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndromeCell1991 655905914
Not in our library10.1016/0092-8674(91)90397-h
- 708.
Lightbody AA Reiss AL Gene, brain, and behavior relationships in fragile X syndrome: Evidence from neuroimaging studiesDev Disabil Res Rev2009 154343352
Not in our library10.1002/ddrr.77
- 709.
Bennetto L Pennington BF Porter D Taylor AK Hagerman RJ Profile of cognitive functioning in women with the fragile X mutationNeuropsychology2001 152290299
Not in our library
- 710.
Lightbody AA Hall SS Reiss AL Chronological age, but not FMRP levels, predicts neuropsychological performance in girls with Fragile X syndromeAm J Med Genet2006 1415468472
Not in our library10.1002/ajmg.b.30307
- 711.
Roberts JE Schaaf JM Skinner M Wheeler A Hooper S Hatton DD Bailey DB Academic skills of boys with Fragile X syndrome: Profiles and predictorsAm J Ment Retard2005 1102107120
Not in our library10.1352/0895-8017(2005)110<107:asobwf>2.0.co;2
- 712.
Bakker CE Verheij C Willemsen R van der Helm R Oerlemans F Vermey M Bygrave A Hoogeveen AT Oostra BA Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X ConsortiumCell1994 7812333
Not in our library
- 713.
Fulks JL O'Bryhim BE Wenzel SK Fowler SC Vorontsova E Pinkston JW Ortiz AN Johnson MA Dopamine release and uptake impairments and behavioral alterations observed in mice that model Fragile X mental retardation syndromeACS Chem Neurosci2010 110679690
Not in our library10.1021/cn100032f
- 714.
Weinshenker D Warren ST Neuroscience: fragile dopamineNature2008 4557213607608
Not in our library10.1038/455607a
- 715.
Wang H Wu LJ Kim SS Lee FJ Gong B Toyoda H Ren M Shang YZ Xu H Liu F Zhao MG Zhuo M FMRP acts as a key messenger for dopamine modulation in the forebrainNeuron2008 594634647
Not in our library10.1016/j.neuron.2008.06.027
- 716.
Wang H Kim SS Zhuo M Roles of Fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalizationJ Biol Chem2010 285282188821901
Not in our library10.1074/jbc.m110.116293
- 717.
Farzin F Perry H Hessl D Loesch D Cohen J Bacalman S Gane L Tassone F Hagerman P Hagerman R Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the Fragile X premutationJ Dev Behaiv Pediatr2006 272 SupplS137S144
Not in our library10.1097/00004703-200604002-00012
- 718.
Mazzocco MM Pennington BF Hagerman RJ Social cognition skills among females with Fragile XJ Autism Dev Disord1994 244473485
Not in our library10.1007/bf02172129
- 719.
Smith DV Hayden BY Truong TK Song AW Platt ML Huettel SA Distinct value signals in anterior and posterior ventromedial prefrontal cortexJ Neurosci2010 3072490
Not in our library10.1523/jneurosci.3319-09.2010
- 720.
Garrett AS Menon V MacKenzie K Reiss AL Here's looking at you, kid: Neural systems underlying face and gaze processing in Fragile X syndromeArch Gen Psychiatr2004 613281288
Not in our library10.1001/archpsyc.61.3.281
- 721.
Watson C Hoeft F Garrett AS Hall SS Reiss AL Aberrant brain activation during gaze processing in boys with Fragile X syndromeArch Gen Psychiatr2008 651113151323
Not in our library10.1001/archpsyc.65.11.1315
- 722.
Holsen LM Dalton KM Johnstone T Davidson RJ Prefrontal social cognition network dysfunction underlying face encoding and social anxiety in fragile X syndromeNeuroimage2008 433592604
Not in our library10.1016/j.neuroimage.2008.08.009
- 723.
Dalton KM Holsen L Abbeduto L Davidson RJ Brain function and gaze fixation during facial-emotion processing in fragile X and autismAutism Res2008 14231239
Not in our library10.1002/aur.32
- 724.
Ceravolo R Antonini A Volterrani D Rossi C Goldwurm S Di Maria E Kiferle L Bonuccelli U Murri L Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriersNeurology2005 651219711973
Not in our library10.1212/01.wnl.0000188821.51055.52
- 725.
Berry-Kravis E Lewin F Wuu J Leehey M Hagerman R Hagerman P Goetz CG Tremor and ataxia in fragile X premutation carriers: Blinded videotape studyAnn Neurol2003 535616623
Not in our library10.1002/ana.10522
- 726.
Roberts J Symons F Johnson AM Hatton D Boccia M Blink rate in boys with fragile X syndrome: Preliminary evidence for altered dopamine functionJ Intellect Disabil Res2005 499647656
Not in our library10.1111/j.1365-2788.2005.00713.x
- 727.
Berry-Kravis E Potanos K Psychopharmacology in fragile X syndrome–present and futureMent Retard Dev Disabil Res Rev2004 1014248
Not in our library10.1002/mrdd.20007
- 728.
Hagerman RJ Hagerman RJ, Hagerman PJMedical follow-up and pharmacotherapyFragile X Syndrome: Diagnosis, Treatment, and Research2002 3The Johns Hopkins University Press, Baltimore287338
Not in our library
- 729.
Valdovinos MG Parsa RA Alexander ML Results of a nation-wide survey evaluating psychotropic medication use in Fragile X syndromeJ Dev Phys Disabil2009 212337
Not in our library
- 730.
Hall SS Treatments for fragile X syndrome: a closer look at the dataDev Disabil Res Rev2009 154353360
Not in our library10.1002/ddrr.78
- 731.
Hagerman RJ Murphy MA Wittenberger MD A controlled trial of stimulant medication in children with the fragile X syndromeAm J Med Genet1988 301–2377392
Not in our library10.1002/ajmg.1320300138
- 732.
Erickson CA Stigler KA Posey DJ McDougle CJ Aripiprazole in Autism Spectrum Disorders and Fragile X syndromeNeurotherapeutics2010 73258263
Not in our library10.1016/j.nurt.2010.04.001
- 733.
Erickson CA Stigler KA Wink LK Mullett JE Kohn A Posey DJ McDougle CJ A prospective open-label study of aripiprazole in Fragile X syndromePsychopharmacology2011 2168590
Not in our library10.1007/s00213-011-2194-7
- 734.
World Health OrganizationInternational statistical classification of diseases and related health problems2007 10Retrieved from http://apps.who.int/classifications/apps/icd/icd10online.
Not in our library
- 735.
Robinson TE Berridge KC AddictionAnnu Rev Psychol2003 542553
Not in our library10.1146/annurev.psych.54.101601.145237
- 736.
McGinty VB Hayden BY Heilbronner SR Dumont EC Graves SM Mirrione MM du Hoffmann J Sartor GC Espana RA Millan EZ Difeliceantonio AG Marchant NJ Napier TC Root DH Borgland SL Treadway MT Floresco SB McGinty JF Haber S Emerging, reemerging, and forgotten brain areas of the reward circuit: Notes from the 2010 Motivational Neural Networks conferenceBehav Brain Res2011 2251348357
Not in our library10.1016/j.bbr.2011.07.036
- 737.
Pecina S Smith KS Berridge KC Hedonic hot spots in the brainNeuroscientist2006 126500511
Not in our library10.1177/1073858406293154
- 738.
Baxter MG Murray EA The amygdala and rewardNat Rev Neurosci2002 37563573
Not in our library10.1038/nrn875
- 739.
Cardinal RN Parkinson JA Hall J Everitt BJ Emotion and motivation: The role of the amygdala, ventral striatum, and prefrontal cortexNeurosci Biobehav Rev2002 263321352
Not in our library10.1016/s0149-7634(02)00007-6
- 740.
Volkow ND Fowler JS Wang GJ The addicted human brain: Insights from imaging studiesJ Clin Investig2003 1111014441451
Not in our library10.1172/jci18533
- 741.
Carlezon WA Thomas MJ Biological substrates of reward and aversion: A nucleus accumbens activity hypothesisNeuropharmacology2009 56Suppl 1122132
Not in our library10.1016/j.neuropharm.2008.06.075
- 742.
Matsumoto M Hikosaka O Two types of dopamine neuron distinctly convey positive and negative motivational signalsNature2009 4597248837841
Not in our library10.1038/nature08028
- 743.
Carver CS White TL Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS scalesJ Pers Soc Psychol1994 672319333
Not in our library
- 744.
Chapman LJ Chapman JP Raulin ML Scales for physical and social anhedoniaJ Abnorm Psychol1976 854374382
Not in our library10.1037//0021-843x.85.4.374
- 745.
Gard DE Gard MG Kring AM John OP Anticipatory and consummatory components of the experience of pleasure: a scale development studyJ Res Pers2006 4010861102
Not in our library
- 746.
Heerey EA Robinson BM McMahon RP Gold JM Delay discounting in schizophreniaCognit Neuropsychiatry2007 123213221
Not in our library10.1080/13546800601005900
- 747.
Kessler RC The epidemiology of dual diagnosisBiol Psychiatr2004 5610730737
Not in our library10.1016/j.biopsych.2004.06.034
- 748.
Lasser K Boyd JW Woolhandler S Himmelstein DU McCormick D Bor DH Smoking and mental illness: A population-based prevalence studyJAMA2000 2842026062610
Not in our library10.1001/jama.284.20.2606
- 749.
Ziedonis D Hitsman B Beckham JC Tobacco use cessation in psychiatric disordersNicotine Tobac Res Nat Inst Ment Health (NIMH) Rep2008 1016911715
Not in our library10.1080/14622200802443569
- 750.
Regier DA Farmer ME Rae DS Locke BZ Keith SJ Judd LL Goodwin FK Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) StudyJAMA1990 2641925112518
Not in our library
- 751.
Towbin KE Pradella A Gorrindo T Pine DS Leibenluft E Autism spectrum traits in children with mood and anxiety disordersJ Child Adoles Psychopharmacol2005 153452464
Not in our library10.1089/cap.2005.15.452
- 752.
Cederlund M Hagberg B Gillberg C Asperger syndrome in adolescent and young adult males. Interview, self- and parent assessment of social, emotional, and cognitive problemsRes Dev Disabil2010 312287298
Not in our library10.1016/j.ridd.2009.09.006
- 753.
Leyfer OT Folstein SE Bacalman S Davis NO Dinh E Morgan J Tager-Flusberg H Lainhart JE Comorbid psychiatric disorders in children with autism: Interview development and rates of disordersJ Autism Dev Disord2006 367849861
Not in our library10.1007/s10803-006-0123-0
- 754.
Glassman AH Cigarette smoking: Implications for psychiatric illnessAm J Psychiatr1993 1504546553
Not in our library10.1176/ajp.150.4.546
- 755.
Hughes JR Hatsukami DK Mitchell JE Dahlgren LA Prevalence of smoking among psychiatric outpatientsAm J Psychiatr1986 1438993997
Not in our library10.1176/ajp.143.8.993
- 756.
Mueser KT Drake RE Wallach MA Dual diagnosis: a review of etiological theoriesAddict Behav1998 236717734
Not in our library
Cited by papers we hold 4
- The Potential Role of Gut Microbiota in Alzheimer’s Disease: From Diagnosis to Treatment · 2022No notice
- The Neurochemistry of Autism · 2020No notice
- Neurocognitive Precursors of Substance Misuse Corresponding to Risk, Resistance, and Resilience Pathways: Implications for Prevention Science · 2019Not checked
- Enteric Bacterial Metabolites Propionic and Butyric Acid Modulate Gene Expression, Including CREB-Dependent Catecholaminergic Neurotransmission, in PC12 Cells - Possible Relevance to Autism Spectrum Disorders · 2014No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.